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ABSTRACT 
GM1 gangliosidosis is a lysosomal storage disorder caused by a 
deficiency in the catabolizing enzyme β-galactosidase (βgal).  This leads to 
accumulation of GM1-ganglioside (GM1) in the lysosome inducing ER stress and 
cell death.  GM1 gangliosidosis is primarily a disorder of the central nervous 
system (CNS) with peripheral organ involvement.  In this work we report two 
major findings, 1) systemic treatment of GM1 gangliosidosis with an adeno-
associated virus (AAV9) encoding mouse-βgal (mβgal) in a GM1 gangliosidosis 
mouse model (βGal-/-), and 2) an investigation into an intracranial injection of a 
therapeutic AAVrh8 encoding mβgal.  Systemic treatment of GM1 gangliosidosis 
with AAV9 resulted in a moderate expression of enzyme in the CNS, reduction of 
GM1 storage, significant retention of motor function and a significant increase in 
lifespan.  Interestingly, the therapeutic effect was more robust in females.  
Intracranial injections of AAVrh8 vector expressing high levels of βgal resulted in 
enzyme spread throughout the brain, significant retention of motor function and a 
significant increase in lifespan. Histological alterations were also found at the 
injection site in both βGal-/- and normal animals.  We constructed a series of 
vectors with a range of decreasing enzyme expression levels to investigate the 
cause for the unanticipated result.  Microarrays were performed on the injection 
site and we showed that a lower expressing AAVrh8-mβgal vector mitigated the 
negative response.  Intracranial injection of this newly developed vector was 
shown to clear lysosomal storage throughout the CNS of βGal-/- mice. Taken 
together, these studies indicate that a combined systemic and fine-tuned 
intracranial approach may be the most effective in clearing lysosomal storage 
completely in the CNS while providing therapeutic benefit to the periphery.   
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CHAPTER I:  Introduction 
 
GM1-Gangliosidosis 
 
Clinical Description 
 Lysosomal storage disorders (LSD) are a class of recessive diseases that 
are caused primarily by the reduction of a catabolizing lysosomal resident 
enzyme and subsequent storage of the substrate in the lysosome.  These 
disorders result in lysosomal dysfunction, alterations in cell homeostasis, and cell 
death (1).  There are more than 50 known LSD’s, and ~70% of them have a 
central nervous system involvement.  One well known LSD is GM1-
gangliosidosis which was first identified in 1959 (2).  GM1-gangliosidosis results 
from the lack of the enzyme β-galactosidase (βgal, encoded by the GLB1 gene) 
and subsequent storage of GM1-ganglioside (GM1) and the asialo derivative 
GA1 (GM1 lacking sialic acid group), in the lysosomes in cells of the central and 
peripheral nervous system (CNS and PNS, respectively) (3).  Also associated 
with this disease is the storage of other glycoconjugates with terminal β-
galactose residues, along with oligosaccharides and keratan sulfate, in the 
lysosomes of cells of the visceral organs.  Cells burdened with GM1 storage 
activate the unfolded protein response (UPR) and undergo endoplasmic 
reticulum (ER) stress which leads to Ca2+-mediated mitochondrial apoptosis (4, 
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5) and inflammation (6), resulting in progressive neurological decline that leads to 
generalized paralysis and death (7). 
There are three forms of GM1-gangliosidosis: infantile, juvenile and adult; 
in which severity, disease onset and progression are correlated with the amount 
of βgal activity which ranges from >1–9% of normal activity.  Onset of infantile 
and juvenile GM1-gangliosidosis occurs between birth and 3 years.  This form of 
the disease primarily affects the CNS, however, hepatosplenomegaly, and 
macular cherry red spots have also been documented (7).  Two distinguishing 
features of the infantile form include the occurrence of facial dysmorphism, and 
skeletal abnormalities, which are not present in the juvenile form of this disease.  
In contrast to infantile and juvenile forms, onset of adult GM1-gangliosidosis 
occurs between 3 and 30 years of age.  This disease manifests as  primarily non-
neurological, however, symptoms of dystonia with minimal skeletal abnormalities 
can also be present (7).   
GM1-gangliosidosis occurs in 1:100,000-200,000 births with no known 
ethnic dominance, although some mutations in the GLB1 gene have common 
lineages such as Italian, American, Brazilian and Japanese (7, 8).  Diagnosis of 
this disease typically results from the presentation of abnormal neurological 
findings such as developmental regression or failure to meet milestones, which 
then trigger further investigation.  The methods of diagnosis include the following:  
(1) retrospective analysis on dried blood spots from newborn screening panels 
(9), or on blood spots from high risk patients with suspected heredity inclinations 
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(10), (2) pre-natal diagnosis from amniotic fluid (11), and (3) molecular analysis 
of the GLB1 gene (12).  Known disease-carrying mutations in GLB1 include gene 
duplication, insertions (which result in splicing defects), missense mutations, and 
nonsense mutations (7, 8).  Currently, there is no cure for this disease.   
 
GLB1 Gene  
The human gene GLB1 is located on chromosome 3p21.33.  The gene is 
62.5kb, contains 16 exons and encodes two, alternately spliced transcripts:  a 
2.4kb mRNA, 677 amino acid (aa) lysosomal acid β-galactosidase (βgal) and a 
2.0kb variant mRNA, 546aa elastin binding protein (EBP) (7, 8, 13).  EBP is a 
67kDa protein that together with the elastin receptor and protective protein 
(carboxypeptidase A or cathepsin A), form an elastin complex on the cell surface 
to bind elastin peptides (8, 13).  The functions of this complex include: the 
assembly of elastic fibers, cytoskeleton reorganization and cell proliferation 
through an increase of intracellular Ca2+ (8, 13, 14).  Defects in EBP result in 
impaired elastogenesis (generation of elastic fibers) and results in a connective 
tissue disease (15).  Interestingly, defects in elastogenesis that were believed to 
result from accumulation of keratan sulfate have also been implicated in patients 
with GM1-gangliosidosis with and without mutations in EBP (15).   
The 677aa protein is the βgal prepropolypeptide which is processed in the 
ER to yield a 654aa product that is then glycosylated and phosphorylated to an 
88kDa precursor.  Final processing of the C-terminal end of βgal to a 67 then a 
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64kDa functional enzyme occurs in the lysosome (8).  A multi-enzyme complex 
consisting of protective protein/cathepsin A, neuraminidase, and the 20kDa 
fragment from the C-terminal end of βgal are necessary for the correct 
processing and activity of the βgal enzyme (16).  The catalytic nucleophile of 
βgal was identified by mass spectrometry (17) and mutation analysis confirmed 
the conserved residue Glu268 as an active site for βgal enzymatic activity (8).  
Recently, a crystal structure of βgal has been constructed which demonstrated 
mutations affecting ligand recognition, within the enzyme core or on the enzyme 
surface that indicates how these mutations may lead to disease (18). 
 
GM1 Ganglioside Biosynthesis and Catabolism   
Biosynthesis of gangliosides occurs through the stepwise addition of sugar 
moieties and sialic acid residues.  This process is regulated both transcriptionally 
and post transcriptionally by enzymes expressed temporally in a cell-specific 
manner (19).  GM1 synthesis (Fig. 1.1) begins with the lipid ceramide (Cer) in the 
ER that is transported to the Golgi by the ceramide transport protein, CERT (20).  
Glucose is transferred from uridine diphosphate glucose (UDP-glucose) to Cer in 
the golgi by glucosylceramide transferase (GlcT) which then becomes 
glucosylceramide (GlcCer).  The final step prior to ganglioside production is the 
glycosylation of GlcCer to lactosylceramide (LacCer) by galactosyltransferase I 
(GalT I) from uridine diphosphate galactose (UDP-galactose) (21).   
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Figure 1.1 Ganglioside biosynthetic and catabolic pathway 
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Each ganglioside series is defined by the number of sialic acid groups: no sialic 
acid (0-series), 1 (A-series), 2 (B-series) and 3 (C-series) (19).  Addition of one 
sialic group, N-acetylneuraminic acid (Neu5Ac, sialic acid) to LacCer occurs by 
sialictransferase I (SATI), which produces the GM3-ganglioside (GM3) and leads 
to the A series of gangliosides: GM3-GM2-GM1 (Fig. 1.1 and 1.2) (19).  Sugar 
moieties N-acetylgalactosamine (GalNAc) and UDP-galactose are transferred by 
sequential addition by their respective, specific glycosyltransferases: N-
acetylgalactosaminyltransferase (GalNAcT) (22) to obtain GM2-ganglioside 
(GM2) from GM3, then GM2-GM1 by galactosyltransferase II (GalT II) (19). 
Kotler and colleagues provide a comprehensive review of this process (19).  
The mature gangliosides are transported to the cell surface by vesicular 
transport and become part of the cell membrane.  Eventually, gangliosides are 
endocytosed from the plasma membrane and catabolizing enzymes then 
degrade the mature gangliosides back to their initial components within the 
lysosomes.  The degradation of membrane bound GM1 is processed to GM2 by 
lysosomal acid β-galactosidase, which removes the terminal β-galactose residue.  
This process occurs in the presence of GM2 activator protein and saposin B (23).  
As discussed above, mature βgal activity requires a multienzyme complex of 
sialidase and capthepsin A and the presence of the proteolyzed C-terminal end 
of βgal (16).  The process of ganglioside degradation has been recently reviewed 
(24).   
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Figure 1.2 A Series Gangliosides 
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GM1-Ganglioside Function 
Gangliosides are important components of cell membranes and have 
specific functions in the CNS.  The concentration and complexity of gangliosides 
in the developing brain increase over time and have been studied in both mice 
and humans.  Normal mice have an ~8-fold increase in ganglioside concentration 
from embryonic day E12 to adult (25).  During this time, the composition of 
gangliosides shifts from simple GM3 ganglioside (GM3) (less sugar moieties) to 
complex GM1 and GD1a due to the differential expression of 
glycosyltransferases in neural precursor cells (25).  This process is concomitant 
with neurogenesis and astrocytogenesis.  In the human brain, it has been shown 
that total ganglioside concentrations increase 3-fold from fetal week 10-to-5 
years of age, and during this time GM1 and GD1a increased 12-to-15-fold (26).  
Notably, the GM1 precursors GalCer and sulfatide also increase during 
development, specifically when myelin is forming and oligodendrocytes are 
differentiating (25).  Importantly, mice deficient in glycosyltransferases and 
therefore lacking complex gangliosides, show axonal loss and decreased 
myelination within the nervous system (27).  These findings further support the 
role of complex gangliosides in myelination and neuronal growth in the 
developing brain.  In the adult brain, GM1 is located on the cell surface as a 
component of the membrane, specifically in lipid rafts, and has been shown to 
play a part in cell signaling (28-30).  In these roles, GM1 has been demonstrated 
to have neuroprotective effects.  One example is from an increase in nuclear 
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Ca2+ that can lead to apoptotic cell death, where a complex of GM1 with 
sodium/calcium exchanger NCX facilitates transport of nuclear Ca2+  to the ER 
(31, 32).   
GM1 has been investigated as a therapeutic agent for aging and 
neurodegeneration due to identification of the ganglioside in several diseases.  In 
Huntingtin’s disease multiple groups had discovered a decrease in the amount of 
GM1 ganglioside in animal models of this disease (33, 34) as well as postmortem 
human brain samples (33, 34) and cultured fibroblasts from those patients (34).  
Therapeutic intervention for huntingtin was attempted to increase the amount of 
GM1 by an intraventricular infusion of the ganglioside in a mutant-huntingtin 
expressing mouse.  Excitingly, this infusion led to phosphorylation of the mutant 
huntingtin which rendered the mutant less-toxic, and corrected motor behavior 
(35).  In Parkinson’s disease there has been no association with the disease 
state and the alternation of endogenous levels of GM1, however GM1 has been 
shown to inhibit the aggregation of α-synuclein (36) which is a major component 
of Lewy bodies present in this disease.  In Parkinson’s pre-clinical studies GM1 
was demonstrated to partially restore dopamine levels within the mouse striatum 
after insult (37) and in parkinsonian monkeys (38), and in clinical trial 
subcutaneous administration of purified GM1 has shown great promise in 
improving motor function (39).  In contrast, GM1 presence in Alzheimer’s disease 
has been implicated in the formation of toxic Aβ fibrils by the recruitment of 
soluble Aβ to GM1 on lipid rafts specifically when GM1 is in a β-sheet 
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confirmation (40). GM1 concentration in the brains of Alzheimer’s disease 
patients is significantly increased (41), however various mouse models of this 
disease show either no change or a decrease in GM1 (42).  Interestingly, due to 
its neuroprotective roles GM1 has also been suggested to have therapeutic 
benefits in this disease.  In one study, the pre-treatment of GM1 on rat 
hippocampal slices inhibited Aβ formation as well as the downstream activation 
of apoptosis pathways (43).  Follow up work from this group treated rats with 
GM1 then challenged Aβ fibrils showing that GM1 played a role in preventing 
cognitive decline (44) 
 
GM1-Gangliosidosis 
Disease mechanisms of GM1-gangliosidosis have been examined in 
several studies using GM1-gangliosidosis mice (βGal-/-) (4, 6, 45, 46).  (i) 
Autophagy is a major mechanism driving disease progression in this disease.  
Enhanced autophagy was observed in the brains of end-stage βGal-/- mice, 
where GM1 was highly accumulated, but not in 10-day old mice (45).  (ii) 
Inflammation and associated downstream effects were also identified.  
Jeyakumar et al demonstrated that GM1 accumulation over time resulted in 
inflammation in deep brain structures of the thalamus and brainstem (6).  This 
inflammation leads to expression of activated macrophage or microglial cells, 
major histocompatibility complex class II (MHC class II) positive cells and nitric 
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oxide (NO) formation (6).  NO accumulation leads to oxidative damage and can 
result in neurotoxicity (47). Inflammatory cytokines tumor necrosis factor alpha 
(TNF-α) and interleukin 1 beta (IL-1β) were also seen at the site of GM1 storage, 
however transforming growth factor beta (TGFβ1) was only in end stage βGal-/- 
mice providing a time course response to accumulation (6). (iii) ER stress was 
also shown to be factor leading to neurodegeneration.  Tessitore et al 
investigated the excessive accumulation of GM1 in neurons, stress on the ER, 
and initiation of the unfolded protein response (UPR).  They show that these 
actions lead to apoptosis, but that those effects were not seen in a double 
knockout mouse that did not produce GM1 (4).  Further work from this lab 
demonstrated that the apoptotic effect was due to Ca2+ flux caused by GM1 
presence from ER to the mitochondria, creating membrane permeabilization on 
the mitochondria leading to mitochondrial-mediated apoptosis (5).   
Taken together, these studies demonstrate that a cascade of events 
beginning with accumulation of GM1 within the lysosome and initiation of 
compensatory mechanisms results in upregulation of autophagy.  Continued 
accrual of GM1 storage recruits inflammatory cytokines and accumulation of 
neurotoxic NO species.  Concomitantly, GM1 accumulation activates the UPR, 
causes Ca2+ flux through the ER membrane and results in apoptosis from the 
mitochondria.  
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Animal Models of GM1-Gangliosidosis 
 
Murine Models 
Two models of GM1-gangliosidosis currently exist for mice.  (i) Matsuda et 
al produced a mouse through insertion of a neomycin and herpes simplex virus 
thymidine kinase (tk) gene into exon 15 of the GLB1 gene in murine ES cells (48-
50).  (ii) Hahn et al created a mouse also through an insertion of the neomycin 
cassette with a downstream tk gene into ES cells, however this insertion was into 
the middle of exon 6 of the GLB1 gene (51).  Both of these models result 
phenotypically in the same βGal-/- mouse.  They are both authentic 
representations of GM1-gangliosidosis with minimal exceptions.  Each model 
resulted in disruption of the GLB1 gene, loss of the βgal enzyme (50, 51) and 
subsequent storage of GM1 ganglioside within the CNS from birth (50, 51) with 
corresponding histological and neurological phenotypes (48, 49, 51).  
Interestingly, two β-galactosidases, lysosomal acid β-galactosidase and 
galactocerebrosidase, previously identified in human brains, were found to be 
capable of degrading GM1, GA1 and the experimental substrate 4-
methylumbelliferyl β-galactoside in vitro, albeit with different efficiencies (52).  
Evidence that these two β-galactosidases can act on GM1 and corresponding 
substrates could lead to the low level of βgal activity found in the CNS (1-4%) as 
well as visceral tissues (1-8%) in both mouse models (50, 51).   
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Notably, GM1 content (µmol/g) in a the CNS of a 2.75 month old βGal-/- 
mouse was shown to be equivalent in concentration to an 8 month old infantile 
GM1 gangliosidosis patient (51).  Despite the early accumulation of GM1 outward 
phenotypes do not present until ~4 months of age (48, 51).  Both mouse models 
also demonstrated a higher total percentage accumulation of the GM1 asialo 
derivative GA1 (GM1 lacking the sialic acid group) present in the CNS compared 
to humans (49, 51, 53-55).  This finding suggests that an alternate catabolic 
pathway utilizing sialidase is more active in the mouse than in humans.  
Interestingly, GM1 synthase activity was not found to be altered  in a βGal-/-  
mouse in response to storage of the ganglioside, however patient fibroblasts 
from early infantile GM1 patients showed a compensatory down-regulation of the 
synthase that was correlated with decreased active βgal enzyme (56).  This 
indicates that there is a feedback mechanism for regulation of GM1 content by 
GM1 synthase, however in these mouse models with alternate catabolic 
pathways, this feedback is somehow disrupted and may be one factor for the late 
onset of disease phenotypes.  
Vacuolated neurons (50) and then severe gliosis were identified 
throughout the CNS and also increased with time (49, 51).  In the mouse, CNS 
phenotypes of tremor, ataxia, huddled posture when held by tail and abnormal 
gait begin at ~4 months of age and progress until death by emaciation at ~10 
months old (48, 51).  
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In contrast to humans, mice do not have keratan sulfate and therefore the 
bone abnormalities are not present in these animals (49, 51).  Neither 
hepatosplenomegaly, nor correspondingly abnormal urinary oligosaccharides are 
present in the mouse models (50, 51), however thymus, liver, spleen and kidney 
show some pathology of foamy, ballooning or vacuolation phenotypes within the 
lysosome of these organs (49). 
 
Feline Models 
 Feline models of GM1-gangliosidosis are naturally occurring and have 
been identified in Siamese (57, 58) and short-hair domestic cats (57) with slight 
variations between these animals studied.  These models are representative of 
the juvenile form of the disease where CNS and visceral organ involvement are 
present, however with <10% (57), or 15-20% (58) of normal βgal activity in brain, 
kidney, skin and cultured fibroblasts .  In this model, the primary storage material 
is GM1 which accumulates to levels 8-fold higher than normal animals (57, 58).  
These animals have appear normal until 2-3 months (57), or up to 4 months (58) 
of age, however tremors in the extremities are mildly evident .  After the initial 
onset, the disease progresses rapidly with development of ataxia and 
subsequent quadriplegia by 6 months (58) or 7-8 months of age (57).  These 
animals experience corneal clouding, vision loss, an extreme startle response, 
and grand mal seizures by 1 year (57).  Hepatosplenomegaly or cherry red spot 
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in the retina are not present, but vacuolated macrophages and neuronal lipodosis 
results in neuronal degeneration, paralysis and death (57-59).    
 
Canine Models 
 The first dog identified with GM1-ganglisidosis was a mixed breed beagle 
that presented with tremors, ataxia, hyperactivity and visual impairment that 
progressed over a 4 month period.  The animal eventually developed paralysis 
and was euthanized at 9 months of age (60).  Neuronal vacuolation with 
distended cytoplasm and membranous cytoplasmic bodies were found in the 
CNS.  Elevations in GM1 and GA1 were noted in the liver, spleen and grey 
matter of the brain, which corresponded to a large decrease in βgal activity in 
these regions (60).  
Since this time multiple naturally occurring canine models with GM1-
gangliosidosis have been studied including, in English Springer Spaniels (ESS) 
(61), and a Portuguese Water Dogs (PWD) (61, 62), among others.  Both ESS 
and PWD animals are different from the murine and feline models as skeletal 
dysplasia is evident at 2 months of age, and by 4.5 months neurologic 
manifestations of tremor, ataxia, and deteriorating responses from cranial nerves 
are present (61).  ESS puppies with GM1-gangliosidosis are born dwarfed (61).  
These animals progressively decline until requiring euthanasia at 9 months of 
age where grey matter was increased in volume while white matter decreased 
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(61).  Both dogs have <10% βgal activity of wild type (61, 62) and store GM1 in 
the CNS as well as visceral organs  which results in enlarged, vacuolated cells 
(61).  Non-lipid oligosaccharides have also been shown to be stored in the 
lysosome (61).  In addition, these dogs showed decreased myelination 
accompanying the presentation of  astrocytosis, microgliosis and minimal 
macrophages in the CNS (61).  However, due to the heterogeneity of phenotypes 
in these animals, classification as to disease form in relation to human 
manifestation was not made.   
In Shiba Inu dogs extensive study has occurred which advances the 
therapeutic investigation into GM1-gangliosidosis in humans.  These dogs differ 
from the  ESS and PWD model as no skeletal abnormalities, dwarfism, seizures 
(63, 64) or hepatosplenomegaly (63) were present in these animals. In addition, 
the course of the disease is slightly delayed with progressive neurological decline 
beginning at 5-6 months of age including tremors, ataxia, intermittent lameness 
and loss of balance resulting in an inability to stand by 8-10 months of age (63, 
64).  Visual impairments with corneal clouding, muscle rigor and lethargy (63, 64) 
lead to the animals being sacrificed at 14-15 months old (63).  Vacuolated 
lymphocytes (63, 64) and distended neurons with membranous cytoplasmic 
bodies were present in the CNS (64).  Severe reduction in βgal corresponded 
with increases in GM1-ganglioside 10-20 fold normal in the brain (64).  Serial 
magnetic resonance imaging (MRI) had also been performed on these animals 
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showing progressive hyperintensity in white matter of the cerebrum beginning at 
2 months of age and progressing through the course of the disease (65).   
Studies in Shiba Inus have provided new tools for the diagnosis and 
monitoring of GM1-gangliosidosis (65-67).  Satoh et al profiled the cerebral spinal 
fluid (CSF) of affected GM1-gangliosidosis canines and determined molecular 
signatures which indicate increases ganglioside concentrations and 
corresponding downstream effects until the humane endpoint (67) . Changes in 
aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) increased 
until 7 months (67) of age which was hypothesized to represent leakage from the 
neurons as noted in other brain disrupting disorders.  LDH has been indicated as 
a biochemical measure of cytotoxicity (68).  In addition, more classical markers of 
degeneration or neuronal injury, neuron specific enolase (NSE) in the CSF (69, 
70) was correlated with disease progression in these animals (67).  Myelin basic 
protein (MBP) rose in CSF, but only after 9 months of age when it is suspected 
that myelin degeneration occurs in these animals (67).  More recently, a matrix-
assisted laser desorption ionization time-of-flight mass spectrometry (MALDI 
TOF) method was developed for GM1 ganglioside in the CSF of these animals 
(66). 
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Additional models 
 Other species with naturally occurring GM1-gangliosidosis include bovine 
(59, 71), sheep (72, 73) and black bears (74).  Practical considerations of 
housing and studying such large animals do not lend these models easily to 
preclinical therapeutic investigation.   
 
 
Current Therapeutic and Non-Viral  
Approaches for GM1-Gangliosidosis 
 
Clinical Approach 
 Despite significant research efforts, there is currently no cure for GM1-
gangliosidosis.  In the clinic the only treatment options are palliative.  One 
therapy employed is substrate reduction therapy (SRT), with a drug named 
Miglustat (75-77). This orally administered therapy aims to reduce GM1-
ganglioside accumulation by the inhibition of glycosylceramide synthase which in 
turn depletes GM1 precursor glycoslceramide (78).  This regimen provides 
temporary modulation of symptoms in some patients although the disease still 
eventually progresses.  Known side effects of Miglustat include chronic diarrhea 
and weight loss which makes it intolerable for certain patients (75-77).    
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Molecular Chaperone and Substrate Reduction Therapy 
Currently, all other therapeutic approaches for GM1-gangliosidosis are in 
preclinical studies.  Matsuda et al are utilizing molecular chaperone therapy 
which targets a specific mutation in the β-galactosidase enzyme (79).  The 
objective of this therapy is to stabilize unstable and/or misfolded enzymes by the 
chaperone so it can be properly transported to the lysosome.  In mice, chaperone 
N-octyl-4-epi-β-valienamine (NOEV) (79) lead to increased amounts of active 
βgal and reduced the storage of GM1 with minimal to no adverse responses.  
The limitation of chaperone therapy, however is that they are mutation specific 
and therefore lack application in the remaining GLB1 resulting diseases.  To 
increase the utility of chaperones, a combined treatment with SRT has also been 
attempted. Glycosphingolipid biosynthesis was targeted by competitive inhibition 
with imino-sugar N-butyldeoxygalactonojirimycin in mice (80) which successfully 
reduced total brain ganglioside as well as GM1-ganglioside content.  In addition, 
an sp2-immunosugar analogue SRT-chaperone combination in vitro (81) was 
able to increase βgal activity at levels similar to NOEV. 
 
Bone Marrow or Cell Transplantation 
The transplantation of bone marrow or intracerebral cell transplantation 
has been investigated for GM1-gangliosidosis in GM1 dogs (82),  a human 
patient (83) and in mice with a mixture of cell types (84).  In these studies, 
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successful donor cell engraftment was achieved, but therapeutic levels of βgal 
were not detected in the CNS and therefore disease progression and 
neurodegeneration occurred (82-84).  Possible causes for the lack of therapeutic 
efficacy include the low level of endogenous enzyme from donor-derived 
migrating microglia (82, 83) and/or eventual rejection of newly resident cells (84).  
 
Enzyme Replacement Therapy 
Enzyme replacement therapy (ERT) is the practice of introducing 
recombinant enzymes into the organism by direct injection into the parachyma or 
vascular system.  These enzymes are taken up via endosomes which contain a 
mannose-6-phosphate receptor (M6PR) on the surface that targets the payload 
to lysosomal compartments.  Utilizing the property of cross correction (Fig. 1.3), 
those cells that receive the metabolically active enzyme are also able to excrete 
the from the loaded endosomes into the intracellular space to be taken up by 
neighboring cells (85-88).  ERT has been investigated in GM1-gangliosidosis 
feline models, but no preclinical study has been published (89, 90) and this work 
has not advanced to human trials.  
Disorders of the CNS are a challenge for intravenous ERT because the 
blood brain barrier restricts the entry of large, charged molecules into the 
parenchyma (91).  Furthermore, the differential expression of M6PR such as in 
the skeletal 
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Figure 1.3 Cross correction mechanism  
 
  
22 
 
muscle of patients with the LSD Pompe disease can hinder therapeutic success.  
In Pompe disease, ERT presents a challenge as not only the uptake of the 
extracellular enzyme is restricted (92), but mouse studies suggest a decline in 
intracellular trafficking to the lysosome as indicated by reduction in storage 
clearance (93).  One strategy to circumvent this obstacle utilized β2 agonist 
Clenbuterol as an adjunct therapy to enhance M6PR expression in skeletal 
muscle and lead to increased enzymatic efficacy with ERT (94).   
New approaches to deliver recombinant enzyme to the cerebral spinal 
fluid (CSF) either by intrathecal (IT) injection alone or in combination with 
intravenous (IV) administration indicates positive advancements in ERT in 
several models. An IT and/or IV approach in the LSD mucopolysaccharidosis I 
(MPS1) dogs (95-98) or cats (99) have shown great promise in increasing 
enzyme activity in the CNS.  In addition, intracranial infusion in the lateral 
ventricles in the LSD late infantile neuronal ceroid lipofuscinosis (LINCL) mouse 
(100), wild type rat and non-human primates (NHP) (101) have shown moderate 
to extreme effectiveness in targeting the CNS.  In larger models of dogs and 
NHP’s, a gradient of enzyme concentration were demonstrated where areas of 
the brain closest to CSF at high levels and distal parenchyma considerably lower, 
however still above therapeutic range (95-97, 101).  Sly et al indicate that the 
mannose receptors present on macrophages and Kupffer cells are responsible 
for the initial clearance of available enzyme from plasma shortly after 
administration of ERT (102).  They suggest that previous approaches to ERT 
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using high doses saturated these receptors and allowed for uptake by M6PR and 
subsequent entry into the CNS.  A final approach for the delivery of recombinant 
enzyme aims to capitalize on maternal transmission of IgG for therapeutic 
intervention in utero.  This study in the LSD mucopolysaccharidosis VII (MPS VII) 
mice used β-glucuronidase tagged with an Fc receptor (103).  Despite low 
amounts of enzyme transferred to the fetus, this route has the potential to 
combat prenatal disease phenotypes and provide tolerance to the absent 
enzyme.   
Limitations to ERT include the need for expensive, frequent injections, or 
lack of endogenous protein in the host leading to the production of neutralizing 
antibodies.  In addition, the absence of M6PR in certain diseases or cell types 
can result in less uptake of enzyme, the culmination of which is reduced efficacy 
in this therapy.      
 
Gene Therapy for Lysosomal Storage Disorders 
 
Gene Therapy Overview 
The use of gene therapy for lysosomal storage disorders is quite 
promising.  Gene therapy works on a simple premise – the addition or depletion 
of a gene into the system to achieve a therapeutic impact.  As recessive 
diseases, LSD’s are well suited for this therapeutic modality.  In addition, the 
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majority of these diseases involve secreted enzymes that can also benefit from 
cross correction, where a transduced cell can essentially become an enzyme 
producing factory for neighboring cells (Fig. 1.3) (85-88). 
Gene therapy can be employed as a modified viral vector, or utilizing non-
viral approaches such as liposomes, polymers and modified peptides.  For a 
comprehensive review on non-viral gene therapy, refer to O’Mahony et al (104).  
In viral gene therapy, the choice of which vector is appropriate is dependent on 
factors such as transgene size, cell type transduction, route of administration, 
integration capabilities and potential immune responses (105, 106).  Lentiviral 
(LV) based vectors have a capacity up to 8kb in a single stranded (ss) RNA 
genome, transduce dividing and non-dividing cells, can randomly insert into the 
genome and have the risk of immune responses.  Adenoviral (Ad) vectors have a 
transgene capacity of 36kb in a double stranded (ds) DNA genome, transduce 
dividing and non-dividing cells, show no integration into the host genome are 
highly immunogenic and can lead to toxicity in the CNS.  Herpesviral (herpes 
simplex virus-1, HSV-1) vectors have an extra large capacity of 150kb in a 
dsDNA genome, transduce only dividing cells, do not integrate into the host 
genome, and have a high risk of immune reactions.  Recombinant adeno-
associated viral (AAV) vectors have a capacity of up to 4.7kb, in a ssDNA 
genome, transduce both dividing and non-dividing cells, are not known to 
integrate into the host genome (wild type AAV can integrate) and have little to no 
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immune concerns.  For a review on viral gene therapy refer to Giacca and 
Zacchigna (105) and Byrne et al (106).   
For the work in this thesis, AAV has been chosen as the therapeutic 
vector due to the transduction capability in non-dividing cells and safety aspects 
of this virus.  A detailed overview of AAV is provided below. 
 
AAV Virology  
AAV was originally identified as a contaminant of an adeno-viral 
preparation and was hence named adeno-associated virus (107).  AAV is a 
linear, single stranded, non-enveloped virus, with a molecular weight of 1.4x106 
Da (108).  It is a DNA parvovirus of the dependovirus group which is replication 
deficient, and as the name implies, depends on another virus for replication 
(107).  The wild type virus consists of two 145bp inverted terminal repeats (ITR) 
which contain elements that allow packaging of the viral DNA into the capsid 
(108, 109).  Two open reading frames encode the Rep and Cap genes which 
function in the replication and capsid formation of the virus (110).  Three 
structural Cap proteins VP1, VP2, and VP3 exist at a ratio of 1:1:18, where VP1 
expresses from the translation initiation codon, VP2 and VP3 results from 
alternate splice sites expressed from two possible initiation sites either ACG or 
AUG (111).  More recently, a 23kDa protein has been identified from an alternate 
open reading frame (ORF) within the Cap gene (112).  This assembly-activating 
protein (AAP) assists in the targeting of capsid proteins to the nucleous for 
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capsid formation (112, 113) by interaction with the C-terminus of the VP proteins 
(114).  In general, capsid proteins function in cell recognition, entry, trafficking, 
uncoating, assembly and export. The structure of the capsid is a T=1 
icosahedral, created from 60 total monomers of VP1, VP2, and VP3 proteins.  
The capsid is ~25nM in diameter (107). The Rep gene functions in DNA 
replication as well as expression of the AAV and encodes for 4 proteins.  
Transcription of Rep78 and Rep68 come from p5 promoter and are controllers of 
the AAV lifecycle, where Rep52 and Rep40 initiate from a downstream p19 
promoter.  AAV DNA is packaged as equal amount of either plus or minus ss 
genomes, and in the nucleus exists as a linear monomer, linear oligomers or 
duplex circles (108) or after transduction they exist as concatemers which are 
multi head to tail linear or circular dsDNA (115).   
AAV enters the cell by interactions on the AAV capsid to receptors on the 
cell surface and into clathrin-coated vesicles via receptor-mediated endocytosis 
(116-118).  Each capsid has a different composition and therefore a variety of 
receptors play a role in cell entry.  More than 100 different versions or ‘serotypes’ 
of AAV have been identified which have been isolated from various species (119-
121).  However, serotypes of AAV capsids are not the classical definition as 
these capsids are not immunologically distinguished.  The natural variations of 
these capsids lead to the ability to target a variety of cell populations.  For 
example, AAV1 and AAV6 bind α2,3 and α2,6, N-linked sialic acid (122, 123) 
with a coreceptor for AAV6 of epidermal growth factor receptor (124).  AAV2 and 
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AAV3 have a primary receptor of heparin sulfate proteoglycan (HSPG) binding 
domain (125) both with coreceptors of 37/67 kDa laminin receptor where this 
receptor also binds AAV8 and AAV9 (126).  AAV2 has additional co-receptors of 
the fibroblast growth factor receptor (FGFR) (127), hepatocyte growth factor 
receptor (HGFR) (128) and integrin α5β1 (129).  AAV4 and AAV5 both use α2.3 
O-linked sialic acid (130, 131) with a co-receptor for AAV5 of platelet-derived 
growth factor receptor (132).  Finally, AAV9 primarily binds galactose (133).  Zinn 
and Vandenberghe provide a review of capsid evolution and tropism (134).  
Taken together, these studies allow for the intentional selection of capsids and in 
turn, specific cell populations and tissue targets according to experimental needs.  
After cell entry, endosomes bearing AAV’s are then trafficked to the golgi 
(118, 135), and interact with microtubules associated proteins (136, 137).  
Endosomal escape occurs as a change in conformation from the VP1 and VP2 
proteins leads to exposure of the N-terminus (138-140) with phospholipase A2 
domains (141) and nuclear localization signals (142, 143).  Recent reports 
indicate that nuclear entry occurs through the native nuclear import pathway, 
using the host cell’s machinery to enter the nuclear pore complex (144).  
Uncoating of the virus occurs in the nucleus (145-147). Two theories then exist 
for transgene expression i) second strand synthesis (148, 149) and ii) recruitment 
of plus and minus ssAAV genomes (150).  i) Second strand synthesis is where 
the ssDNA then converts into dsDNA which is believed to be the rate limiting step 
to gene expression (148, 149).  The generation of the second strand occurs as 
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the ITR’s fold upon each other to form a hairpin (151).  Only 125 nucleotides of 
the 145bp in the ITR are complementary, where unpaired bases are named the 
D sequence.  DNA polymerase then synthesizes the second strand using the ITR 
as the origin of replication.  ii) Recruitment of plus and minus strands occurs by 
first an accumulation of linear ssAAV genomes in the nucleus from AAV viral 
particles that contain either a plus or minus ss genome.  The plus and minus 
strands then self-anneal and form a double stranded (ds) linear genomes which 
are then converted to ds circular monomers (150).  Combination of the 
monomers to concatemers occurs through the intermolecular recombination of 
the ITRs (152).  All ds forms are thought to be able to produce transgene 
expression (152, 153).  AAV can persist within the nucleus of a non-dividing cell 
and produce transgene product for extended, unknown periods (>10 years) if not 
subject to an immune response elicited by the transgene (154) or capsid (155, 
156).   
When not replicating, wild type virus can use the ITR’s and the Rep 
protein to integrate into the genome in a site specific manner into human 
chromosome 19q (AAVS1) locus which contains a Rep binding element (157, 
158), and occurs in 0.1% of wild type infecting genomes.  In contrast, 
recombinant AAV (rAAV) is not thought to integrate as long as no Rep gene is 
present in the rAAV transgene (159).  The non-replicative nature of rAAV’s lends 
to safety of the vector in therapeutic application.  In addition, no known disease 
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has been caused by a wild type virus despite >90% of humans being seropositive 
(160).   
 
AAV as a Gene Therapy Vector 
In the creation of viral vectors for therapeutic intervention a dual vector 
approach was developed which removes all replicative and structural proteins, 
only retaining the ITR’s for packaging (161).  In this system, the Rep and Cap 
genes are provided in trans by an adenoviral helper plasmid while the AAV DNA 
of those genes are replaced with the transgene of interest (162).  AAV2 wild type 
ITR’s are retained for packaging with the AAV2 specific Rep gene, however the 
supplied Cap genes determine the resulting capsid which then provide user 
specificity and determine cell or tissue tropism as detailed above. AAV’s have a 
packaging capacity of 4.7kb which can be limiting if employing a large cDNA or 
promoter.  However, if the gene of interest is small, a self complementary (sc) 
AAV is also an option, which has a packaging capacity of 2.2kb.  scAAV’s have 
the added benefit of fast transcription as it bypasses the need for second strand 
synthesis by packing inverted terminal repeat DNA (163, 164).   
 
Distribution of Lysosomal Enzymes in the Brain 
Lysosomal enzymes distribute through the CNS in multiple ways including 
diffusion (165-167), axonal transport (167), and CSF (167).  Formative work in 
this area was performed using AAV2-human β-glucuronidase (GUSB), and 
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corresponding adult mucopolysaccharidosis MPS VII mice (165).  Diffusion is 
described as a sphere of enzyme in cells surrounding the injection site.  
Therefore, enzymes found in distal sites but lacking mRNA presence are 
investigated for axonal transport.  Injections into brain regions with known axonal 
connections were performed into the hippocampus or dentate gryus.  This 
resulted in enzyme expression which lacked mRNA presence in those predicted 
axonal connections in the contralateral hemisphere as early as 1 month and up 
to 18 months post-injection (165).  Hippocampal injections demonstrated enzyme 
activity related to the clearance of storage product from axonal connections, but 
not in structures close to the injection site which do not have direct connections.  
This result indicated axonal transport and not diffusion lead to the clearance.  
Finally, injection into the subventricular zone (SVZ) resulted in enzyme 
expression, but not mRNA, in cells in the olfactory bulb demonstrating cross 
correction by secretion of GUSB from the SVZ and uptake by cells of the rostral 
migratory stream (RMS) (165).  Davidson and colleagues further investigated the 
MPS VII mouse model utilizing AAV4-RSV-human β-glucuronidase unilaterally 
into the lateral ventricle of adult mice (166).  Diffusion into the extracellular space 
from ventricular spaces, transduced ependymal cells, in conjunction with 
endocytosis and cross-correction in both the RMS and the SVZ lead to enzyme 
expression in the olfactory bulb.  In addition, movement of enzyme through the 
CSF led to enzyme positive cells which were found near microvasculature 
throughout the cerebrum, cerebellum and brain stem, and resulted in large 
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reduction of storage materials and pathology as well as improvement in 
behavioral deficits (166).  Work investigating GM1-gangliosidosis in adult mice 
with AAV1-mouse-βgal injected into the hippocampus showed presence of the 
enzyme βgal in projections consistent with anterograde transport, evidence of 
diffusion as indicated by enzyme activity in the surrounding cortex without mRNA 
presence, as well as enzyme activity in the leptomeninges and perivascular 
space indicative of CSF flow dissemination.  A resulting correction of storage 
material was associated with all regions positive for enzyme.  This study also 
exhibited  anterograde and retrograde transport of mRNA as determined by in 
situ hybridization in the contralateral hippocampus and along the perforant 
pathway, respectively (167).  
 
Targeting of the Central Nervous System in LSDs 
Advances in targeting the CNS for treatment in LSDs have occurred 
through the injection of highly connected structures in the brain and development 
of new AAV capsids.  A variety of novel AAV serotypes have been discovered 
whose tropisms provide gene therapy with many options for brain targeting (168-
171).  In a study utilizing MPS VII mice, AAV9-hGUSB injected into the striatum, 
hippocampus and ventral tegmental area (VTA) resulted in widespread 
distribution of vector mRNA and enzyme distal to the injection site which followed 
known projection sites specific to those targets.  This work also presented 
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variable distribution patterns from AAV1, 9 and rh10 injected into the VTA. In 
addition, AAV9-CY3 vector provided evidence of viral presence in neurons at 1 
and 24 hrs post injection indicating distribution by fast axonal transport (170).  
Further work by this group evaluated 17 additional serotypes in neonatal brains, 
and further studied 6 of these in adult mice based on ability to transduce brain 
tissues after lateral ventricular injection (169).  In this study, AAV-GFP injections 
into adult mouse cortex, striatum, hippocampus and thalamus indicated that rh8, 
hu48R3, hu11, pi2, hu37, and hu32 all transduced more brain volume and cells 
than AAV9.  However, all but hu37 and hu48R3 were in distal sites with known 
projections indicating axonal transport.  Overall, AAVs appear to trend toward 
neuronal transduction, and all but hu37 also transduced astrocytes and 
oligodendrocytes which can be important in additional CNS diseases specifically 
those involving demyelination (169).  The Bankiewicz group continued to 
investigate axonal transport in the primate brain with AAV2-glial-derived 
neurotrophic factor (GDNF) and also with non-secreted AAV2-GFP injected into 
the thalamus, where both provided delivery to the neurons of the cerebral cortex, 
a known destination for efferent projections and indicative of anterograde 
transport (172).  In further studies, this group also examined AAV2 or AAV6-GFP 
in the thalamus or striatum of rat brain, where thalamic injection resulted in GFP 
positive cells in the striatum with AAV2, but not AAV6, indicating a lack of 
anterograde transport with this capsid (171).  Conversely, striatal injection of 
AAV6 provided GFP expression in the cortex, thalamus and substantia nigra pars 
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compacta, but not substantia nigra pars reticulata which receives projections 
from the striatum.  However, GFP positive fibers were found within the substantia 
nigra pars reticulata indicating the transduction of GABAergic neurons. This work 
implies a bias of AAV6 towards retrograde transport in the areas examined and 
demonstrates that the direction of axonal transport is serotype dependent (171).  
Recently, a study comparing the transport of AAV1, 8 and 9 in rat cultured 
cortical neurons and in vivo showed that conserved anterograde and retrograde 
axonal transport mechanisms existed in all three serotypes, and that increasing 
vector uptake by an increase in receptor availability lead to greater axonal 
transport (173).  Additional studies focused on targeting the cerebellum were 
performed in mouse model of the LSD Niemann-Pick type A where the loss of 
Purkinje cells is a major phenotype (174).  This work investigated AAV’s 1, 2, 5, 
7, and 8 encoding human acid sphingomyelinase (ASM) with bilateral injections 
into the deep cerebellar nuclei (DCN), a known projection site for Purkinje cells 
and highly connected to the brain stem and spinal cord.  Results suggest AAV1 
and 8 to be most widespread in the transduced area, where amount of enzyme 
expression and clearance of storage material appeared throughout cerebellum 
and surprisingly provided a reduction in storage in the cerebrum however without 
overt enzyme presence.  Cell type transduction also varied, with AAV1 and 5 
mainly transducing Purkinje cells, AAV2 in granular neurons, and AAV7 and 8 
mostly in the molecular layer (174).   
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Potential Limitations to CNS Centric Approaches for LSD’s 
Considerable progress has been made in treatment of lysosomal storage 
diseases with central nervous system involvement.  However, while CNS 
directed therapy mitigates the primary cause of mortality, additional phenotypes 
from peripheral involvement become more prominent.  Successful treatment of 
the CNS was achieved in a mouse model of the LDS GM2 gangliosidosis, also 
known as Sandhoff disease (175).  This study utilized AAV1-hexα and AAV1-
hexβ plus 20% wt/vol mannitol with bilateral injections into striatum and DCN 
which resulted in unprecedented survival.  Interestingly, despite successful 
correction of storage material throughout most of the CNS, many of these 
animals eventually succumbed to unanticipated peripheral organs disease, such 
as the urinary bladder and/or colon which was attributed to autonomic 
neuropathy (175). 
 
Ex-vivo Lentiviral Modification Approaches for LSD’s 
Ex-vivo lentiviral (LV) mediated genetic modification of autologous 
hematopoietic stem and progenitor cells (HSC/HSPC) can be a useful technique 
to treat lysosomal storage disorders; however this method also faces some 
challenges. The treatment of LSD in the CNS has been shown to be extremely 
effective as it was revealed that donor HSPC’s will enter the CNS, differentiate 
into microglia and engraft into the brain; a process that is enhanced by exploiting 
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intrinsic properties of these cells to migrate to the site of neuronal damage (176).  
A study investigating the LSD metachromatic leukodystrophy (MLD) utilized 
either modified purified donor HSPC’s from mutated arylsulfatase A mice (As2-/- 
MLD) transduced with a lentiviral vector (LV) encoding the missing arylsulfatase 
A (ARSA) enzyme, or non-modified HSPC’s from wild type (WT) mice.  
Transplanting mice with LV modified HSPC’s, but not WT HSC’s, resulted in 
repopulation of CNS and PNS microglia and macrophages respectively, as well 
as restored enzyme activity leading to resolution of storage material, and 
provided almost total protection from demyelination where motor, learning and 
coordination functions were retained.  These results indicate cross correction 
resulting from higher levels of enzyme from LV donor cells is necessary to 
achieve therapeutic benefit in this model. Trepidation regarding this therapy is 
from the possibility of insertional mutagenesis (177).  Visigalli et al used LV 
HSPC transplantation in the adult LSD MPS I mouse (178).  This study 
demonstrated a dose dependent correlation to therapeutic outcome, with ~100 
fold > WT expression of enzyme activity from circulating hematopoietic cells 
necessary to attain absolute resolution of disease.  Most notably, this was the 
first report showing correction of neurological and skeletal abnormalities in this 
model. They also revealed that this supranormal level of expression had no 
negative impact on the functionality of HSPC’s in vivo, and that considerably 
lower LV copy number (1 vs 5 on average) may be required for similar 
expression in human HSPC’s where the phosphoglycerate kinase promoter in 
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the transgene is more effective (178).   In some systems however, 
overexpression of an enzyme can have toxic implications as identified in the 
mouse model for the LSD Globoid cell leukodystrophy (GLD or Krabbe disease) 
where cultured GALC -/- mouse cells transfected with LV galactocerebrosidase 
(GALC), but not with LV GFP resulted in apoptosis, and LV GALC HSPC 
transplanted GALC -/- mice failed to engraft and had a severely reduced life span 
(179).  An elegant solution to this issue was provided by the discovery that 
microRNA-126 (miR-126) was enriched in HSPC’s, but severely decreased in 
differentiated hematopoietic cells.  To this end, a microRNA de-targeting 
sequence (miRT) was added into the transgene and effectively regulated 
expression only to differentiated cells.  Indeed, when applied to newborn GALC-/- 
mouse, the LV GALC-miRT-126 transplanted HSPC’s led to increased enzyme 
activity in brain and liver, diminished storage and neuroinflammation, protection 
from peripheral demyelination and overall phenotypic improvement and survival 
(179).  Another potential limitation in the treatment of some LSD’s is the rapid 
progression of symptoms that may exceed the ability for efficient transgene 
expression through HSC therapy.  For effective enzyme expression utilizing 
HSC’s, enzyme deficient brain microglia must be replaced by LV modified HSC 
progeny, which can be a lengthy process.  However, utilizing direct AAV brain 
parenchymal injections can reduce the time for therapeutic onset with expression 
ensuing in 3 weeks or less (180).   
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Systemic Administration of AAV Vectors for the CNS 
Advent of new AAV vectors capable of targeting the brain after systemic 
delivery provides a therapeutic approach that may bridge the gap between direct 
CNS and peripheral treatment modalities.  Successful demonstration of an IV 
approach resulting in AAV delivered transgene expression in the brain was 
shown with scAAV9-GFP injection into the facial vein of day 1 C57BL/6 mice or 
the tail vein of adult mice (181).  This study established a tropism for transgene 
expression in the lower motor neurons (LMN) of the spinal cord, and pyramidal 
and Purkinje neurons in the brain from neonatal injections.  However, a 
considerable reduction of LMN targeting from adult injections indicating restricted 
access to these cells in the post-developmental period.  In contrast, adult 
injections led to mainly astrocyte transduction which were previously inaccessible 
utilizing parenchymal administration (181).  Additional systemically delivered AAV 
serotypes were identified by injection into P1 neonates with scAAV-GFP into the 
superficial temporal vein (182).  This study characterized AAVrh.10 > rh.39 > 
rh.43 as serotypes with similar or enhanced AAV transduction as compared to 
AAV9 in the brain, and AAVrh.43 > rh.39 > rh.10 in the spinal cord with gray and 
white matter GFP expression.  Transduction of lateral, 3rd, and 4th ventricles, 
specifically in choroid plexus cells, were greatest in AAVrh.39 > rh.10 > rh.43 > 7 
and followed by 9, where a descending gradation of expression was evident as 
distance from the ventricles increased.  Finally, it was determined that this 
intravascular delivery did not activate microglial cells at the 3 week post injection 
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time point as compared to PBS or non-injected controls indicating a lack of 
immune response to this approach (182).  Another direct comparison of vectors 
was performed in adult C57BL/6 mice which gave a profile of vectors in 
descending order of transduction capacity using GFP in the brain and spinal 
cord:  AAVrh8 = rh10 = 9 > 8 = 7 = hr.43 = rh.39 > 6.2 > 6 > 1 > 2 (183).  Further 
providing a transition into human studies, NHP were injected with scAAV9-GFP 
into the saphenous vein at P1, 30, or 90, or into the thoracic cord at 3 years of 
age (184), and recently with scAAVrh.10-GFP into the saphenous vein in adult 
marmosets with or without detargeting sequences miR1 and miR122 3x for heart 
and muscle or liver detargeting, respectively (183).  The AAV9 animals all 
resulted in GFP expression throughout the brain in a pattern similar to the mouse 
study, however with minimal neuronal cells and a predominance of microglia and 
astrocytes targeted at all ages of NHP’s tested (184).  Spinal cord analysis 
revealed efficient motor neuron transduction through the entire length of the 
tissue in P1-P90 animals, and in the 3 year old NHP a similar pattern of 
transduction, but also with a slight reduction (184).  Peripheral organs affirmed 
previous work with expression evident in all skeletal muscles taken in P1-P90 
samples, with a slight decrease, but discernible in the aged animal; liver, heart, 
adrenal medulla from P1 intestines and testis were also positive in P1-P90 to 
varying degrees and with lung, kidney and spleen showing few positive cells 
(184).  AAVrh10-GFP led to GFP expression throughout the motor neurons in the 
entire spinal cord  (183).  The brain expression was more restricted to particular 
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nuclei such as ventral midbrain, substantial nigra, inferior olivary nucleus, lateral 
reticular nucleus and red nucleus (183).  Excitingly, these results demonstrate 
that motor neurons in the spinal cord (174, 184), and glia in brain of NHP’s (184) 
are accessible to transduction at all ages studied indicating a larger therapeutic 
window for IV treatment of disorders involving these cell types then previously 
believed (184).   
The ability to deliver a therapeutically relevant gene was demonstrated in 
several studies.  Vascular endothelial growth factor (VEGF) in a scAAV9 vector 
was delivered into neonatal and adult mice, produced expression in the brain, 
spinal cord and peripheral organs (liver and heart) and sustained expression 
through the end of the study, up to 5 months post injection (185).  In the lower 
motor neuron disease Spinal Muscular Atrophy (SMA), mice receiving treatment 
at P1-P5 showed therapeutic benefit in lifespan, weight gain and correction of 
synaptic current from an injection of a the missing gene scAAV9-survival motor 
neuron 1 (SMN1) (186).  In the LSD MPS IIIB adult mouse IV injection into the 
tail vein successfully extended survival from 8-12M to >22M (187).  This 
approach normalized rotarod performance, prevented astrocytosis and 
neurodegeneration, transduced neurons, glia and endothelia expressing enzyme 
throughout the brain, heart and muscle at supranormal levels, while normalizing 
enzyme in liver, lung, and intestine, and in turn providing correction of lysosomal 
storage (187).  Ruzo et al investigated the IV treatment of the LSD MPS IIIA with 
AAV9-sulfamidase (Sgsh) in adult mice (188).  In this work enzyme was effective 
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at targeting the CNS, clearing storage and significantly extending lifespan. Once 
again, high liver expression was seen, but was restricted to levels of 5-fold in 
males and wild type levels in females (188). Together, these unprecedented 
results hold much promise for diseases involving CNS, PNS and peripheral 
organ pathology; however extremely high expression in certain tissues could 
indicate a “sink” for which the enzyme accumulates.  If the transgene product is 
expressing at high levels in particular tissues and leads to decreased availability 
to the target organs, a high total vector dosing may be required in order to obtain 
therapeutic impact and could possibly lead to long term toxic effects.  As 
mentioned earlier, microRNA’s are a promising tool to repress expression in non-
desired cell or organ groups. This idea was exploited by engineering miRNA sites 
with perfect complementary to liver miRNA, miR-122 and/or heart and muscle 
miR-1 into the 3’ untranslated region of a nLacZ or GFP transgene packaged into 
AAV9 (189).  This study elegantly revealed that expression of a transgene can be 
modulated with addition of 1 or 3x the miRNA sites corresponding to non-target 
organs. Target transgene mRNA’s were cleaved at expected sites when bound to 
Argonaute proteins, and that this addition does not affect the endogenous 
function of miRNA’s or their target proteins within those tissues (189).    
 
Additional Approaches and Considerations for CNS Gene Therapy 
Targeting to a specific organ or cell type as a source of enzyme 
production is another approach for CNS gene therapy.  One method employed in 
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an MPS III model was to utilize a liver directed promoter within an AAV8 capsid 
using systemic delivery (190).  In this work, IV injection of AAV8 containing a liver 
directed promoter produced wild type or greater levels of circulating enzyme in 
the serum, led to an uptake of enzyme through M6PR on the cell surface and 
resulted in 10% wild type levels in the brain and a significant extension of 
lifespan.  However, this effect was male specific due to the phenomenon 
identified by Davidoff et al where testosterone in the male animals enhanced 
transduction of liver cells (191).  This interesting gender dependent finding was 
also identified within CNS where athymic NU/NU nude and C57BL/6N mice were 
injected with AAV9 expressing firefly luciferase (Fluc) (192).  In this study, Fluc 
expression as well as vector genomes were found to be present in greater 
amounts in female versus male mice.  Taken together, these studies indicate that 
in the IV administration of AAV one must consider a possible liver ‘sink’ for vector 
in male mice that could increase the availability of vector in the other organs of 
female mice and result in differing transduction amounts between the sexes.   
Genetic targeting of disease specific brain endothelium can create a 
localized hub to deliver therapeutic proteins to the brain.  This approach was 
investigated by modification of AAV2 capsid at site 587 (a known receptor 
binding location) after independent 5x phage panning in both WT and two LSD 
mouse models MPS VII or LINCL (193).  Epitopes identified by this screening 
were unique to each mouse model signifying distinctive coinciding alternations in 
the vasculature, and upon tail vein injection of modified capsids only those 
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specific peptides provided novel tropism to the corresponding model’s brain 
microvascular.  CNS therapeutic outcomes included pathological correction, 
enzyme expression, and storage resolution in multiple cell types.  Prevention of a 
tremor phenotype was also noted, indicating cross correction from the 
transduced endothelia, and providing a viable alternative to intracranial injections 
for CNS affecting diseases in which the therapeutic gene involves secreted 
proteins (193).  In a subsequent study, the modified AAV2- brain targeting 
peptides (AAV2-PFG) and AAV9 were compared by injections into the tail vein of 
adult MPS VII mice (194).  Surprisingly, the AAV-PFG-β-glucuronidase (βGlu) 
vector, but not AAV9-βGlu provided enzyme to the brain, reversed storage in the 
CNS, corrected learning phenotypes, and extended survival.  Upon further 
investigation, a novel accumulation of sialic acid in the brain vasculature was 
revealed in the MPS VII mice, which lead to decreased transduction by AAV9 
(194).  This finding is extremely noteworthy, as it is further demonstration that 
despite common traits, researchers must consider biochemical features unique to 
each disease that can affect therapeutic outcomes.  
 
Gene therapy for GM1-gangliosidosis 
Previous attempts at gene therapy based approaches for GM1-
gangliosidosis utilized RV (46), HSV-AAV hybrid (195), adenoviral (AD) (196), 
and adeno-associated viral (AAV) (197-199) vectors.   
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Sano et al used the RV murine stem cell virus to transduce donor derived 
bone marrow cells (BMC) with human-β-galactosidase-(βgal)-GFP and 
introduced by tail vein into lethally irritated, 3-4 week old βGal-/- acceptor mice 
(46).  These modified BMCs were successfully engrafted and expressed enzyme 
in both the CNS and peripheral organs.  Reduction in GM1 storage, cytokines, 
inflammatory markers, unfold protein response hallmarks, as well as a reduction 
in histological pathology was noted from 3-6 months post transplant.  Correction 
from bone marrow transplant (BMT) cells were mostly focused on areas which 
typically undergo inflammatory response in this disease (and thus recruit 
microglia derived BMC’s) such as the thalamus, brain stem, cerebellum and 
spinal cord (6, 46).  Behavior was also significantly improved, but not normalized 
in rotarod and open field testing (46).  Notably, not all mice responded similarly 
which may reflect the success of the integration of the provirus in BMC in 
favorable regions for transcriptional activity, or those BMC that had higher 
transduction efficiencies prior to transplantation (46).   
Oehmig et al employed a hybrid HSV/AAV vector for the integration of 
human βgal gene, GLB1 in vivo in cells of either a GM1-ganglioside patient or 
glioblastoma cell line (195).  Expression of βgal enzyme was successful in 80% 
of clones tested, and provided 2 fold upregulation of activity for up to 4 months. 
Integration of the gene into the AAVS1 site was achieved in 33% of clones (195).   
Takaura et al applied an AD vector encoding mouse-βgal in neonatal mice 
24-48 hrs after birth into the superficial temporal vein (196).  Animals were 
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evaluated at 30 and 60 days post infection.  Both the CNS and periphery 
demonstrated varying enzyme expression and reduction in GM1-ganglioside 
storage in half the animals tested.  Enzyme expression was increased in most 
tissues at 10-20% of wild type levels, but ranged from normalized to 
supraphysiological in the liver, lung and heart.  The authors attribute the 
variability in storage reduction in the CNS to age of injection and the permeability 
of the blood brain barrier (196).   
AAV therapy has been applied in both neonatal (197) and adult mice (198) 
as well as adult cats (200).  Neonatal animals were treated with AAV1-mouse-β-
galactosidase by intracerebroventricular (ICV) injection in P0 mice (197).  At 3 
months post injection, enzymatic activity was significantly increased in all brain 
regions at levels 7-65 fold over wild type controls, but had no effect on the liver.  
Storage of GM1-ganglioside in treated animals was significantly decreased 
versus untreated βgal-/- controls and was similar to wild type levels. Interestingly, 
analysis of neutral and acidic lipid species revealed a reduction in cerebrosides 
and sulfatides (implicated as myelin-enriched lipids) in untreated βgal-/- controls, 
but these lipids were normalized in treated animals (197).  In adult mice at 6-8 
weeks of age, AAV1 was injected bilaterally into the thalamus or the thalamus 
and DCN (198).  In addition, in another set of animals AAV with a liver-specific 
promoter was infused intravenously prior to intracranial injections in order to 
prevent immune responses; however, no immune responses were observed in 
any cohort.  In situ hybridization on sections from thalamic alone injections 
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reveled AAV-transduced cells only in the dorsal and lateral thalamic nuclei and 
slightly in the ipsilateral cortex.  Enzyme expression and ganglioside content 
were analyzed at 1 and 4 months as well as at the humane point (~9 months for 
untreated βgal-/- compared to 12 months in treated mice).  All treatment groups 
resulted in a 10 fold increase in enzyme expression over βgal+/- mice in the 
cerebrum, brainstem and subcortical regions, however only the thalamic + DCN 
group was > 10 fold higher than βgal+/- in the cerebellum.  In contrast, the spinal 
cord was up to ~80% of βgal+/- levels at 4 months and to ~35% at endpoint in 
thalamic alone, versus a consistent ~50% of βgal+/- levels in the thalamic + DCN 
grouping.  Notably, GM1-ganglioside content was similar in reduction for all 
regions in all groups (30-90% of untreated βgal-/- levels) except cerebellum where 
thalamic + DCN provided additional reduction of ~90% versus thalamic alone of 
~25%.  Markers of inflammation were also investigated and were found in the 
same CNS areas that had persisting storage after treatment in βgal-/- mice.  
Survival for both groups were significantly increased to 45 weeks for thalamic 
only and > 52 weeks for thalamic + DCN.  Behavioral tests of rotarod for balance 
and coordination and open field testing did not provide any improvement over 
untreated βgal-/- mice with the exception of the thalamic + DCN group improved in 
distance traveled at and rearing at 2.5 months. 
McCurdy et al presented a study in a feline juvenile GM1-gangliosidosis 
model with AAV1 or AAVrh8 encoding feline β-galactosidase (fβgal) injected 
intracranially into both the thalamus and DCN (200).  This work resulted in 
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enzyme expression from 1.1-4.1 fold normal levels throughout the brain, and 0.9-
4.2 fold normal levels in the spinal cord with both capsids.  GM1 content was 
significantly reduced throughout the brain, but remained above normal in 4/15 
sections of the CNS analyzed including the cervical spinal cord.  The 
development of seizures occurred in 50% of the animals studied long term, but 
was well controlled by medication.  Most importantly, these animals had 
significant extension of life span and obtained re-establishment of breeding 
function which was unprecedented  in this model (200). 
Taken together, studies in this disease either suffered from lack of enzyme 
expression in the intended regions, or a non-significant reduction of storage.  
Often, the lack of therapeutic efficacy resulted in secondary pathology and/or 
eventual disease progression.    
The following chapters will discuss the investigation of a gene therapy 
based treatment for GM1-gangliosdiosis in a βgal mouse model.  In Chapter II, 
an intravenous approach using a rAAV9-mβgal vector led to enzyme activity in 
the CNS, unprecedented motor retention and survival of these animals. In 
Chapter III, an intracranial technique using rAAVrh8-mβgal vector provided 
significant extension of lifespan and motor function, but also resulted in abnormal 
findings.  These unusual results were then investigated in both normal and 
diseased animals leading to a re-engineered vector which provided a therapeutic 
benefit while minimizing negative impact.  Taken together, these studies are an 
important step in the development of a safe and effective gene therapy treatment 
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for GM1-gangliosidosis and, in turn, other lysosomal storage disorders affecting 
the central nervous system. 
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CHAPTER II:  Systemic AAV9 gene Transfer in Adult  
GM1-Gangliosidosis Mice Reduces Lysosomal  
Storage in CNS and Extends Lifespan 
 
Introduction 
 
GM1-gangliosidosis is an autosomal recessive disorder resulting from 
mutations in the GLB1 gene encoding lysosomal acid β-galactosidase (βgal) (3). 
Mutations resulting in enzymatic deficiency lead to storage of a number of 
metabolites in the lysosomes. Namely, storage of GM1-ganglioside (GM1) and its 
asialo derivative GA1 occur primarily in the central nervous system (CNS) (201) 
while oligosaccharides and keratan sulfate accumulate in visceral organs (202).  
GM1-gangliosidosis occurs at a frequency of 1:100K-200K births and manifests 
at different ages: The infantile form is diagnosed in the first 6 months of life, the 
late-infantile/juvenile form manifests between 3 and 36 months of age, and the 
less common chronic/adult form has a wide range of onset from 3-30 years of 
age, and disease progression over 10-30 years (7).  The age of onset is directly 
correlated with the residual activity of mutant enzymes nearly absent in infantile-
associated mutations, and up to 9% of normal in the adult forms (7).  In infantile 
patients the disease is characterized by rapid neurological decline, loss of 
voluntary motor control resulting in generalized paralysis, extreme emaciation, 
and death.  Other organs and tissues are also affected as evidenced by the 
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characteristic hepatosplenomegaly and skeletal dysplasia.  These clinical 
findings are either milder or absent in late-infantile and chronic forms of the 
disease where some residual enzyme activity is present.  Currently there is no 
treatment for GM1-gangliosidosis.   
A number of gene therapy approaches have been tested in animal models 
of GM1-gangliosidosis, including in vivo infusion of adenovirus (196), adeno-
associated virus (AAV)  vectors (197, 198, 200), and ex vivo modification of 
autologous bone marrow stem cells with retrovirus vectors (46).  The feasibility of 
these strategies is based on the ability of genetically modified endogenous cells, 
in vivo or ex vivo, to overexpress and release large quantities of functional 
lysosomal enzymes into the extracellular milieu.  This secretion of enzyme allows 
for its distribution throughout the body via the blood stream. In the CNS several 
mechanisms contribute to the distribution of lysosomal enzymes including the 
flow of cerebral spinal fluid and interstitial fluid, as well as axonal transport (165, 
167, 196).  Most cells in the body are capable of taking up functional lysosomal 
enzymes and target them correctly to lysosomes via mannose-6-phosphate 
receptors on the cell surface (85).  This targeting mechanism is the basis for 
enzyme replacement therapies that are the current standard of care for a number 
of lysosomal storage diseases affecting visceral organs.  This is accomplished by 
regular parenteral infusion of recombinant enzymes. CSF infusion of recombinant 
enzyme is in clinical development for LSDs with neurological features 
(ClinicalTrials.gov: NCT01510028; NCT02055118).  Direct infusion of AAV 
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vectors into CSF or brain parenchyma has been the most effective in vivo gene 
delivery approach in animal models of GM1-gangliosidosis (197, 198, 200) and 
other lysosomal storage diseases with neurological features (97, 98, 100, 203, 
204).  The distribution of AAV vectors after intraparenchymal infusion is largely 
restricted to the injection site, although some AAV capsids also undergo axonal 
transport (168, 170, 171).  One approach to achieve widespread distribution of 
enzymes throughout the CNS via axonal transport is to infuse AAV vectors into 
highly interconnected structures such as striatum (205, 206), deep cerebellar 
nuclei (174), ventral tegmental area (170) or thalamus (198).  In mouse and cat 
models of GM1-gangliosidosis, the combination of bilateral thalamic and deep 
cerebellar injection of AAV vectors has proven exceptionally effective to correct 
lysosomal storage in the CNS (198, 200).  The therapeutic effect of this gene 
therapy approach in GM1 cats is remarkable with nearly complete correction of 
neurological symptoms and dramatic extension in their lifespan with restored 
reproductive capacity (200).  Despite several CNS gene therapy clinical trials 
showing that intraparenchymal infusion of AAV vectors is well tolerated, it is still 
an invasive delivery approach (207-209). 
AAV9 vectors are capable of crossing the blood brain barrier (BBB) after 
intravascular delivery and achieve widespread transduction of neurons and glia 
in neonatal (181) and adult animals (181, 184).  This property of CNS 
transduction after vascular delivery appears to be a property shared by other 
AAV capsids (182, 183).  These new BBB-penetrating AAV vectors are attractive 
51 
 
platforms to address the multisystemic nature of most LSDs as they also 
transduce peripheral organs at high efficiency and thus have the potential to 
become whole body therapies with a single intravascular infusion.  Systemic 
infusion of AAV9 vectors in adult mucopolysaccharidoses (MPS) IIIA (188) and 
IIIB (187) mice has proven highly effective in addressing lysosomal storage in the 
CNS and peripheral organs with resulting extension in lifespan.  Interestingly in 
MPS VII mice it appears the biochemical alterations inherent to the disease 
compromise the therapeutic efficacy of AAV9 (194).  
 In the present study, we assessed the therapeutic efficacy of vascular 
administration of an AAV9 vector encoding mouse lysosomal beta-galactosidase 
in adult GM1-gangliosidosis mice.  A single administration of this single stranded 
AAV vector was sufficient to achieve enzyme expression and reduction of GM1–
ganglioside content throughout the CNS.  Most notably behavioral function 
remained stable longer and the lifespan was significantly increased in all AAV-
treated cohorts.    
 
Materials & Methods 
 
AAV vector design and production   
The vector AAV-mβgal contains a two flanking AAV2 inverted terminal 
repeats, cytomegalovirus enhancer fused to a chicken beta-actin promoter/rabbit 
beta globin intron (210), cDNA of mouse lysosomal acid β-galactosidase, and an 
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SV40 poly A.  Vector stock was produced by transient transfection of 293 cells 
and purified by CsCl gradient ultracentrifugation (UMass Medical School, Gene 
Therapy Center, Worcester, MA). 
 
Animal procedures   
GM1 gangliosidosis mice (51) were obtained from Dr. Kunihido Suzuki 
(Neuroscience Center, University of North Carolina, Chapel Hill, NC).  In our 
studies, animals reach humane endpoint either when paralysis of any limb is 
present or if weight loss is >15% of highest weight achieved per animal. βGal+/+, 
+/- and -/- mice were generated by breeding of male βGal+/- or -/- to female βGal+/-.  
Six-week old mice were injected with 200 µl of AAV9-mβgal vector at 1x1011 or 
3x1011 vg via the tail vein using a 27G insulin syringe (BD Biosciences, Franklin 
Lakes, NJ).  At 3 months, 9 months, or human endpoint, animals were sacrificed 
by an overdose of ketamine/xylazine (Fort Dodge Animal Health, Fort Dodge, IA 
and Lloyd Laboratories, Inc, Shenandoah, IA), cleared by transcardiac perfusion 
with ice cold PBS, and harvested according to assay needs.  One brain 
hemisphere and half a spinal cord was embedded in freezing medium, Neg 50 
(Richard-Allan Scientific, Kalamazoo, MI) and quick frozen in a dry ice/2-
methylbutane bath (ThermoFisher Scientific, Waltham, MA).  The remaining brain 
hemisphere was separated into cerebrum, cerebellum, and brain stem, and, 
along with the second half of the spinal cord, frozen over dry ice and stored at -
80°C.  All other organs were frozen over dry ice or fixed in 4% paraformaldehyde 
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in PBS (Sigma-Aldrich, St. Louis, MO). All procedures were approved by the 
University of Massachusetts Medical School, Institutional Animal Care and Use 
Committee and performed in compliance with the NIH Guide for Care and Use of 
Laboratory Animals.  
 
Histological analysis   
Fresh frozen, sagittal oriented brains and spinal cords were cut in 20 μm 
sections on a cryostat (ThermoFisher Scientific, Waltham, MA) at -12/-13°C.  
βgal enzyme presence was determined by an Xgal assay as described 
previously(197).  GM1 storage was detected by Filipin staining as described 
previously(197).   All histological analysis was performed as non-blinded, 
qualitative analysis on an N ≥ 2-3 animals with representative pictures shown in 
figures. 
 
βgal enzymatic assay 
Tissues were homogenized and βgal activity (nmol/hr/mg protein) was 
determined by reaction 4-methylumbelliferyl (4-MU) assay with βgal substrate = 
1mM 4-Methylumbelliferyl--D-galactoside (4-MUG) with 4-methylumberlliferyl-β-
D-galactopyranoside in a 96-well plate format and normalized for protein content 
by Bradford assay (Bio-Rad, Waltham, MA) as described previously(197).      
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Genome copy number 
Tissue sections were extracted in a DNA clean environment and rinsed in 
sterile PBS. DNA was isolated by Qiagan DNeasy Blood and Tissue Kit (Qiagen, 
Valencia, CA). QPCR was performed on 100-400 ng of genomic DNA using 
Taqman probes (Applied Biosystems, Foster City, CA), with standard curve 
containing a known quantity of reference DNA containing an SV40 poly A. Probe 
to SV40 (TaqMan Probe, 6FAM- AGC ATT TTT TTC ACT GCA TTC TAG TTG 
TGG TTT GTC -TAMRA).  Samples with genome copies ≥ 100 vg/ µg of DNA 
were considered positive for vector genomes.  Data was represented as 
vg/diploid genome considering that 100 ng of mouse genomic DNA corresponds 
to 36,263 diploid genomes.   
 
GM1 ganglioside content  
A liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay 
(Weismann et al, in preparation) was used for quantification of GM1-ganglioside 
in CNS. Briefly, 0.01-0.04 mg/µL of tissue homogenate was diluted to 25 µL in 
buffer containing 0.2M sodium acetate and 0.1M NaCl (pH 4.3).  To each sample 
3 µg of d3-labeled GM1 (Matreya, LLC, Pleasant Gap, PA ) was added as an 
internal standard. Calibration curves were made neat with GM1 (Avanti Polar 
Lipids, Alabaster, AL) over the range of 200-3,000 ng and spiked with 3,000 ng of 
d3-GM1. Total lipids were extracted by the Folch method(211) two successive 
times in chloroform/methanol (1:1), the supernatants combined, and the 
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glycolipids partitioned to aqueous phase by adjusting the composition to 
chloroform/methanol/water (2:1:0.6).  The upper aqueous phase was removed 
and the lower phase was washed once with chloroform/methanol/water (3:48:47) 
and the upper phases combined.  Samples were dried, re-suspended in 0.2 mL 
0.1M NaCl and applied to an equilibrated 1cc C18 reverse-phase Bond Elute 
column (Agilent Technologies, Santa Clara, CA), washed with 5 mL water, eluted 
with 0.6 mL CH3OH followed by 1 mL CHCl3:CH3OH (1:1), dried, and re-
suspended in 100 µL solution of 1:4 (A:B) where A is 0.1% (v/v) formic acid and 
B is methanol:2-propanol:0.1% formic acid (47.5:47.5:4.9).  Gangliosides were 
separated on a Phenomenex (Torrance, CA) 2.1 x 50mm Kinetex 1.7 µm (100Å) 
C18 column using a Waters (Milford, MA) Acquity UPLC using a fast gradient 
program (0-1 min, 80%B; 1-5 min, 80-100%B; 5-7 min 100%B; 7.1, 80%B) and 
eluted to a Waters Quattro Premier XE triple quadrupole mass spectrometer 
operating in the negative ion mode.  Multiple reaction monitoring (MRM) 
transitions for all GM1 and GM2 species were monitored using a cone voltage of 
90V, a collision energy of 70V, and recorded the common sialic fragment anion 
at m/z 290.  The area of all the individual GM1 lipid species (16:0, 18:0, 18:1, 
20:0, 20:1) were combined for each ganglioside and the ratios were calculated to 
the corresponding d3-18:0 GM1 internal standard.  Calculated concentrations 
were normalized to protein content by Bradford (Bio-Rad, Waltham, MA).     
 
 
56 
 
Behavioral assays 
Rotarod testing was conducted on a Rotarod apparatus (Med Associates, 
St Albans, VT) accelerating from 4 to 40 rpm over 5 minutes and latency to falling 
recorded.  Testing was conducted with one practice trial of 1 minute accelerating 
from 2 to 20 rpm at the beginning of the session followed by 3 trials with 15-20 
minute resting in between.  Latency to fall for each mouse in a testing session 
was recorded, and the longest time on the rotarod in any of the 3 trials was 
reported.   
Inverted screen testing was performed on an apparatus created in 
conjunction with UMass Machine Shop (UMass Medical School, Shrewsbury, 
MA) and implemented as described previously (212).  Briefly, animals were 
placed on a square wire mesh of 30cm2 with 25mm2 holes, over a cushioned 
surface.  The screen was inverted slowly over a 2 second period, head over tail, 
until a 60° angle was reached and the screen then locked in place.  Animals were 
assessed for latency to falling up to 2 minutes and number of hind leg 
movements occurring during this time.  One practice trial and one testing run 
were administered to each mouse per time point with 15-20 minute resting 
periods between trials.  
Home cage testing was performed in an isolation cubicle (Med-
Associates, St Albans, VT), where mouse movement was tracked by video 
camera and processed by HomeCageScan software (CeleverSys, Reston, VA) 
as described previously (213).  Briefly, one animal was placed into the isolation 
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cubicle in a clean cage identical to normal housing and containing food and 
water.  The background area was subtracted in both light and dark conditions, 
and the animal’s dimensions identified by the software.  Data was taken 
regarding the animal’s movement or inactivity and reported in seconds/behavior 
for a 26 hour time period then collated according to behaviors.  
 
Results 
 
The therapeutic efficacy of systemic AAV9-mβgal delivery was evaluated 
in βGal-/- mice infused with 1x1011 vector genomes (vg) (low dose cohort; N = 
20), or 3x1011 vg (high dose cohort; N = 34) via the tail vein at 6 weeks of age (± 
2 days).  Controls included PBS-injected βGal-/- mice (N=19), and naïve age 
matched βGal+/- and βGal+/+ mice (N=49) (Fig. 2.15c, d, Table 2.2).  Untreated 
βGal-/- mice appear normal until approximately 20 weeks of age when gait 
abnormalities and tremors become apparent.  Untreated βGal-/- mice reach the 
humane endpoint at approximately 37 weeks of age, defined by >15% loss from 
maximum body weight or paralysis of any limb.  Animals were removed for 
histological and biochemical studies at 37 weeks of age to compare with 
untreated βGal-/- mice at the humane endpoint, and ultimately when AAV-treated 
mice reached the humane endpoint.  Behavioral testing was performed at 10 and 
30 weeks of age.  
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Partial restoration of βgal activity in CNS and overexpression in peripheral 
organs 
Histochemical staining of brain sections revealed an increase in βgal 
activity throughout the brain of 37-week old βGal-/- males and females in the 
high-dose (HD) cohort (Fig. 2.1, first and second rows, respectively) compared to 
PBS-injected βGal-/- animals (Fig. 2.1, bottom row).  Distribution of βgal activity 
appeared largely similar to that in control βGal+/- animals (Fig. 2.1, third row).   
Biochemical quantification showed a significant increase in βgal activity 
throughout the central nervous system (CNS) of AAV-treated βGal-/- mice 
compared to age-matched PBS-injected βGal-/- mice (Fig. 2.2a, b).  The relative 
βgal activity (% WT) in cerebrum, cerebellum, and brainstem of AAV-treated 
βGal-/- mice was dose dependent and ranged 6-25% in males and 7-90% in 
females (Table 2.1).  The relative βgal activity in the spinal cord of AAV-treated 
βGal-/- males and females ranged between 29-135% and 30-516%, respectively 
(Table 2.1).  As expected βgal activity was dramatically elevated in liver, heart, 
muscle, and serum of AAV treated βGal-/- male and female mice (Fig. 2.2a; Table 
2.1).  The relative βgal activity (% WT) in peripheral organs ranged between 140-
11,841% in males, and 29-5,150% in females (Table 2.1).  
The content of AAV vector genomes in CNS and peripheral organs was 
consistent with enzymatic findings, with the highest amount of vector 
genomes/diploid genome (vg/dg) found in liver (22-173 vg/dg) and the lowest in 
CNS (3.4-13.5x10-3 vg/dg) (Fig. 2.3).  
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Figure 2.1 βgal enzyme expression and activity by Xgal in βGal+/-, βGal-/- + 
PBS and βGal-/- + AAV 3e11vg treated mice  
Xgal staining (blue) for βgal enzyme presence and counterstained with Nuclear 
Fast Red (red) at 37 weeks throughout the brain in a representative βGal-/- + AAV 
3x1011 vg treated male (a-g) and female (h-n) (KO + AAV), untreated βGal+/- (CA 
Untreated, o-u), and βGal-/- mouse with mock treatment of phosphate buffered 
saline (PBS) (KO + PBS, v-bb).  N = 3 per group. 
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Table 2.1 β-galactosidase activity in CNS and peripheral tissues 
  
Tissue 3e11vg 1e11vg 3e11vg 1e11vg
Cerebrum 7.9 - 23.6% 6.3 - 16.9% 14.4 - 37.3% 6.9 - 17.4%
Cerebellum 9.2 - 22.0% 9.1 - 11.0% 19.3 - 26.7% 11.2 - 13.2%
Brainstem 21.2 - 25.4% 9.2 - 10.4% 15.1 - 90.3% 7.4 - 26.7%
Spinal Cord 49.3 - 135% 29.1 - 41.9% 98.4 - 516% 30.2 - 131%
Serum 140 - 2,811% 1,529 - 2,399% 28.9 - 54.5% 43.1 - 121%
Liver 868 - 6,015% 4,501 - 11,841% 228 - 542% 128 - 1052%
Heart 2,397 - 6,486% 560 - 828% 1,434 - 3,583% 350 - 5,130%
Muscle 498 - 5,296% 226 - 358% 1,002 - 1,192% 129 - 1,347%
Male Female
β-galactosidase activity (range of % WT)
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Figure 2.2 βgal enzyme activity in WT, βGal-/- + PBS and βGal-/- + AAV 
treated mice 
(a & b) Enzyme activity in selected tissues determined by 4-MU assay at 37 
weeks of age in (a) male or (b) female mice.  Enzyme activity is normalized to 
protein concentration by Bradford, and is reported as nmol/hour/mg protein.  
Error bars represent mean + SD, N ≥ 3/group, and significance was determined 
by unpaired multiple T tests where * = p < 0.05, ** = p < 0.01, and *** = p < 
0.001.  In βGal+/+ (WT) untreated or βGal-/- + PBS mice, both males & females 
are represented as no difference in enzyme activity between the sexes was 
observed in the untreated or mock-treated animals. NS = no significant 
difference. 
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Figure 2.3 Viral induced transgene presence in tissues of βGal-/- + AAV 
3e11vg treated mice  
Vector amount was quantified per diploid genome in selected tissues for βGal-/- + 
AAV 3x1011 vg male and female mice as determined by qPCR to the SV40 poly 
A on the transgene.  Samples were taken at 20 weeks of age.  Error bars 
represent mean + SD, N ≥ 3/group, and significant difference of βGal-/- + AAV 
male vs. female was determined using unpaired multiple T tests where * = p < 
0.05, ** = p < 0.01. 
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Reduction of GM1 ganglioside content and reduction in astrogliosis 
throughout CNS 
In βGal-/- mice and humans with GM1 gangliosidosis, reduced βgal activity 
results in accumulation of GM1 ganglioside (GM1) in the CNS.  Previously we 
have shown that filipin can be used to detect lysosomal storage in the brain of 
βGal-/- mice where it appears as bright perinuclear puncta (197).  This histological  
marker correlates with GM1 ganglioside storage as AAV-mediated βgal delivery 
to the βGal-/- mouse brain corrects the neurochemistry and eliminates filipin 
staining (197).  Recent work has shown that filipin binds cholesterol and GM1 
(214).  Filipin staining of βGal +/-/βGal +/+ brains does not reveal any defined 
cellular structures most likely due to the normal membrane localization of GM1 
(197) (data not shown).  Filipin staining of brain sections from males and female 
in the HD cohort at 37 weeks (Fig. 2.4 top and middle rows) revealed partial 
correction of lysosomal storage in most brain regions (Fig. 2.4, bottom row).  The 
impact on lysosomal storage appeared to be modest in thalamus, striatum, and 
granule/Purkinje cell layers in the cerebellum. Interestingly we observed 
complete clearance of storage in deep cerebellar nuclei (DCN) (Fig. 2.4, top row 
and middle row thin and thick arrows respectively).  The reduction in lysosomal 
storage material in the brain appeared to be more pronounced in female than in 
male mice (Fig. 2.4, top and middle row).  Similarly, in spinal cord, there was a 
dramatic reduction in storage in HD cohort females (Fig. 2.5, third row), but 
variable response in males (Fig. 2.5, top two rows).  The impact on lysosomal   
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Figure 2.4 GM1 presence in the brain of βGal-/- + PBS and βGal-/- + AAV 
3e11vg treated mice. 
Filipin staining of selected brain regions in a representative βGal-/- + AAV 3x1011 
vg treated male (a-g), female (h-n) (KO + AAV), and a βGal-/- + PBS (o-u, KO + 
PBS) mouse at 37 weeks of age.  N = 3 per group.  Scale bar =100 mm. Thick 
arrows indicate the DCN, thin arrows indicate the molecular and purkinje layers. 
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Figure 2.5 GM1 presence in the spinal cord of βGal-/- + PBS and βGal-/- + 
AAV 3e11vg treated mice 
Filipin staining of cervical and thoracic region of spinal cord in 37 weeks old mice.  
Representative βGal-/- + AAV 3x1011 vg treated male (a-d), female (d-f) (KO + 
AAV), and a βGal-/- + PBS (g-h, KO + PBS) mouse.  Arrows indicate areas of 
remaining storage.  N = 3 per group.  Scale bar =100 mm. 
 
  
66 
 
 
Figure 2.6 GM1 presence in the brain of βGal-/- + PBS and βGal-/- + AAV 
1e11vg treated mice 
Filipin staining of selected brain regions in a representative βGal-/- + AAV 1x1011 
vg treated male (a-g), female (h-n) (KO + AAV), and a βGal-/- + PBS (o-u, KO + 
PBS) mouse at 37 weeks of age.  ToPro3 staining for nuclear presence in βGal-/- 
+ PBS (v-bb, KO + PBS) mouse.  N = 3 per group.  Scale bar =100 mm 
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Figure 2.7 GM1 presence in the spinal cord of βGal-/- + PBS and βGal-/- + 
1e11vg AAV treated mice 
Filipin staining of cervical and thoracic region of spinal cord in 37 weeks old mice.  
Representative βGal-/- + AAV 1x1011 vg treated male (a-b), female (c-f) (KO + 
AAV), and a βGal-/- + PBS (g-h, KO + PBS) mouse.  ToPro3 staining for nuclear 
presence in βGal-/- + PBS (i-j, KO + PBS) mouse. N = 3/group.  Scale bar = 100 
mm. 
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Figure 2.8 GM1 content in the CNS of WT, βGal-/- +PBS and βGal-/- + 3e11vg 
AAV treated mice  
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Figure 2.8 GM1 content in the CNS of WT, βGal-/- +PBS and βGal-/- + 3e11vg 
AAV mice  
GM1 content quantitated by liquid chromatography tandem mass spectrometry in 
CNS tissues.  βGal-/- + AAV from 3x1011 vg treated males and females (KO + 
AAV) at 37 weeks.  βGal +/+ (WT Untreated) or βGal-/- + PBS (KO + PBS) mice 
include both males and females as no sex difference in GM1 content was 
observed in the untreated or mock-treated animals.  GM1 content was 
determined by ratio of d3-GM1 internal standard to total GM1 content, normalized 
to protein concentration by Bradford, and represented as ng GM1/µg protein.  
Error bars represent mean + SD, N ≥ 3/group (except βGal-/- + AAV, female, N = 
2).  Significant difference of βGal-/- + AAV vs. KO + PBS, or βGal-/- + AAV males 
vs. females was determined using unpaired T tests where * = p < 0.05, ** = p < 
0.01, and *** = p < 0.001.  NS indicates no significant difference between βGal-/- 
+ AAV vs. βGal +/+ untreated.    
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storage in CNS was considerably smaller in the low dose (LD) cohort (1x1011 vg) 
(Figs. 2.6 & 2.7).  Measurement of GM1 content in different CNS regions of male 
and female mice in the HD cohort by liquid chromatography-tandem mass 
spectrometry (LC MS/MS) (Fig. 2.8) showed significant reductions in the 
cerebrum (51 and 76%, respectively), brainstem (64 and 68%, respectively), and 
spinal cord (75 and 86%, respectively) compared to PBS-injected controls at 37 
weeks of age.  Interestingly, the impact of AAV9 treatment on GM1 content in 
cerebrum is significantly different between male and females (p = 0.04, Fig. 2.8).  
The GM1 content in cerebellum was not significantly changed by AAV9 
treatment.   
Astrogliosis was apparent throughout the CNS of PBS-treated βGal-/- 
controls (Figs. 2.9 & 2.10, bottom rows), as described previously in these GM1 
gangliosidosis mice (6).  High dose AAV treatment resulted in marked reduction 
across the cerebrum (Fig. 2.9, first and second rows), but reactive astrocytes 
remained in some brain structures such as striatum, especially in males (Fig. 2.9, 
top row).  In contrast, the spinal cords of AAV-treated animals of both genders 
were comparable to that of normal controls (Fig. 2.10).  
 
Dose and gender dependent behavioral performance 
A number of tests were carried out at 10 and 30 weeks of age to assess 
motor performance and behavior over time. In the rotarod test, 30 week-old 
AAV9-treated mice performed significantly better than age-matched PBS-treated   
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Figure 2.9 Astrogliosis in the brain of βGal+/-, βGal-/- + PBS and βGal-/- + 
AAV 3e11vg treated mice 
GFAP staining in the hippocampal, CA1 region, cortex and striatum in a 
representative βGal-/- + AAV 3x1011 vg treated male (a-c), female (d-f) (KO + 
AAV), an untreated βGal+/- (g-I, CA Untreated) and a βGal-/- + PBS (j-l, KO + 
PBS) mice at 37 weeks of age.  N = 3/group.  Scale bar = 100µm.  
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Figure 2.10 Astrogliosis in the spinal cord of βGal+/-, βGal-/- + PBS and  
βGal-/- + 3e11vg AAV treated mice 
GFAP staining of cervical and thoracic region of spinal cord in 37 weeks old 
mice.  Representative βGal-/- + AAV 3x1011 vg treated male (a-b), female (c-d) 
(KO + AAV), an untreated βGal+/- mouse (e-f, CA Untreated), and a βGal-/- + PBS 
(g-h, KO + PBS) mouse.  N = 3/group.   
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Figure 2.11 Rotoard performance of WT/βGal+/-, βGal-/- + PBS and βGal-/- + 
AAV treated mice  
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Figure 2.11 Rotoard performance of WT/βGal+/-, βGal-/- + PBS and βGal-/- + 
AAV treated mice  
Rotarod testing of βGal-/- + AAV, 1x1011 and 3x1011 vg (KO + AAV) treated males 
(a) or females (b). Untreated βGal+/-, and βGal-/- (WT/CA Untreated), mock 
treated βGal-/- + PBS (KO + PBS).  Rotarod testing was performed on a 4-40 rpm 
accelerating rotarod over 300 seconds at both 10 and 30 weeks of age.  Highest 
score of 3 trials reported.  Symbols indicate performance of one animal, error 
bars represent mean + SD, N=5-25 animals/group. * indicates significant 
difference of βGal-/- + AAV vs. βGal-/-  + PBS, or βGal-/- + AAV, 1x1011 vs. 
3x1011vg using unpaired T tests where * = p < 0.05, ** = p < 0.01, and *** = p < 
0.001.  NS indicates no significant difference between βGal-/- + AAV vs. βGal+/+ 
untreated or 1x1011 vs. 3x1011vg βGal-/- + AAV.    
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Figure 2.12 Inverted screen testing performance of WT/βGal+/-, βGal-/- + PBS 
and βGal-/- + AAV treated mice 
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Figure 2.12 Inverted screen testing performance of WT/βGal+/-, βGal-/- + PBS 
and βGal-/- + AAV treated mice 
Inverted screen testing of βGal-/- + AAV, 1x1011 and 3x1011 vg (KO + AAV) 
treated males (a, c) or females (b, d). Untreated βGal+/-, and βGal-/- (WT/CA 
Untreated), mock treated βGal-/- + PBS (KO + PBS).  Inverted screen testing is 
shown as (a & b) percentage of time on screen up to 2 minutes and (c & d) 
number of hind leg movements during this time.  The second score of two trials is 
reported. Symbols indicate performance of one animal, error bars represent 
mean + SD, N=5-25 animals/group. * indicates significant difference of βGal-/- + 
AAV vs. βGal-/-  + PBS, or βGal-/- + AAV, 1x1011 vs. 3x1011vg using unpaired T 
tests where * = p < 0.05, ** = p < 0.01, and *** = p < 0.001.  NS indicates no 
significant difference between βGal-/- + AAV vs. βGal+/+ untreated or 1x1011 vs. 
3x1011vg βGal-/- + AAV.   
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controls and were comparable to normal controls (βGal +/-/βGal +/+) except 
females in the LD cohort (Fig. 2.11a, b).  In the inverted screen test, AAV9-
treated females in the HD cohort, but not the LD cohort, scored significantly 
better in both time on screen and number of hind limb movements than PBS-
treated females at 30 weeks of age (Fig. 2.12a, b).  In contrast, only males in the  
LD cohort performed better than PBS-treated males in percentage of time on 
screen at 30 weeks of age (Fig. 2.12a).   
Home cage testing captures a large number of behaviors of an animal in a 
familiar environment and can identify phenotypic alterations not detectable by 
traditional motor function testing (213).  Animals were evaluated over a 24 hr 
period that spans the 12 hr light cycle when animals are less active (Fig. 2.13a, 
b, left graphs), and the 12 hr dark cycle when animals are most active (Fig. 
2.13a, b right graphs).  AAV-treated males in HD and LD cohorts performed 
significantly better than PBS-treated males in vertical reaching in both periods 
(Fig. 2.13a) and in exploratory behavior during the day (Fig. 2.13a, left side).  
However, only the HD males performed significantly better than PBS controls in 
exploratory behavior during the night (Fig. 2.13a, right side).  Females in HD and 
LD cohorts performed significantly better than PBS-treated females in daytime 
vertical movements and exploratory behavior (Fig. 2.13b, left side), however only 
females in the HD cohort retained significantly better performance than PBS-
treated controls in these measured behaviors during the nighttime (Fig. 2.13b, 
right side).  Females in the HD cohort were able to hang from the overhead wire   
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Figure 2.13 Home cage testing: verticals, hangs and exploratory analysis of 
WT/βGal+/-, βGal-/- + PBS and βGal-/- + AAV treated mice 
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Figure 2.13 Home cage testing: verticals, hangs and exploratory analysis of 
WT/βGal+/-, βGal-/- + PBS and βGal-/- + AAV treated mice 
Home cage testing of βGal-/- + AAV, 1x1011 and 3x1011 vg (KO + AAV) treated 
males (a) or females (b). Untreated βGal+/-, and βGal+/+ /βGal+/- (WT/CA 
Untreated), mock treated βGal-/- + PBS (KO + PBS).  Evaluation of daytime 
activity (left graphs) and nighttime activity (right graphs) of verticals, hangs and 
exploratory behaviors were assessed by time reaching, hanging and moving 
around the cage, respectively.  Home cage testing behavioral data was collected 
per second, tabulated per hour, averaged per animal and consolidated to 
represent a 10 hour period of day or night.  Error bars represent mean + SD, 
N=5-7 animals.  Significant difference of βGal-/- + AAV vs. βGal-/-  + PBS, or βGal-
/- + AAV, 1x1011 vs. 3x1011 vg was calculated using non-paired T tests where * = 
p < 0.05, ** = p < 0.01, and *** = p < 0.001.  NS indicates no significant difference 
between βGal-/- + AAV vs. βGal +/+ /βGal+/- untreated.    
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Figure 2.14 Home cage testing: walking and traveling analysis of WT/βGal+/-, 
βGal-/- + PBS and βGal-/- + AAV treated mice   
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Figure 2.14 Home cage testing: walking and traveling analysis of WT/βGal+/-, 
βGal-/- + PBS and βGal-/- + AAV treated mice  
Home cage testing of βGal-/- + AAV, 1x1011 and 3x1011 vg (KO + AAV) treated 
males (a) or females (b). Untreated βGal+/-, and βGal+/+ βGal+/- (WT/CA 
Untreated), mock treated βGal-/- + PBS (KO + PBS).  Evaluation daytime activity 
(a & c) and nighttime activity (b & d) of walking and traveling behaviors were 
assed by time moving around the cage and distance traveled, respectively. 
Home cage testing behavioral data was collected per second, tabulated per hour, 
averaged per animal and consolidated to represent a 10 hour period of day or 
night.  Error bars represent mean + SD, N=5-7 animals.  Significant difference of 
βGal-/- + AAV vs. βGal-/-  + PBS, or βGal-/- + AAV, 1x1011 vs. 3x1011 vg was 
calculated using unpaired T tests where * = p < 0.05, ** = p < 0.01, and *** = p < 
0.001.  NS indicates no significant difference between βGal-/- + AAV vs. βGal +/+ 
untreated.    
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feed tray significantly better than PBS-treated control females in both light cycles 
(Fig. 2.13). 
Animals were video recorded at 220-260 days old to document phenotypes of 
treated and untreated animals close to the median humane endpoint of untreated 
βGal-/- mice.  In all videos with PBS-treated control mice (Videos 2.1 - 2.4), 
hallmark phenotypes of GM1 gangliosidosis were noted as previously reported in 
this model (48, 51).  Whole body tremors and gait abnormalities were evident in 
these mice.  The front legs were tucked under the torso but remained functional 
and the body was consistently tilted forward suggesting weakness in forelimbs or 
shoulder muscles.  The hind legs were splayed outward but remained capable of 
supporting body weight.  Interestingly, hind leg movement appeared to be 
initiated by hip rotation suggestive of quadriceps weakness, which may also be 
the cause for reduced rearing or vertical movements.  Tail stiffness and curling 
over the body was also a common phenotype in these control mice as described 
previously in the GM1 mouse model (48).  Male mice in the HD cohort displayed 
some tail stiffness, but normal body position, mobility, and rearing activity at 258 
days (Video 2.1).  Male mice in the LD cohort at 263 days showed tail stiffness, 
unsteady gait, and slight tremors.  Rearing was still apparent during grooming 
(Video 2.3).  Female mice in the HD cohort at 260 days (Video 2.2) were largely 
indistinguishable from normal βGal+/+ controls.  Female mice in the LD cohort at 
264 days (Video 2.4) displayed some tremors, but body position was close to 
normal albeit lower to the ground, and gait abnormalities such as occasional 
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hopping were milder than in PBS-treated controls at comparable age.  Long lived 
females in the HD cohort remained ambulatory but displayed clear signs of 
decline with stiff tails, jerky movements, whole body tremors, and walking low to 
the ground at 590 days old (Video 2.5) and 566 days old (Video 2.6).  
AAV treatment extends lifespan of βGal-/- mice 
PBS-treated control βGal-/- mice reached maximum weight at an average 
of 175  21 days of age, (>15% body weight loss from maximum) (Fig. 2.15a b; 
Table 2.2).  Maximum body weight was comparable across all groups. AAV9-
treated βGal-/- males reached maximum body weight at 245.7  53.2 days (p = 
0.007, LD cohort) and 278.6  61.6 days (p = 0.001, HD cohort).  AAV9-treated 
βGal-/- females reached maximum body weight at 230.3  38.5 days (p = 0.004, 
LD cohort) and 458.8  76.3 days (p = 0.0007, HD cohort) (Fig. 2.15a, b; Table 
2.2).  Survival analysis showed a significant increase in median survival for both 
genders and doses (p < 0.0001) compared to PBS-treated βGal-/- mice (Fig. 
2.15c, d; Table 2.2).  In addition, there was a significant difference in survival 
between doses for females (p = 0.0007), and between males and females in the 
HD cohort (p = 0.01) (Fig. 2.15c, d; Table 2.2).  
  
84 
 
 
Figure 2.15 Weight and survival of WT/βGal+/-, βGal-/- + PBS and βGal-/- + 
AAV treated mice  
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Figure 2.15 Weight and survival of WT/βGal+/-, βGal-/- + PBS and βGal-/- + 
AAV treated mice  
 (a & b) Weights and (c & d) survival of βGal -/- + AAV, 1x1011 and 3x1011 vg 
treated (KO + AAV), βGal+/- and βGal +/+ untreated (WT/CA Untreated) and βGal-/- 
+ PBS mock treated (KO + PBS) male and female mice.  Error bars represent 
mean + SD, N=9-26 animals/group.  (a & b) Weights are represented as an 
average of 1 weighing during a 4 week period beginning at pre-injection (6 
weeks) and continued until removal from the study up to 80 weeks of age.  (c & 
d) Survival analysis of all animals entered into the study.  *** indicates significant 
difference vs. KO + PBS using Log-rank (Mantel-Cox) test where p=0.0001.  
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Table 2.2 Weight and survival statistics of WT/βGal+/-, βGal-/- + PBS and 
βGal-/- + AAV treated mice  
Significant difference for age at max weight for βGal-/- + AAV vs. βGal-/- + PBS 
was calculated using unpaired T tests where ** = p <  0.01, and *** = p < 0.001. 
Significant difference for median survival of βGal-/- + AAV vs. βGal-/- + PBS was 
calculated using Log-rank (Mantel-Cox) test where *** p = 0.0001. 
  
Gender Genotype Treatment
Enrolled 
animals
Max weight         
(g ± std, N)
Age at max 
weight (days)
Median survival   
(days)
Max survival 
(days)
Male CA/WT Untreated 25 42.3 ± 4.7, 7 513.8 ± 10.5 N/A N/A
Male KO PBS 9 38.8 ± 5.9, 8 178.5 ± 23.1 250.5 265
Male KO 1x1011vg 10 38.6 ± 4.6, 7 245.7 ± 53.2** 316.0*** 339†
Male KO 3x1011vg 17 42.2 ± 9.1, 6 278.6 ± 61.6** 398.0*** 499
Female CA/WT Untreated 24 38.9 ± 10.5, 7 510.3 ± 42.0 N/A N/A
Female KO PBS 10 26.9 ± 1.8, 10 179.2 ± 24.5 264.0 298
Female KO 1x1011vg 10 27.2 ± 3.3, 7 230.3 ± 38.5** 344.0*** 447
Female KO 3x10
11vg 17 28.7 ± 2.2, 7 458.5 ± 76.3*** 576.5*** 673
† 1 animal survived until 561 days.
Weight and survival statistics of βGal and βGal-/- + AAV treated mice
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Discussion 
Previous studies from our lab have shown intracranial delivery of 
recombinant AAV vectors in neonatal (197) and adult GM1 mice (198) to be 
effective approaches to achieve widespread expression of functional βgal and 
reduce lysosomal storage of GM1-ganglioside in the CNS.  The intracranial AAV 
delivery approach in adult GM1 mice delayed the onset of disease symptoms, 
but had little to no impact on the decline of motor function and only a modest 
improvement in survival (198).   
In this study we show that vascular delivery of a single-stranded AAV9 
vector in adult GM1 gangliosidosis mice (βGal-/-) extended the survival of all 
AAV-treated animals (Fig. 2.15c, d; Table 2.2), but was not successful in 
arresting disease progression at the doses tested (1x1011 and 3x1011 vg/mouse).  
The therapeutic impact was considerably better in females with a median survival 
in the high dose cohort of 576.5 days compared to 398.0 days for males (Fig. 
2.15c, d; Table 2.2).  The therapeutic outcomes correlate well with the findings 
from biochemical and histological studies of the CNS where we observed 
increased βgal activity (Figs. 2.1, 2.2a, b; Table 2.1) and partial correction of 
GM1 ganglioside content (Figs. 2.4, 2.5 & 2.8).  
Histological analysis of lysosomal storage revealed dramatic reduction in 
HD cohort cerebral cortex, hippocampus, brainstem, and spinal cord, but lesser 
impact in deep brain structures such as thalamus, and striatum, and importantly 
in the cerebellum (Figs. 2.4 & 2.5).  The reduction in lysosomal storage observed 
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in deep brain structures likely contributed to slower disease progression as the 
onset of symptoms in GM1 gangliosidosis mice coincides with the detection of 
inflammatory markers in different brain regions, especially in thalamus, 
brainstem, and spinal cord (6).  Despite partial correction in several CNS regions, 
the impact of AAV treatment on disease physiology was nonetheless profound in 
the HD cohort as indicated by the dramatic reduction in reactive astrocytes 
throughout the brain (Fig.2.9) that correlated with reduction in GM1 storage (Figs. 
2.4 & 2.8).  The therapeutic impact in the spinal cord with normalization of GM1 
ganglioside content (Figs. 2.5 & 2.8) and resolution of astrogliosis (Fig. 2.10) was 
likely a major factor in extending the lifespan and preserving ambulation of 
AAV9-treated animals (Videos 2.1, 2.2, 2.5 & 2.6).  Nonetheless, AAV9-treated 
animals eventually developed whole body tremors and jerky movements, which 
may be related to the marginal therapeutic impact in the cerebellum (Videos 2.5 
& 2.6).  AAV9-HD cohort treated animals showed little or no change in lysosomal 
storage in granular, molecular, or Purkinje cell layers, but complete correction in 
deep cerebellar nuclei (Fig. 2.4f, m; thin and thick arrows, respectively).  The 
failure to resolve storage in the Purkinje cell layer was also reported in another 
study using systemic delivery of an AAV9 vector to treat MPSIIB mice (187).  As 
the output centers of the cerebellum, the deep cerebellar nuclei send projections 
to different levels of the spinal cord and other regions of the brain (215).  Given 
the connectivity of those nuclei and that βgal can be distributed over long 
distances via axonal transport (167), storage correction in DCN is most likely the 
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result of enzyme uptake at axonal terminals in successfully treated structures, 
such as the spinal cord, and its retrograde transport to the cell body where most 
lysosomes reside.  Disease progression in other cerebellar nuclei or cell 
populations may have led to the phenotypes that developed over time in AAV9-
treated GM1 gangliosidosis mice. 
The pattern of lysosomal storage correction in the CNS of GM1 
gangliosidosis mice in this study matches closely with the transduction profile of 
other studies where AAV9 vectors were delivered systemically in adult mice.  The 
most effectively transduced CNS regions are the cerebral cortex, hippocampus, 
and spinal cord (181, 216).  Neuronal transduction in adult mice seems to be 
most pronounced in the spinal cord and hippocampus, but mostly glia and 
endothelial transduction throughout the rest of the brain (181, 216).  Transduction 
of striatum and thalamus is relatively inefficient by comparison to other brain 
regions, and especially inefficient in cerebellum at comparable doses (216).  
Nonetheless previous studies have reported exceptional therapeutic effects using 
systemic delivery of single-stranded AAV9 vectors in mouse models of 
mucopolysaccharidosis type IIIA (188) and IIIB (187).  The difference in 
therapeutic outcomes may be related to rates of disease progression specific to 
each lysosomal storage disease or mouse model.  Also the minimum level of 
enzyme necessary to achieve complete correction of storage in cross-corrected 
cells may be considerably higher for βgal compared to other lysosomal enzymes.  
During synthesis βgal forms a megacomplex with neuraminidase-1 (NEU1) and 
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protective protein/cathepsin A (PPCA) important for transport of NEU1 to 
lysosomes, and processing/protection of βgal (reviewed in (217)).  Since only 
βgal is overexpressed, secreted, and transported into enzyme-deficient cells, it is 
possible that its half-life may be lower in the lysosomes of cross-corrected cells 
because it may not interact with PPCA as the βgal-PPCA complex is normally 
formed before transport to lysosomes (217).  This may render the recombinant 
βgal more susceptible to proteolytic degradation. In addition the enzymatic 
efficiency of βgal by itself may be lower than in its native multienzyme complex.  
Other aspects such as AAV vector design and dosing may also explain the 
difference in outcomes between our study and others.  Finally, biochemical 
changes intrinsic to a particular lysosomal storage disease may affect the 
efficiency of AAV9 CNS gene transfer as shown in MPS VII mice due to sialic 
acid deposition in brain vasculature (194).   
The impact of AAV9 treatment on lysosomal storage in CNS was better in 
females than males in the HD cohort (Figs. 2.4, 2.5 & 2.8), and this likely 
explains the difference in therapeutic outcome between genders.  Survival was 
comparable between genders in the low dose cohort, but females survived 45% 
longer than males in the high dose cohort (Fig. 2.15c, d, Table 2.2).  The 
difference in therapeutic impact between genders is likely the result of a 
difference in CNS gene transfer efficiency as suggested by the analysis of vector 
genome content (Fig. 2.3).  Although the difference between genders did not 
reach statistical significance in most tissues, it is interesting that the average 
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value is 2-3-fold higher in females across all brain regions (p = 0.07 for cerebrum 
and cerebellum) and in most other organs except liver and muscle (Fig. 2.3).  
The higher efficiency of AAV liver gene transfer in male mice has been 
documented in a multiple models (190, 191) and appears to be testosterone 
dependent (191, 218).  Our results show the same gender difference in AAV liver 
gene transfer with a 5-fold higher vector genome content (Fig. 2.3) and 6-7-fold 
higher enzyme activity in males than females in the high dose cohort (Fig. 2.2a, 
b; Table 2.1).  The notion that AAV9 CNS gene transfer after vascular delivery in 
adult GM1 mice is more efficient in females is supported by a recent study 
showing an identical gender difference in different mouse strains infused 
systemically with an AAV9 vector encoding firefly luciferase (192).  In our study 
the higher efficiency of AAV9 CNS gene transfer in females after systemic 
delivery may be partly due to lower affinity to liver as its vector genome content is 
5-fold lower than in males (Fig 2.3).  This suggests that liver tropism/affinity may 
be a major factor in determining the bioavailability of AAV9 (and possibly other 
AAV capsids) to transduce other organs after systemic delivery.  The gender 
effect on AAV liver transduction has not been documented in other mammalian 
species such as cats (218).  Nonetheless, liver tropism remains an important 
issue in the development of systemic AAV9 gene delivery approaches for 
neurological diseases.  The liver tropism of AAV9 is a concern for vascular 
delivery approaches to treat neurological diseases as the high doses required to 
target CNS effectively could lead to collateral liver toxicity related to transgene 
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expression.  Transient liver toxicity may explain the paradoxical finding that the 
range of βgal activities in liver and serum was lower in mice (both sexes) 
receiving higher vector dose (Table 2.1).  Further studies will be necessary to 
assess this possibility and uncover the causes, which could be related to βgal 
overexpression.  Whether this is a finding unique to this enzyme or also applies 
to other lysosomal enzymes remains to be determined.  Different approaches 
have been employed to reduce or eliminate transgene expression in liver after 
vascular delivery of AAV9 vectors, namely using the CMV promoter that is down-
regulated over time (187), or incorporation of perfect miR-122 (highly expressed 
in liver) target sequences in the expression cassette 3’ untranslated region (189).  
These transcriptional de-targeting approaches are likely to increase safety of 
vascular delivery of AAV9 vectors, but have no impact on its liver tropism 
properties.  Interestingly AAV9 mutants engineered to reduce liver tropism by 
more than 10-fold show only marginal increases in CNS gene transfer (219).  
Presently the molecular basis for decreased liver tropism is unknown, namely 
whether the introduced mutations change the affinity to the same cell surface 
receptor, or re-direct the capsid to another receptor entirely.  Clearly, achieving 
higher CNS gene transfer with AAV9 vectors, or derivatives, is not as simple as 
reducing liver tropism. Other AAV capsids may display higher CNS gene transfer 
efficiency than AAV9 in adult mice, as recently shown for AAVrh8 (183). 
The therapeutic outcome in this study is superior to that obtained by 
intracranial injection of an AAV1 vector into thalamus and deep cerebellar nuclei 
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of adult GM1 gangliosidosis mice (198).  This finding is somewhat paradoxical as 
in the present study there was only partial correction of GM1 ganglioside content 
in the brain compared to complete normalization in the intracranial approach, 
while the findings are reversed in the spinal cord.  This suggests that disease 
progression in the spinal cord may be an early driver of disease phenotypes in 
this mouse model, but ultimately partial treatment of other CNS regions will 
compromise survival.  It is possible that treatment of adult GM1 gangliosidosis 
mice with higher doses of AAV9 vector may lead to complete correction of 
lysosomal storage in the CNS and arrest disease progression completely. 
 This is the first study reporting on the therapeutic efficacy of vascular 
delivery of an AAV9 vector encoding βgal in adult GM1 gangliosidosis mice.  We 
showed successful widespread expression of functional enzyme throughout the 
CNS with resulting reduction in GM1 ganglioside storage and significant 
extension of lifespan with retention of motor function.  To improve overall 
therapeutic outcomes, a focus on increasing enzyme delivered to the CNS is 
warranted as enzyme levels achieved in this study were insufficient to normalize 
GM1 ganglioside levels.  This inability to normalize GM1 ganglioside content 
everywhere may have lead to an eventual inflammatory cascade resulting in loss 
of function in partially corrected regions.  Intravascular infusion of AAV9 vector at 
higher doses, or using AAV capsids with higher CNS gene transfer efficiency 
(183), may result in complete biochemical correction of disease with 
normalization of phenotype and lifespan.  
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CHAPTER III:  AAVrh8-Mediated Intracranial Gene Delivery of a 
Lysosomal Enzyme to the CNS:  Therapeutic Benefits, 
Challenges and Considerations in a GM1 Mouse Model 
 
Introduction 
Lysosomal storage disorders (LSD) are a class of >50 disorders 
associated with malfunction of a resident enzyme which leads to accumulation of 
undegraded substrates in lysosomes (7).  Over time, this accumulation can lead 
to lysosomal malfunction which results in a cascade of events (220-223) often 
resulting in cell death (4, 5, 7).  LSDs with central nervous system (CNS) 
involvement require the intended therapy to cross or bypass the blood brain 
barrier in order to deliver functional enzyme to target cells to achieve disease 
resolution (91).  However, obtaining enzyme levels at high enough 
concentrations or with sufficient distribution throughout the CNS to achieve a 
therapeutic impact has been challenging.  Strategies employed to overcome 
these obstacles in the CNS focus on utilizing inherent properties of these 
enzymes such as cross correction (the release and uptake of enzymes from 
neighboring cells) (85-87), CSF-mediated distribution, and axonal transport (165, 
167).  A successful approach has been to target gene delivery to highly 
connected structures in the brain for maximum spread of enzymes (100, 165-
167, 170-172, 174, 175, 198, 203, 204, 215, 224, 225).   
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Gene therapy by intracranial injection of adeno-associated virus (AAV) 
vectors has been the most effective approach to obtain high levels gene transfer 
to target structures (165, 166, 170-172, 174, 175, 198-200, 215).  Typical 
approaches seek to express the highest amount of enzyme possible in order to 
obtain maximum therapeutic benefit and have been optimized by addition of 
enhancers, ubiquitous promoters (210, 226, 227), and post transcriptional 
regulatory elements (228, 229).  However, accumulation of undegraded 
substrates or dysregulation of the lysosomal compartment can lead to responses 
to upregulate lysosomal biogenesis (220, 221), substrate reduction (222) or 
exocytosis (223).  It is also possible that introduction of supraphysiological levels 
of a therapeutic protein can also trigger deleterious “protection” cascades which 
may be associated with unfolded protein response common in these disorders 
(4).  
GM1-gangliosidosis is a LSD resulting from the deficiency in the 
catabolizing enzyme β-galactosidase (βgal) (3, 7).  GM1-gangliosidosis is 
primarily a disease of the CNS where accumulation of GM1 ganglioside (GM1) 
results in lysosomal dysfunction, ER stress and calcium mediated apoptosis 
leading to neuronal loss, generalize paralysis and death (4, 5, 7).  The amount of 
residual enzyme activity determines the severity and age of disease onset. 
Infantile and late infantile/juvenile patients usually have 1-4% of normal activity, 
while adult onset or chronic patients have 4-<10% βgal activity (7). As no cases 
of GM1-gangliosidosis have been reported with >10% βgal activity, it is thought 
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that 10-20% of normal activity should be sufficient to treat this disease.  
Currently, there is no cure or effective treatment for GM1-gangliosidosis patients.  
Attempts at therapies for GM1-gangliosidosis include enzyme replacement (89, 
90), bone marrow (82, 83) or cell transplantation (84), molecular chaperones (79, 
230), substrate reduction therapy (75, 78, 80, 81), and gene therapy (196-198).  
Despite success in cell lines or animal models in delivering or regaining active 
enzyme (79, 83, 84, 90, 197, 198), reducing substrates (75, 78, 80), and 
resolution of GM1 storage (80, 84, 197, 198), no experimental approach has 
been successful in treating all disease aspects and eventually animals succumb 
to disease progression.  Previous work in our lab focused on the delivery of 
enzyme to the CNS through AAV vectors injected into the lateral ventricle of 
neonatal mice (197), or intracranial bilateral injections into the thalamus and 
deep cerebellar nuclei of adult mice (197).  Both of these approaches achieved 
high expression of active βgal in the brain with an AAV1 capsid, but found some 
regions of the CNS lacking in enzyme expression and without resolution of GM1 
storage.   
In this current study, we first investigated possible reasons for the lack of 
overall efficacy by employing i) an AAVrh8 vector (121) as it has been shown 
very effective at expressing enzyme in the mouse CNS (169), and cat brain (199, 
200), and ii) modification of target coordinates for the DCN.  We were able to 
achieve widespread distribution of βgal throughout the cerebrum and cerebellum, 
significant retention of motor function and extension of lifespan.  The resulting 
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expression of βgal was very high in the injection sites, and surprisingly was one 
of the remaining regions in brain with strong staining of our storage marker, 
Filipin.  In addition, we found evidence of neuropathology at the injection sites 
suggestive of toxicity, which decreased with lower vector dose.  We examined 
these unexpected results in both GM1-gangliosidosis βgal-/- mice and unaffected 
βgal+/- animals and found this abnormal Filipin staining to be consistent.  To 
investigate the cause for this unusual result we constructed a variety of AAVrh8 
vectors with decreasing enzyme expression levels.  Microarray analysis of the 
thalamic target showed increased expression of a number of genes associated 
with microglia and astrocyte activation, which did not occur in a low expressing 
vector or in control animals.  Finally, we tested these AAVrh8 vectors in βgal-/- 
mice for therapeutic efficacy and identified a vector that both minimized 
consequences of over expression and maximized therapeutic benefit.  
Taken together, this work demonstrates that in treatment of a lysosomal 
storage disorder by intracranial injection one must consider impact of 
supraphysiological levels of enzyme as well as transgene delivery efficiency for a 
safe and effective therapeutic intervention.   
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Materials and Methods 
 
Vector design, construction and viral creation.   
Construction of the original AAV vector was previously described (197) 
and carries an expression cassette driven by a promoter composed of 
cytomegalovirus immediate early enhancer (CMV) fused to the chicken beta-
actin promoter followed by a chimeric chicken beta-actin/rabbit beta globin intron 
(CBA), the mouse lysosomal acid β-galactosidase cDNA (mβgal), a woodchuck 
hepatitis virus post-transcriptional regulatory element (WPRE), and two polyA 
signals in tandem derived from the bovine growth hormone (BGH) and SV40. 
This vector is called AAV-CBA-mβgal-WPRE.  AAV-CBA-mβgalE269Q-WPRE 
was generated by PCR mutagenesis with of the following primers: AAA CGT 
CTC ACT AGT CCG CGG AAT TC , Rev1: AAA CGT CTC ACT GAG AAT TGA 
TCA AA , For2:  AAA GGT CTC CGG CCG CTA GCG TCA G, Rev2:  AAA GGT 
CTC ATC AGT TCT ATA CTG GC.  The resulting PCR product was digested 
with SpeI and Not I restriction enzymes and cloned in place of the wild type βgal 
cDNA.  All other AAV vectors were generated by removal of different elements 
from AAV-CBA-mβgal-WPRE vector. All AAVrh8 vector stocks were produced as 
previously described (231).  
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Animal procedures.  
GM1-gangliosidosis mice (βgal-/-), a knock out version created by insertion 
of a neomycin cassette in exon 6 of the β-galactosidase gene, GLB1 (51), were 
obtained from Dr. Kunihido Suzuki (Neuroscience Center, University of North 
Carolina, Chapel Hill, NC).  βgal-/-, βgal+/-, and βgal+/+ mice weregenerated by 
mating of male βgal-/- and female βgal+/- mice or βgal+/- males and females.   
 
Intracranial injections.  
Six to eight week-old βgal-/- or βgal+/- mice were anesthetized by 
intraperitoneal injection of ketamine (125 mg/kg) and xylazine (12.5 mg/kg) in 
0.9% saline and placed in a rodent stereotaxic frame (Stoelting, Wood Dale, IL). 
The fur around the incision site was clipped, and the was skin scrubbed with 
povidine-iodine pads and 70% EtOH. The skull was exposed by a small 
longitudinal incision (< 1 cm) along the midline. The periosteum was removed 
from the surgical area with sterile cotton tipped applicators. Small burr holes (< 1 
mm) were made using a high-speed drill (Dremel, Robert Bosch LLC, Waltham, 
MA) at the appropriate stereotaxic coordinates. AAV vectors, or PBS, were 
infused in βgal-/- or βgal+/- mice with 1 µl bilaterally into the thalamus (stereotaxic 
coordinates: AP –2.0 mm, ML ±1.5 mm from bregma; DV -3.5 mm from brain 
surface) and in βgal-/- mice with 0.3 or 1 µl into the deep cerebellar nuclei (AP -
6.0 mm, ML ±1.5 mm from bregma; DV -3.5 mm from brain surface) at a rate of 
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0.2 µl/min using an Ultramicro Pump (World Precision Instruments, Sarasota, FL) 
to drive a 10 µl gastight glass syringe fitted with a 33G needle (Hamilton, Reno, 
NV). Infusions were started 1 min after placement of the needle in the target 
structures and slowly withdrawn 2.5 min after conclusion of the infusion. The 
scalp was closed with sterile wound clips (9 mm). All animal experiments were 
approved by the Institutional Animal Care and Use Committee at the University of 
Massachusetts Medical School, and complied with the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals. 
 
Behavioral assays.   
Rotarod testing was conducted on a Rotarod apparatus (Med Associates, 
St. Albans, VT) accelerating from 4 to 40 rpm over 5 minutes, with latency to fall 
recorded. Testing was conducted with one practice trial of 1 minute accelerating 
from 2 to 20 rpm at the beginning of the session followed by 3 trials with 15-20 
minute resting in between.  Latency to fall for each mouse in a testing session 
was recorded, and the longest time on the rotarod among the 3 trials was 
reported.   
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Tissue processing.  
For biochemical studies in βgal+/- mice, the brain was removed and sliced 
into 2 mm coronal blocks using a brain matrix (Stoelting, Co., Wood Dale, IL), 
and immediately frozen on dry ice.  The block containing the thalamus was 
identified by morphology and the presence of needle entry points on the dorsal 
brain surface.  A 2 mm diameter biopsy punch (Integra Miltex, York, PA) was 
used to sample the thalamus and the tissue plug placed in the appropriate buffer 
for analysis.  For histological studies the brain and spinal cord were removed and 
placed in Neg 50 freezing medium (Richard-Allan Scientific, Kalamazoo, MI) and 
frozen in a dry ice/2-methylbutane bath (ThermoFisher Scientific, Waltham, MA). 
For biochemical studies in βgal-/- mice, cerebrum, cerebellum + brainstem, and 
spinal cord were removed and immediately frozen on dry ice.  
 
Histological analysis.   
20 µm brain (sagittal and coronal) and spinal cord (transverse) sections 
were cut in a cryostat (ThermoFisher Scientific, Waltham, MA) and stored at -
80oC.  
Brain sections were stained with X-gal to assess the distribution of βgal as 
described previously (197), with modifications.  Briefly, slides were fixed in 0.5% 
glutaraldhyde in PBS, washed 3x in ice cold citrate phosphate buffer (CPB) 
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(50mM C6H8O, 50mM Na2HPO4, 10mM NaCl, pH=4.2) incubated overnight at 
37°C in X-gal staining solution [20mM K4Fe(CN)6, 20mM K3Fe(CN)6, 2mM MgCl2, 
0.01% C24H39NaO4, 0.02% (C2H4O)nC14H22O (IGEPAL CA-630, 
SigmaAldrich),97% CPB @ pH=4.2, 2mg/ml 5-bromo-4-chloro-3-indolyl-β-D-
galactosidase (X-gal) in HCON(CH3)2).  The next day, slides were rinsed in CPB 
then water, counterstained with Vector Nuclear Fast Red (Vector Laboratories, 
Inc., Burlingame, CA), dehydrated through a series of ethanol 50%-100%, 
cleared with CitriSolv (ThermoFisher Scientific, Waltham, MA) and mounted with 
Permount (ThermoFisher Scientific, Waltham, MA).   
Brain and spinal cord sections were stained with Filipin to assess 
lysosomal storage as described previously (197), with modifications.  Briefly, 
slides were fixed in 4% paraformaldehyde in phosphate buffered saline (PBS), 
washed with PBS, incubated with 1.5% glycine in water, washed with PBS, 
incubated with 100 µg/ml of Filipin (Santa Cruz Biotechnology, Inc., Dallas, TX) 
and 1 µg/ml of ToPro3 Iodide (Life Technologies, Grand Island, NY) for 1-2 
hours, washed with PBS and mounted with fluorescence mounting media, 
PermaFluor (ThermoScientific, Fremont, CA).   
Brain sections were stained with Mayer’s Hematoxylin and Eosin to 
assess morphological changes in the tissue.  Briefly, slides were dried at room 
temperature, fixed in 4% paraformaldehyde in phosphate buffered saline (PBS), 
washed with water, incubated with Mayer’s Hematoxylin (Sigma-Aldrich, St. 
103 
 
Louis, MO), washed in running tap water, counterstained with Eosin (Sigma-
Aldrich, St. Louis, MO), rinsed with deionized water, dehydrated through a series 
of ethanol 50%-100%, cleared with CitriSolv (ThermoFisher Scientific, Waltham, 
MA) and mounted with Permount (ThermoFisher Scientific, Waltham, MA).   
Whole brain slice images were captured using white light on a Nikon 
Super CoolScan 5000 ED with a medical slide holder (Nikon, Inc., Melville, NY). 
Microscope images were captured on a Leica DM550 B microscope, equipped 
with Leica DFC425 C and DFC365 FX digital cameras (Leica Microsystems, 
Buffalo Grove, IL).  Filipin was imaged at 405nm and ToPro3 Iodide at 636nm.  
H&E was imaged using brightfield.  
All histological analysis was performed as non-blinded, qualitative analysis 
on an N ≥ 2-3 animals with representative pictures shown in figures.   
 
βgal enzymatic assays and Immunobloting.   
Biopsy punches, one hemisphere of brain tissue or one half spinal cord 
were homogenized in lysis buffer (0.1% Triton X-100 in 0.2M CH3COONa , 0.1M 
NaCl, pH 4.3) and assayed for βgal enzymatic activity as described previously 
(197, 199).  Briefly, a reaction with βgal substrate = 1mM 4-Methylumbelliferyl--
D-galactoside (4-MUG) was performed in a 96-well plate format and the amount 
of 4-methylumbelliferyl (4-MU) released was measured against a standard curve 
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with fluorescence detection by excitation at 360 nm and emission at 460nm using 
a BioTek Synergy HT plate reader (BioTek, Winooski, VT).  Enzymatic activity 
was normalized to protein content as determined by Bradford assay (Bio-Rad, 
Waltham, MA) and reported as nmol (of substrate converted)/hour/mg protein.  
For immunobloting injection site biopsy punches were homogenized in T-PER 
buffer (ThermoFisher Scientific, Waltham, MA) supplemented with Complete Mini 
protease inhibitor cocktail (Roche Molecular Systems, Inc., Branchburg, NJ), 
incubated on ice for 10 min and then centrifuged at 10,000 x g for 5 min. The 
supernatant was collected and protein concentration determined using a 
Bradford assay (Bio-Rad, Waltham, MA). Total protein (20 µg) was separated by 
polyacrylamide gel electrophoresis using Mini-PROTEAN TGX precast gels (Bio-
Rad, Waltham, MA), and protein transferred to NitroPure nitrocellulose 
membrane (Maine Manufacturing, LLC, Sanford, ME). Blots were blocked in Tris-
buffered saline-Tween-20 (TBST) with 5% fat-free milk, and then incubated with 
primary antibodies to α-rabbit GLB1 (β-galactosidase antibody) (1:250; 
Proteintech, Chicago, IL) and α-mouse β-Actin (1:1000; GenScript, Piscataway, 
NJ). HRP-conjugated anti-rabbit and anti-mouse secondary antibodies were used 
(1:4000; GE Healthcare, Westborough, MA) and signal detection was done with 
Pierce ECL Western Blotting Substrate (ThermoFisher Scientific, Waltham, MA) 
and blots exposed to Amersham Hyperfilm ECL (GE Healthcare, Westborough, 
MA). 
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Genome copies  
Genomic DNA from injection site biopsy punches was isolated using 
Qiagen DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA), and concentration 
determined using a Nanodrop spectrophotometer (ThermoFisher Scientific, 
Waltham, MA) The number of AAV vector genome copies in 100 ng of genomic 
DNA were determined by qPCR using the following primers and Taqman probe 
specific for BGH polyA in the vector genome: (TaqMan Probe, 6FAM- AGC ATT 
TTT TTC ACT GCA TTC TAG TTG TGG TTT GTC -TAMRA) (Integrated DNA 
Technologies, Coralville, IA).  Samples with ≥ 100 vg genome copies per µg of 
DNA were deemed positive for vector genomes.  Data was represented as 
vg/diploid genome considering that 100 ng of mouse genomic DNA corresponds 
to 36,263 diploid genomes.   
 
Microarray 
Total RNA was isolated from biopsy punches using Trizol (Life 
Technologies, Woburn, MA) and further purified using RNeasy Plus Mini Kit 
(Qiagen, Valencia, CA), and its quality analyzed on an Agilent Bioanalyzer 
(Agilent Technologies, Santa Clara, CA). Bioanalyzer RNA integrity number 
(RINs) values were 8.7-9.5, which indicates high quality RNA (data not shown). 
Sample preparation and microarray hybridization was done at the UMass 
Medical School Genomics Core using Affymetrix Mouse Gene 2.0ST Arrays 
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(Affymetrix, Santa Clara, CA).  Three independent samples were analyzed per 
group.  Resulting data was processed and P values <0.05 and 1.5-fold change in 
relation to PBS controls were considered differentially expressed genes.   
 
Quantification of GM1 ganglioside content 
A liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay 
(Weismann et al, in preparation) was used for quantification of GM1-ganglioside 
in CNS. Briefly, 0.01-0.04 mg/µL of tissue homogenate was diluted to 25 µL in 
buffer containing 0.2M sodium acetate and 0.1M NaCl (pH 4.3).  To each sample 
3 µg of d3-labeled GM1 (Matreya, LLC, Pleasant Gap, PA ) was added as an 
internal standard. Calibration curves were made neat with GM1 (Avanti Polar 
Lipids, Alabaster, AL) over the range of 200-3,000 ng and spiked with 3,000 ng of 
d3-GM1. Total lipids were extracted by the Folch method(211) two successive 
times in chloroform/methanol (1:1), the supernatants combined, and the 
glycolipids partitioned to aqueous phase by adjusting the composition to 
chloroform/methanol/water (2:1:0.6).  The upper aqueous phase was removed 
and the lower phase was washed once with chloroform/methanol/water (3:48:47) 
and the upper phases combined.  Samples were dried, re-suspended in 0.2 mL 
0.1M NaCl and applied to an equilibrated 1cc C18 reverse-phase Bond Elute 
column (Agilent Technologies, Santa Clara, CA), washed with 5 mL water, eluted 
with 0.6 mL CH3OH followed by 1 mL CHCl3:CH3OH (1:1), dried, and re-
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suspended in 100 µL solution of 1:4 (A:B) where A is 0.1% (v/v) formic acid and 
B is methanol:2-propanol:0.1% formic acid (47.5:47.5:4.9).  Gangliosides were 
separated on a Phenomenex (Torrance, CA) 2.1 x 50mm Kinetex 1.7 µm (100Å) 
C18 column using a Waters (Milford, MA) Acquity UPLC using a fast gradient 
program (0-1 min, 80%B; 1-5 min, 80-100%B; 5-7 min 100%B; 7.1, 80%B) and 
eluted to a Waters Quattro Premier XE triple quadrupole mass spectrometer 
operating in the negative ion mode.  Multiple reaction monitoring (MRM) 
transitions for all GM1 and GM2 species were monitored using a cone voltage of 
90V, a collision energy of 70V, and recorded the common sialic fragment anion 
at m/z 290.  The area of all the individual GM1 lipid species (16:0, 18:0, 18:1, 
20:0, 20:1) were combined for each ganglioside and the ratios were calculated to 
the corresponding d3-18:0 GM1 internal standard.  Calculated concentrations 
were normalized to protein content by Bradford (Bio-Rad, Waltham, MA).     
 
Results 
 
AAV dose dependent distribution of βgal in brain  
AAVrh8-CBA-mβgal-WPRE vector (Fig. 3.1) was infused into the brain of 
6-8 week old GM1 gangliosidosis mice (gal-/-) by bilateral injections in the 
thalamus and deep cerebellar nuclei at total doses of 4e10vg, 2.6e10vg and 
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2.6e9vg.  Animals in the highest dose cohort received bilateral injections of 1 µl 
in thalamus and DCN, while animals in the other two cohorts received 1 µl in 
thalamus and 0.3 µl in DCN.  The βgal distribution pattern in brain at 3 months 
post-injection appeared to be dose dependent with the highest intensity of gal 
activity at the injection site (Fig. 3.2). The highest dose (4e10vg) provided 
enzyme activity throughout much of the section in the cerebrum (Fig. 3.2a) and 
cerebellum (Fig. 3.2b).  Middle dose, 2.6e10vg had similar level of activity in the 
cerebrum (Fig. 3.2e), and the cerebellum (Fig. 3.2f) appeared to provide slightly 
less activity but still spread of enzyme throughout the structure.  Low dose, 
2.6e9vg had less spread in both the cerebrum and cerebellum (Fig. 3.2i & j, 
respectively).  
 
AAV treated animals retain motor function in a dose dependent manner. 
The motor function of AAVrh8-treated mice was assessed over time using 
the rotarod test (Fig. 3.3). All cohorts of AAVrh8-treated βgal-/- performed 
significantly better than untreated βgal-/- controls at the 6 month post-treatment 
time point (high dose 4e10vg p = 0.006, middle dose 2.6e10vg p = 0.0009, and 
low dose 2.6e9vg p = 0.005).  N = 6-10 animals/group at 6 months post-
treatment.  Nonetheless, the rotarod performance of AAVrh8-treated animals 
declined over time.   
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Figure 3.1 Vector design and components 
Vector CBA-mβgal-WPRE.  Two inverted terminal repeats (ITRs) from AAV2 
flank the vector on each end.  The CBA promoter is composed of a 
cytomegalovirus immediate early enhancer (CMV) fused to the chicken beta-
actin promoter followed by a chimeric chicken beta-actin/rabbit beta globin intron 
(CBA), the mouse lysosomal acid β-galactosidase cDNA (mβgal), a woodchuck 
hepatitis virus post-transcriptional regulatory element (WPRE), and two polyA 
signals in tandem derived from the bovine growth hormone (BGH) and SV40.  
This vector was then packaged in an AAVrh8 capsid.   
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Figure 3.2. AAVrh8-mβgal intracranially injected in βgal-/- mice produces 
dose dependent enzyme distribution 
βgal expression in the brain of representative AAVrh8-injected animals and age-
matched controls was analyzed at 2 weeks (4e10vg) or 3 months (2.6e10vg and 
2.6e9vg) post-injection by histochemical staining of 20 µm coronal brain sections 
with X-gal and counterstaining with Nuclear Fast Red. (a, b) 4e10vg (e, f) 
2.6e10vg (i, j) 2.6e9vg (c, d) naïve βgal-/- and (g, h) naïve βgal+/- mice.  Images 
are representative of N ≥ 3 mice/group.   
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Figure 3.3. βgal-/- mice intracranially injected with AAV retain significant 
motor performance on the rotarod 
Animals were assessed for motor function on an accelerating rotarod test (4-40 
rpm over 5 minutes).  Highest value from three trials was recorded. βgal-/- 
animals treated with a total dose of AAVrh8 vector of (a) 4e10vg (b) 2.6e10vg 
and (c) 2.6e9vg all retained motor performance significantly better than naïve 
βgal-/-  controls at 6 months post injection using non-parametric, unpaired 
Student T Test and Welsh-correction (P = 0.006, 0.0009, 0.005 respectively).  N 
= 3-15 animals/group at each time point, and N = 6-10 animals/group at 6 
months post-treatment. 
  
112 
 
AAV treatment extends lifespan 
The lifespan of AAVrh8-treated βgal-/- mice was significantly increased 
compared to naïve βgal-/- controls (Fig. 3.4).  Median survival for naïve βgal-/- 
controls was 245.5 days (N = 18), 293.5 days for the 4e10vg cohort (N = 12, p = 
0.0004), 349 days for the 2.6e10vg cohort (N = 13, p = 0.002) and 389 days for 
the 2.6e9vg cohort (N = 12, p < 0.0001).  Of note, there were a subset of animals 
in the 4e10vg that developed tremor and circling behavior ~2weeks post 
injection.  These animals were excluded from lifespan and behavioral testing.  
We retained these animals for analysis to understand this phenomenon.   
 
GM1-ganglioside storage persists at the injection site and in the spinal 
cord of long-lived AAV treated animals 
Histological analysis of lysosomal storage by Filipin staining in the CNS of 
animals at 3 months post injection (data not shown) revealed nearly complete 
correction in the brain and cerebellum that was corresponding to enzyme 
presence as seen in Xgal staining at the same time point (Fig. 3.2).  Surprisingly 
Filipin-positive cells were only found at the injection sites, or along the injection 
track (Fig 4.5c, e). Filipin was originally identified as a potent anti-fungal with UV-
VIS and IR properties (232), but was found to also bind directly to cholesterol and 
GM1 ganglioside (214).     
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:Figure 3.4 AAVhr8 intracranially injected βgal-/- mice achieve significant 
extension in lifespan 
Kaplan-Meier survival curves for intracranial AAVrh8 treated βgal-/- mice.  Treated 
mice with a total dose of AAVrh8 vector of (blue) 4e10vg (green) 2.6e10vg and 
(orange) 2.6e9vg all had a significant extension of life span vs. naïve βgal-/- 
controls using Log-rank (Mantel-Cox) test (p = 0.0004, 0.002, < 0.0001 
respectively).  Median survival was increased from (red) naïve βgal-/- controls 
(245.5 days, N = 13) to 4e10vg cohort (293.5 days, N = 12), 2.6e10vg cohort 
(349.0 days, N = 13) and 2.6e9vg cohort (389.0 days, N = 13).   
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Figure 3.5 Intracranial injections of AAV in βgal-/- mice result in abnormal 
Filipin staining in areas of highest enzyme expression. 
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Figure 3.5 Intracranial injections of AAV in βgal-/- mice result in abnormal 
Filipin staining in areas of highest enzyme expression. 
Coronal sections of mouse brain stained with Xgal (blue) for βgal enzyme 
presence and counterstained with Nuclear Fast Red (red) at 12 weeks post 
injection in (a) representative βgal-/- (KO + AAV) injected with 1µl of AAVrh8-
CBA-mβgal-WPRE (2.6e10vg total dose) bilateral into the thalamus and (b)   
βgal-/- mouse untreated (KO Untreated).  Red boxes represent location of 
pictures in (c)-(f), Filipin staining on adjacent brain sections in (c, e) βgal-/- animal 
treated with 2.6e10vg of AAVrh8-CBA-mβgal-WPRE or (d, f) a βgal-/- mouse 
untreated (KO Untreated).  Filipin images taken at 10X magnification. .  Images 
are representative of N ≥ 3 mice/group.   
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The presence of Filipin-positive cells in the thalamus of AAVrh8-injected 
gal-/- mice was surprising as it is also the brain region that displays the most 
intense X-gal histochemical staining in the brain (Fig. 3.5a, red boxes), which we 
interpret as a semi-quantitative indicator of high gal enzyme activity. In the 
spinal cord of long-lived AAV-treated mice (495-612 days) the impact on 
lysosomal storage was variable ranging from regions with very few remaining 
Filipin-positive cells to regions with no apparent change compared to untreated 
gal-/- controls (Fig. 3.6a, d, f and b, c, e, respectively).  
 
Neuropathology at the injection sites  
Animals were histologically assessed with Hematoxylin & Eosin (H&E) after early 
loss or at 3 months post injection.  These animals were found to have 
morphological changes at the injection site that correlated with dose.  βgal-/- + 
AAV 4e10vg at 2 weeks post injection demonstrated large amounts of changes in 
the thalamus such as vascular cuffing (large amount of cells with small nuclei 
surrounding a blood vesicle) and the appearance of inflammation (concentration 
of cells with small nuclei) (Fig. 3.7a & b, thick and thin arrows, respectively), and 
in the DCN with vascular cuffing and apparent neuronal engulfment (Fig. 3.8a, 
thick arrow and b, arrow heads, respectively).  In βgal-/- + AAV 2e10vg at 3 
months post-treatment thalamic alterations were also seen with vascular cuffing 
and inflammation (Fig. 3.7e & f, thick and thin arrows, respectively).  However,   
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Figure 3.6 Lysosomal storage persists in the spinal cords of long-lived AAV 
intracranial injected βgal-/- mice 
Spinal cord sections cut at 20μm were stained with Filipin for GM1-ganglioside 
storage.  All long-lived animals showed some amount of clearance in the spinal 
cord, but also contained regions where clearance did not occur.  (a, b) 4e10vg at 
621 days (c, d) 2.6e10vg at 547 days, (e, f) 2.6e9vg at 495 days and (g, h) Naïve 
βgal-/- ~250 days with storage throughout.  Images are representative of N ≥ 2 
mice/group.   
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Figure 3.7 Intracranial injections of AAV in βgal-/- mice result in 
morphological changes at the site of injection in the thalamus 
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Figure 3.7 Intracranial injections of AAV in βgal-/- mice result in 
morphological changes at the site of injection in the thalamus 
Intracranially injected βgal-/- mice were analyzed at 2 week (4e10vg) or 3 months 
(2.6e10vg and 2.6e9vg) post-injection by H&E staining of 20 µm coronal brain 
sections. Morphological changes in the injected region of the thalamus: thick 
arrow denotes vascular cuffing, thin arrow indicates inflammation.  Left panel 
taken at 10x, right panel a 40x picture (from regions on the left panel).  
Morphological changes and neuronal loss appear to lessen at lowest inject dose.  
(a, b) 4e10vg at 2 weeks post-treatment (e, f) 2.6e10vg at 3 months post-
treatment, (i, j) 2.6e9vg at 3 months post-treatment, (c, d) Naïve βgal+/- at age of 
treated animals, (e, f) Naïve βgal-/- at age of treated animals, (k) example 
cerebrum injected with AAVrh8-mβgal.  Red arrow indicates injection site in βgal 
animals and location of pictures shown here.  Scale bar represents 100um.  
Images are representative of N ≥ 3 mice/group.   
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Figure 3.8 Intracranial injections of AAV in βgal-/- mice result in 
morphological changes at the site of injection in the deep cerebellar nuclei 
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Figure 3.8 Intracranial injections of AAV in βgal-/- mice result in 
morphological changes at the site of injection in the deep cerebellar nuclei 
Intracranially injected βgal-/- mice were analyzed at 2 week (4e10vg) or 3 months 
(2.6e10vg and 2.6e9vg) post-injection by H&E staining of 20 µm coronal brain 
sections. Morphological changes noted in the injected region of the DCN. Thick 
arrow denotes vascular cuffing. Arrowhead indicates suspected neuronal 
engulfment.  Left panel taken at 10x, right panel at 40x (from regions depicted on 
the left panel).  Morphological changes and neuronal loss appear to lessen at 
lowest inject dose.  (a, b) 4e10vg at 2 weeks post-treatment (e, f) 2.6e10vg at 3 
months post-treatment, (i, j) 2.6e9vg at 3 months post-treatment, (c, d) Naïve 
βgal+/- at age of treated animals, (e, f) Naïve βgal-/- at age of treated animals, (k) 
example DCN injected with AAVrh8-mβgal.  Red arrow indicates injection site in 
βgal animals and location of pictures shown here.  Scale bar represents 100um.  
Images are representative of N ≥ 3 mice/group.   
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βgal-/- + AAV 2e10vg dose in the DCN had less vascular cuffing only (Fig. 3.8e, 
thick arrow).  In the lowest dose representative animal, βgal-/- + AAV 2e9vg at 3 
months post injection only very minimal inflammation was seen in the thalamus 
(Fig. 3.7j, thin arrow) and this effect was absent in the DCN (Fig. 3.8i & j).  
Neither vascular cuffing nor inflammation was seen in untreated βgal-/- controls 
(Fig. 3.7c, d and Fig. 3.8c, d) or in untreated βgal+/- controls (Fig. 3.7g, h and Fig. 
3.8g, h).   
 
High levels of βgal induce an unexpected response in injected brain 
structure. 
The paradoxical presence of Filipin-positive cells at the injection sites (Fig. 
3.5c, e) could be the result of treatment failure, or an unexpected response to 
AAV gene transfer in gal-/- mice.  To understand this phenomenon, normal, 
unaffected gal+/- littermates were injected intracranially with AAVrh8 vector to 
distinguish between those two possibilities. Similar to the results in gal-/- mice 
(Fig. 3.5c & e), large numbers of Filipin-positive cells were present in brain 
regions with the highest gal staining intensity (Fig. 3.9a, b) in AAVrh8-injected 
gal+/- mice (Fig. 3.9d, g, j). This result indicates that the presence of Filipin-
positive cells in the targeted brain structures is an unexpected adverse response 
to an aspect of AAV gene transfer.   
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Figure 3.9 Intracranial injections of AAV in βgal+/- and βgal-/- mice result in 
abnormal Filipin staining in areas of most intense enzyme expression. 
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Figure 3.9 Intracranial injections of AAV in βgal+/- and βgal-/- mice result in 
abnormal Filipin staining in areas of most intense enzyme expression. 
Sagittal sections of mouse brain stained with Xgal (blue) for βgal enzyme 
presence and counterstained with Nuclear Fast Red (red) at 10 weeks post 
injection in representative (a) βgal+/- (CA + AAV) (b) βgal-/- (KO + AAV) injected 
with 1µl of  AAVrh8-CBA-mβgal-WPRE at 1.7x1012vg/µl bilateral into the 
thalamus, 2ul into intracerebral ventricles and 0.3ul in the deep cerebellar nuclei, 
and (c) βgal-/- mouse untreated (KO Untreated).  Red boxes represent location of 
pictures in (d)-(i).  Filipin staining was positive in regions of most intense enzyme 
expression in both (d, g, j) βgal+/- (CA + AAV) (e, h, k) βgal-/- (KO + AAV) injected 
animals.  (f, i, l) βgal-/- mouse untreated (KO Untreated) had no change in Filipin 
content.  Filipin staining on brain sections taken at 10X magnification. Images are 
representative of N ≥ 3 mice/group.   
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Validation of AAVrh8 vector series to assess contribution of enzyme 
activity, protein levels, and AAVrh8 capsid to Filipin-detected response.  
A series of AAVrh8 vectors were designed to understand the nature of this 
unexpected response at the injection sites (Table 3.1). This series of AAVrh8 
consisted in sequential removal of elements that influence transgene expression 
levels in the original vector, AAVrh8-CBA-mgal-WPRE, which will be referred to 
as ‘CBA-WPRE’ from here on. In vector 2 ‘CBA’, the woodchuck hepatitis virus 
post-transcriptional regulatory element (WPRE) was removed. Vector 3 ‘CBA-EI-
WPRE’ has the exact same backbone as vector 1 but encodes a gal protein 
carrying an E269Q mutation in the putative active site (8, 17). This vector was 
designed to assess whether the observed response was caused by enzymatic 
activity or protein production. Vector 4 ‘CB6’ contained mgal cDNA, but did not 
carry WPRE or the chimeric intron present in the other vectors.  This vector was 
tested at two doses, ‘CB6 Low’ (same dose as all other vectors), and ‘CB6 High’ 
(2.0e10vg).  Vector 5 ‘transgene empty’ or ‘T. Empty’ contained all components 
of vector 1, but lacked the mβgal cDNA.    
 The newly constructed AAVrh8 vectors were injected bilaterally into the 
thalamus of normal βgal+/- mice (1 µl/site for total dose of 3.4e9vg), except the 
CB6 vector, which was also injected at a higher dose (1 µl/site for total dose of 
2.0e10vg).  Controls were βgal+/- mice injected with phosphate buffered saline 
(PBS), and naïve βgal+/- mice. Enzyme activity and protein production in the   
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Table 3.1 List of alterations in vectors designed to evaluate storage 
biomarker Filipin persistence  
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Figure 3.10 Alterations in vector design lead to a changes in βgal protein 
presence and/or enzyme activity in βgal+/- mice 
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Figure 3.10 Alterations in vector design lead to a decrease in βgal  
protein presence and/or enzyme activity in βgal+/- mice. 
 
 (a) βgal enzyme activity in 2mm x 2mm biopsy punches in injected structures.  
1µl of AAVrh8-vector (total dose 3.4e9vg, or 2.0e10vg, CB6 High only) or mock 
treated PBS bilateral into the thalamus, as determined by 4-MU assay at ~6 
weeks post injections.  Enzyme activity is normalized to protein concentration by 
Bradford, and is reported as nmol/hour/mg protein.  Error bars represent mean + 
SD, N = 3/group, and * indicates significant difference of βgal+/- + AAV (CA + 
vector name) vs. βgal+/- Untreated (CA Untreated) or as indicated by connecting 
line.  P value calculated using unpaired multiple T tests (Holm-Sidak) where * = p 
< 0.05, ** = p < 0.01, and *** = p < 0.001.  (b) Endogenous βgal protein presence 
as determined by Western blot which appears at 67kd, where transgene 
expression from the AAV vector appears as a higher weight band.  Loading 
control is Actin appearing at 42kd.  Western blot shown is representative of N = 3 
blots ran.  Samples analyzed for enzyme activity (a) are from either the 
contralateral side of animals in (b) or from injected animals in the same cohort .   
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thalamus were measured by 4-methylumbelliferyl (4-MU) biochemical assay and 
western blot 6 weeks after injection (Fig. 3.10). 
The CBA-WPRE vector generated the highest enzyme activity at 686 fold 
above that in thalamus of naïve βgal+/- mice (Fig. 3.10a), and corresponding 
elevation in protein (Fig. 3.10b, lane 1).  The CBA vector resulted in βgal activity 
224 fold over βgal+/- level, which was significantly lower than that obtained with 
CBA-WPRE vector (Fig. 3.10a, orange bar, p = 0.001) and an apparent 
corresponding decrease in protein product (Fig. 3.10b, lane 2).  In thalami of 
mice injected with CBA-EI-WPRE vector the βgal activity was comparable to that 
in naïve control mice (Fig. 3.10a), but the protein was expressed at comparable 
levels to those in CBA-WPRE injected thalami (Fig. 3.10b, lane 3 vs. lane 1). 
Therefore, the E269Q mutation abrogates enzyme activity but does not seem to 
affect protein expression levels.  Injection of CB6 vector at the same dose as the 
other vectors (CB6-Low) resulted in βgal activity 54 fold above over βgal+/- level 
(Fig. 3.4a, green bar), and protein presence at a correspondingly lower amount 
that with the other vectors (Fig. 3.10b, lane 4).  Injection of this vector at higher 
dose (CB6-High) resulted βgal activity 420 fold above over βgal+/- level, which is 
significantly higher than in the CB6-Low cohort (Fig. 3.10a-b, p = 0.03).  The βgal 
activity level in the CB6-High cohort was comparable to that measured in the 
CBA-WPRE cohort, and appeared similar in protein levels (Fig. 3.10a-b, blue bar 
& lane 1 vs. pink bar & lane 5).  The thalami of animals injected with transgene 
empty vector (T. Empty) or PBS showed no change in βgal activity or protein   
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Figure 3.11 Vector genome presence in injected structure biopsy punches in 
βgal+/- mice 
Vector genomes per diploid genome in a 2mm x 2mm biopsy punches in injected 
structure where 1µl of AAVrh8-vector (total dose 3.4e9vg, or 2.0e10vg, CBA High 
only) bilateral into the thalamus of βgal+/- mice (CA + vector name) as determined 
by qPCR to the SV40 poly A on the transgene.  Samples were taken at 6 weeks 
post injection.  Error bars represent mean + SD, N=3/group, and * indicates 
significant difference indicated by connecting line and using unpaired multiple T 
tests (Holm-Sidak) where * = p < 0.05, ** = p < 0.01 and *** = p < 0.001.   
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level compared to naïve βgal+/- levels (Fig. 3.10a-b).  The number of vector 
genome copies in AAV-injected thalami were shown to be comparable in most 
cohorts injected with a total dose of 3.4e9 vg, except in the T.empty cohort (Fig. 
3.11).  As expected, the CB6-High cohort infused with 2.0e10 vg showed 
significantly increased number of vector genome copies (Fig. 3.11, blue bar).  
 
Filipin-detected response correlates with protein levels. 
The brains of AAVrh8-injected and control βgal+/- mice were analyzed for 
βgal enzymatic activity by Xgal staining (Fig. 3.12a, d, g, j, m, p, s) and for 
presence or absence of Filipin-positive cells in the thalamus (Fig. 3.12b, e, h, k, 
n, q, t).. The thalamic regions with the most intense βgal staining (Fig. 3.11a & d, 
red boxes) also contained Filipin-positive cells in CBA-WPRE and CBA injected 
animals, albeit at apparently lower numbers in the latter cohort (Fig. 3.11b, e).  
The thalami in the CBA-EI-WPRE cohort had large numbers of Filipin-positive 
cells, but no active βgal enzyme (Fig. 3.11k & j, respectively).  Similar Filipin 
staining was apparent in the thalami of T-empty and CB6-low cohorts (Fig. 3.11 k 
&q), but it appeared as small puncta distinct from the pattern observed in the 
CBA-WPRE and CBA-EI-WPRE cohorts. Filipin staining was also observed in 
the thalami of CB6-High cohort and the pattern appeared a mix of that observed 
in the CBA-WPRE and CB6-Low cohorts (Fig. 3.11h). These results suggest the  
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Figure 3.12 Vectors with decreasing protein presence lead to decrease in 
Filipin positive regions in βgal+/- mice  
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Figure 3.12 Vectors with decreasing protein presence lead to decrease in 
Filipin positive regions in βgal+/- mice. 
Coronal sections of mouse brain stained with Xgal (blue) for βgal enzyme 
presence and counterstained with Nuclear Fast Red (red) at 6 weeks post 
injection in (a, d, g, j, m, p) in representative βgal+/- (CA + vector name) injected 
with 1µl of AAVrh8-vector (total dose 3.4e9vg, or 2.0e10vg in the CBA High only) 
bilaterally into the thalamus or βgal+/- un-injected (CA Untreated). (b, e, h, k, n, q) 
Filipin staining and ToPro3 nuclear stain (c, f, i, l, o, r) in parallel sections of the 
same animals in (a, d, g, j, m, p).  Red boxes represent approximate location of 
pictures in (b, c, e, f, h, i, k, l, n, o, q, r) Filipin and ToPro3 staining on brain 
sections taken at 20x magnification.  Scale bar = 250 µm.  Images are 
representative of N ≥ 2 mice/group.   
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abnormal Filipin accumulation at the injection site is related to protein expression 
levels and not enzyme activity.  
 
Transcriptomic changes in injected thalami correlate with Filipin-detected  
abnormal response. 
Microarray analysis was performed in the thalami to further characterize 
the tissue response to this apparent pathological change induced by gene 
transfer. Total thalamic RNA was isolated from CBA-mβgal-WPRE, CB6-Low, 
T.Empty and PBS-injected cohorts.  Transcriptomic changes (fold change > 1.8-
fold, p<0.05) for all samples analyzed are represented in a heat map (Fig. 3.13a).  
CB6-low and T.Empty samples cluster together with PBS, and are different from 
CBA-WPRE samples. The number of genes with >2-fold change in expression 
levels (p<0.05) is considerably larger in CBA-WPRE samples compared to CB6 
and T.Empty with a few overlapping genes (Fig. 3.13b). A number of genes up-
regulated in the CBA-WPRE samples are characteristic of activated microglia 
and reactive astrocytes (Table 3.2). None of these genes showed significant 
changes in CB6 or T.Empty samples.  
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Figure 3.13 Clustering heatmap and Venn diagram of all differentially 
expressed genes in βGal+/- mice demonstrate transgene expression 
dependent variation. 
(a) Heatmap and (b) Venn diagram of all differentially expressed genes from a 
2mm x 2mm biopsy punch of thalamus injected with 1 µl of AAVrh8-vector  
(3.4e9vg total dose)  or mock treated with PBS bilaterally, at ~6 weeks post 
injection in βgal+/- mice (CA + vector name). Microarray results determined by 
Affymetrix Mouse Gene 2.0ST, N = 3/group, P<0.05 and >1.8 fold change.   
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Table 3.2 Select genes upregulated in microarray analysis of the CBA-
WPRE vector.  Fold change is CBA-WPRE vector over PBS. 
  
Gene Gene name Function Fold change Reference
Serpina3n serine (or 
cysteine) 
peptidase 
inhibitor, clade A
Peptidase inhibitor, response to 
cytokine, marker of reactive gliosis
1.9 Winkler et al , 
2005; Zamanian 
et al , 2012
Gbp3 guanylate 
binding protein 3
Response to interferon β, response 
to interferon γ, upregulated in LPS 
reactive astrocytes
3.2 Burckstummer et 
al , 2009;  
Degrandi et al , 
2007; Zamanian 
et al , 2012
B2m beta-2-
microglobulin
Antigen processing and presentation, 
cellular defense response, 
upregulated in LPS reactive 
astrocytes
2.2 Uginovic et al , 
2005;  Zijilstra et 
al , 1989;  
Zamanian et al , 
2012
Cd86 Cd86 antigen Costimulatory ligand, upreglated in 
SOD1G93A microglia
2.3 Chiu et al , 2013
Trem2 triggering 
receptor 
expressed on 
myeloid cells 2
Transmembrane protein - triggers 
myeloid cells, increase phagocytic 
activity, supress cytokine production, 
upreglated in SOD1G93A microglia
3.0 Melchior et al, 
2010; Trash et al, 
2009;  Chiu et al, 
2013
C1qa complement 
component 1, 
subcomponent, 
alpha 
polypeptide
Complement activiation, upreglated 
in SOD1G93A microglia
3.0 Azeredo da 
Silveira et al , 
2002;  Chiu et al , 
2013
Gfap glia fibrillary 
acidic protein
Marker of reactive gliosis, upreglated 
in SOD1G93A microglia
3.6 Jessen & Mirsky, 
1980; Chiu et al, 
2013
Cybb cytochrome b-
245, beta 
polypeptide
Proinflammatory oxidase, upreglated 
in SOD1G93A microglia
4.8 Harraz et al , 
2008; Chiu et al, 
2013
Genes upregulated in CBA-WPRE 
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Therapeutic impact of different AAVrh8 vectors in GM1-gangliosidosis mice 
From the studies performed in βgal+/- mice above, a correlation was 
determined that reduced protein expression from the transgene could reduce the 
pathological transcription level changes in the injected structure.  We then sought 
to determine if the changes in AAV vector design translated into differences in 
therapeutic outcome in GM1-gangliosidosis mice (βgal-/-).  Six to eight week old 
βgal-/- mice received bilateral injections of AAV vector into thalamus (1 µl/side) 
and deep cerebellar nuclei (0.3 µl/side) and the outcomes measured at ~ 6 
weeks post-injection.  Study cohorts were βgal-/- mice injected with CBA-WPRE, 
CB6 (CB6-Low), and Transgene Empty vectors administered at a total dose of 
4.4e9vg.  In addition, CB6 was injected at a total dose of 2.6e10vg (CB6-High).  
Naïve untreated βgal-/- and βgal+/+ animals were used as controls.  Evaluation of 
βgal activity by 4-MU assay of the CNS (Fig. 3.14) showed that in the cerebrum 
CBA-WPRE was 45-fold higher than wild type level (Fig. 3.14, orange bar), 
where CB6 Low was 9-fold higher (Fig. 3.14, olive bars) and CB6 High was 30-
fold higher (Fig. 3.14, green bar).  As expected T.Empty and untreated cohorts of 
βgal-/- mice had no detectable βgal activity in any CNS region analyzed (Fig. 
3.14, blue and purple bars, respectively).  In the cerebellum + brainstem the 
trend was the same, with CBA-WPRE at 47-fold (Fig. 3.14, orange bar), CB6-
Low at 6-fold (Fig. 3.14, olive bar), and CB6-High at 27-fold above wild type level 
(Fig. 3.14, green bar).  Interestingly, in the spinal cord CBA-WPRE was only 50% 
of wild type level (Fig. 3.14, orange bar), CB6-High was 30% (Fig. 3.14, olive   
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Figure 3.14 Varied anatomical distribution of βgal enzyme activity in the 
CNS of treated βgal-/- mice  
βgal enzyme activity in cerebrum, cerebellum + brainstem or spinal cord of βgal-/-  
injected bilaterally 1µl into the thalamus and 0.3ul in the DCN of AAVrh8-vector 
(total dose 3.4e9vg, or 2.0e10vg, CBA High only) or untreated (KO Untreated) or 
βgal+/+ mice untreated (WT Untreated), as determined by 4-MU assay at ~6 
weeks post injections.  Enzyme activity is normalized to protein concentration by 
Bradford, and is reported as nmol/hour/mg protein.  Values represent mean + 
SD, N = 3/group, and * indicates significant difference of βgal-/- + AAVrh8-CB6 
vector (total dose 3.4e9vg, KO + CB6 Low) vs. βgal-/-- + AAVrh8-CB6 vector (total 
dose 2.0e10vg, KO + CB6 High).  P value calculated using unpaired T tests 
(Holm-Sidak) where *** = p<0.001.   
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bar), and CB6-Low had no detectable activity (Fig. 3.14, green bar).  In all CNS 
tissues analyzed, CB6-High was significantly higher (p < 0.001) in βgal activity 
than the same vector injected at the lower dose, CB6-Low.   
The βgal distribution pattern in the brain as exemplified by histological 
stain X-gal (Fig. 3.15) correlated with the activity levels in the cerebrum or 
cerebellum + brainstem determined by the 4-Mu assay (Fig. 3.14). The CBA-
WPRE vector resulted in dark blue staining in thalamus and DCN and 
widespread distribution of detectable enzyme activity throughout the brain (Fig. 
3.15a).  In contrast, in the CB6-Low cohort (Fig. 3.15b) there was intense 
staining in thalamus and DCN but lower detectable levels throughout the 
cerebrum, cerebellum or brainstem. In CB6-High animals, the βgal pattern of 
distribution in brain appeared broader than in CB6-Low animals (Fig. 3.15c).  As 
anticipated, there was no evidence of increased βgal activity in T.Empty (Fig. 
3.15d) and naïve βgal-/- mouse cohorts (Fig. 3.15e). 
Results of histological analysis of lysosomal storage in brain and spinal 
cord using Filipin staining (Fig. 3.16) paralleled the βgal activities (Fig. 3.14) and 
distribution patterns (Fig. 3.15) described above.  In CBA-WPRE injected 
animals, there was nearly complete clearance of storage throughout the brain 
(Fig. 3.16a-g), except at the injection site and track with Filipin-positive cells in 
ventral hippocampus and throughout the thalamus (Fig. 3.16, d, respectively, 
arrows).  Storage clearance in the CB6-Low cohort appeared less efficient   
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Fig 3.15 Xgal staining for βgal enzyme presence in βgal-/- mice 
demonstrates spread of enzyme throughout the brain in an expression and 
dose dependent manner 
Sagittal sections of mouse brain stained with Xgal (blue) for βgal enzyme activity 
and counterstained with Nuclear Fast Red (red) at ~6 weeks post injection in a 
representative βgal-/- injected bilaterally with 1µl into the thalamus and 0.3ul in the 
DCN of AAVrh8-vector (total dose 3.4e9vg, or 2.0e10vg for the CBA High only), 
or untreated (KO Untreated) or βgal+/- mice untreated (CA Untreated).  N = 2-
3/group.  Scale bar = 10mm. 
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Figure 3.16 Filipin staining for GM1-ganglioside content in the brain of  
βgal-/- mice after therapeutic AAVrh8 treatment 
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Figure 3.16 Filipin staining for GM1-ganglioside content in the brain of  
βgal-/- mice after therapeutic AAVrh8 treatment 
Sagittal sections of mouse brain stained with Filipin for GM1 content or nuclear 
stain ToPro3 (KO Untreated, ToPro3, bottom row) at 6 weeks post injection in a 
representative βgal-/- injected bilaterally with 1µl into the thalamus and 0.3ul in the 
DCN of AAVrh8-vector (total dose 3.4e9vg, or 2.0e10vg, CBA High only), or 
untreated (KO Untreated). N = 2-3/group.  Images taken at 5X, scale = 100mm. 
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Figure 3.17 Filipin staining for GM1 content in spinal cords of βgal-/- mice after 
therapeutic treatment with AAVrh8 vectors  
144 
 
Figure 3.17 Filipin staining for GM1 content in spinal cords of βgal-/- mice after 
therapeutic treatment with AAVrh8 vectors 
Cervical and thoracic sections of spinal cord stained with Filipin for GM1 content 
or nuclear stain ToPro3 (KO Untreated, ToPro3, bottom row) at 6 weeks post 
injection in representative βgal-/- injected bilaterally with 1µl into the thalamus and 
0.3ul in the DCN of AAVrh8-vector (total dose 3.4e9vg, or 2.0e10vg, CBA High 
only), or untreated (KO Untreated).  N = 2-3/group.  Images taken at 5X, scale = 
100mm. 
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(Fig. 3.16h-n) as Filipin-positive cells were still present in anterior cortex, striatum 
and brainstem (Fig. 3.16i, l, n, respectively, arrows).  At the higher dose (CB6-
High) the efficiency of CB6 vector was very high with resolution of lysosomal 
storage throughout the brain (Fig. 3.16o-u).  As before, Filipin-positive cells were 
present in ventral hippocampus and dorsal thalamus, however less then in CBA-
WPRE (Fig. 3.16o, r, respectively, arrows).  The T.Empty cohort (Fig. 3.16v-bb) 
showed no change in lysosomal storage compared to βgal-/- untreated controls 
(Fig. 3.17cc-ii).  
The spinal cords of AAV-treated animals were also evaluated for storage 
content by Filipin staining.  Spinal cords in CBA-WPRE animals had almost no 
remaining storage in the cervical region however, the thoracic region only 
showed minimal reduction (Fig. 3.17a-b, respectively, arrows).  Spinal cords in 
CB6-Low animals had almost no distinguishable reduction in storage compared 
to untreated controls (Fig. 3.17c-d).  Spinal cords in CB6-High animals were 
nearly devoid of lysosomal storage in cervical and thoracic regions (Fig. 3.17e-f, 
arrows).  As anticipated, the spinal cords of T.Empty animals showed no change 
in lysosomal storage compared to untreated βgal-/- control.  (Fig. 3.17g-h and i-j, 
respectively).   
GM1 ganglioside level in CNS was quantified by LC-MS/MS (Fig. 3.18). In 
CBA-WPRE and CB6-Low cohorts there was significant reduction in GM1 
ganglioside content in comparison to untreated βgal-/- controls in cerebrum    
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Figure 3.18 Therapeutic treatment using AAVrh8 in the CNS of βgal-/- mice 
result  in normalization of GM1 content when treated with a lower 
expressing promoter at a higher dose.  
GM1 content as quantitated by LC-MS/MS in cerebrum, cerebellum + brainstem 
or spinal cord of mice at.  6 weeks post injection in βgal-/- injected bilaterally with 
1µl into the thalamus and 0.3ul in the DCN of AAVrh8-vector (total dose 3.4e9vg, 
or 2.0e10vg for the CBA High group only), untreated (KO Untreated), or βgal+/- 
untreated (WT Untreated).  GM1 content represented as ng GM1/µg protein.  
Values represent mean + SD, N ≥ 3/group and * indicates significant difference of 
KO + AAVrh8 vs. KO + PBS, or as indicated by connecting line, using multiple T 
tests (Holm-Sidak) where * = p < 0.05, ** = p < 0.01, and *** = p < 0.001.   
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(p = 0.0009 and p = 0.002, respectively) and cerebellum + brainstem (p < 0.0001 
and p = 0.0001, respectively).  There was no significant change in GM1 
ganglioside content in the spinal cord in either cohort.  In the CB6-High cohort 
the GM1 ganglioside level was normalized in all CNS areas investigated 
cerebrum, cerebellum + brainstem, and spinal cord (Fig. 3.18, green bars, p = 
0.64, p = 0.06 and p = 0.79 respectively).  As anticipated, there was no change in 
GM1 ganglioside content anywhere in CNS in the T.Empty cohort compared to 
naïve βgal-/- controls (Fig. 3.18, blue and purple bars, respectively).   
 
Discussion 
Previous studies from our lab using intracranial injection of AAV gene 
therapy for GM1-gangliosidosis used an AAV1 vector delivered in neonates via 
the cerebral lateral ventricles (197) or injected bilaterally into thalamus and DCN 
in adult animals (198).  These vectors were efficient at delivering high levels of 
active enzyme to the brain and provided a delay in disease onset (197), but were 
not effective at retaining motor function and only provided nominal increases in 
survival outcomes (198).  
In this study we show that intracranial delivery of AAVrh8 into the 
thalamus and DCN of adult animals with total dose 4e10vg, 2.6e10vg, or 2.6e9vg 
successfully delivers enzyme to the brain (Fig 4.2), provides a significant but 
modest retention of motor function (Fig. 3.3) and significantly extends lifespan in 
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all groups (Fig 4.4) in a dose dependent manor.  However, in the course of this 
work we also discovered an unusual occurrence where the histological stain 
indicating the storage of GM1 ganglioside, Filipin, was present at the areas of 
highest enzyme expression.  In addition, this finding was consistent in both GM1 
affected βgal-/- and non-disease carrying βgal+/- mice (Fig.4.5 and 4.9), which 
demonstrates that Filipin was responding in an abnormal manner and may be 
indicating a pathological finding.  Further analysis of AAV treated βgal-/- mice 
showed that these animals displayed signs of neuropathology at the injection site 
of inflammation, vascular cuffing and apparent neuronal engulfment, which were 
lessened with decreasing vector, dose (Fig.4.7 and 4.8). 
Dogma in the LSD field is to try and deliver the largest amount of 
transgene product to the CNS in order to obtain the best therapeutic outcome.  .  
Utilizing the property of cross correction (85-88).and by injection of a viral vector 
into highly connected structures within the brain, it is believed that the largest 
therapeutic impact can be achieved.  In addition, methods to enhance transgene 
output, vector spread throughout the tissue, and entry into the CNS are also 
employed.  To this end, methods used include the application of ubiquitous 
promoters (199, 200, 233) (210) and post-translational elements (198-200, 228), 
capsid selection for tissue/cell tropism (231, 234), convection enhanced delivery 
(235, 236), injecting during the neonatal period when the blood-brain barrier 
(BBB) is not fully formed (197, 231), and blood-brain barrier disrupting agents 
such as mannitol (175, 235).  In our current study we utilized many of these 
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parameters by injecting into the thalamus and DCN, using a broad transduction 
capsid and widely expressing promoter as well as a post transcriptional element. 
However, our results led to questioning the safety of such high expression in a 
sensitive tissue.  The safety of overexpressing an LSD enzyme was previously  
evaluated by two papers from the Sly group investigating the transgenic 
overexpression of the enzyme β-glucuronidase (GUSB) in an animal model of the 
LSD mucopolysaccharidosis VII (MPS VII) in a mouse deficient of the active 
enzyme (237), and a following study with extreme overexpression in a non-
diseasing carrying mouse model (238) .  Interestingly, these studies indicated 
that no abnormal phenotypes were detected, the animals were fertile and 
mortality was not increased even in animals expressing 100-1000s fold increase 
of the enzyme (204).   
Results from our current study suggest there may be an upper limit to 
tolerance of the CNS to enzyme expression levels as the neuropathological 
response at the injection site were dose-dependent.  Gentner et al. support this 
hypothesis, as overexpression of a transgene product was detrimental in cultured 
cells of the lysosomal storage disorder, Globoid cell leukodystrophy (GLD) (179).  
In that study, a lentiviral infection of the missing galactocerebrosidase enzyme, 
but not a GFP expressing vector led to apoptosis (179).  This work demonstrated 
that in particular cell populations, here hematopoietic stem and progenitor cells, 
over expression of the lysosomal enzyme led to deleterious effects.  Salegio et 
al., revealed a pathological response to enzyme over expression (239), A safety 
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study of the intracranially delivered AAV2 vector carrying the lysosomal enzyme 
acid sphigomyelinase for the treatment of LDS Niemann-Pick disease in 
nonhuman primates presented with dose related toxicity behavioral alterations, 
histological alterations, and biochemical responses (239).  Interestingly, this 
effect was not found in AAV2-treated disease carrying rats.  Also noteworthy is 
that the primary substrate of this enzyme, sphingomyelin leads to further 
breakdown products which are known signaling molecules in cell death and cell 
survival pathways. Interestingly, in the safety study of the lysosomal enzyme β-
glucuronidase (GUSB), GUSB overexpression led to lysosomal storage of the 
enzyme itself in peripheral tissues as well as the brain, but did not result in 
neuropathology (237).   
Using a series of AAVrh8 vectors that sequentially varied the amount of 
protein and/or active enzyme in the system after intracranial injection we 
evaluated the abnormal responses to mβgal overexpression  (Table 3.1).  
Modifications included removal of the post translational element, creation of an 
inactive form of the mouse-β-galactosidase enzyme, a minimally expressing 
promoter, and removal of the mβgal cDNA from the transgene.  Analysis of direct 
injection of these viral vectors into the thalami of βgal+/- mice determined a 
protein expression dependent correlation to the abnormal Filipin.  Abnormal 
Filipin staining was detected from a highly expressed vector with an active 
enzyme, CBA-mβgal-WPRE, as well as in a vector with the same backbone 
151 
 
carrying an inactive enzyme, CBA-E269Q-mβgal-WPRE, but was not seen in low 
expressing vector with active enzyme CB6-mβgal (Fig. 3.12).  
Further elucidation of this process was provided by microarray analysis on 
punch biopsies from animals injected with vectors expressing mβgal at levels 
over βgal+/- levels of 686 fold (CBA-mβgal-WPRE), 54 fold (CB6-mβgal), no 
additional expression (CBA-transgene empty-WPRE), and mock-injected (PBS).  
Microarray results (Fig. 3.13a-b) showed that CBA-WPRE provided the biggest 
response with 232 genes upregulated and 7 downregulated.  In comparison, CB6 
had 20 genes up and 12 down and Transgene Empty with 18 genes up and 17 
down.  These resulted indicated that a large effect on transcription was occurring 
from the presence of a high expressing vector, and that this effect was mitigated 
by a low expressing vector or the AAVrh8 capsid alone.  Interestingly, distinct 
upregulation of genes related to immune and astrogliosis responses were also 
determined from the CBA-WPRE vector, but not in the either the CB6 and CBA-
T. Empty-WPRE (Figure 4.2).  This type of upregulation was also seen in from a 
study investing the transcriptional profile of neurodegeneration in ALS effecting 
microglia (the immune cells of the brain) (240), and in another profile of reactive 
astrogliosis (241) (which responds  to CNS insults).  These results support our 
observations of neuropathological effects from our overexpressing insult to the 
brain.  At least 3 genes from these studies were identified as transcriptionally 
responsive in our high expressing vector that were associated with reactive 
gliosis (241), a peptidase inhibitory and cytokine response, Serpina3n (242) or 
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responses to interferon β and γ, Gbp3 (243, 244), and B2m  related to antigen 
processing (245) and cellular defense (246)  (Table 3.2).  In addition, the 
microglia transcriptome also co-identified hits from our CBA-WPRE microarray of 
the costimulatory ligand Cd86 (240), the transmembrane protein which triggers 
myeloid cells and increased phagocytic activity (247), and suppress cytokine 
production and immune responses (248), Trem2, the complement activation 
(249) Clqa, the proinflammatory oxidase (250), Cybb and, reactive gliosis marker 
(251), GFAP.  Taken together, these results indicate that some of the processes 
occurring through the expression of a lysosomal enzyme in the CNS lead to a 
course of inflammation and astrogliosis which is not detectable when expressed 
by a lower expressing promoter or from the capsid alone. 
The reason why this level of overexpression lead to an inflammatory 
process can be addressed by the vector system.  Importantly, the enzyme 
introduced in our work is of mouse origin and is introduced into an animal which 
is already expressing a functional copy of the mouse GLB1 gene. This removes 
the possibility of an immune response to a non-self protein as seen in other 
studies(155), however response to extreme overexpression regardless of origin 
is still an outstanding question.  The effect could be related to the burden of 
individual cells to produce large amounts of protein product.  This is supported by 
the reduction of transcriptional changes seen with a lower producing vector.  In 
addition, injection into the thalami of βgal+/- mice with the CB6 vector with both 
same viral particles as CBA-WPRE as well as CB6 with a log higher dosing 
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appeared to have reduced Filipin staining despite similar amounts of enzyme 
produced.  In addition, dose dependent responses leading to neuropathology at 
the injection site was seen in both our study and with NHP and the lysosomal 
enzyme acid sphigomyelinase (239).  Investigation into a per-cell response to the 
expression of the mβgal enzyme would further enlighten this hypothesis and will 
be studied in detail in future work. 
These newly constructed, reduced expression, minimal transcriptional 
impact vectors were also shown effective as a therapeutic in disease containing 
βgal-/- mice, however this effect was dose dependent.  CB6 at the low dose was 
able to deliver enzyme to the cerebrum and cerebellum, but had surprisingly no 
activity for CB6 low in the spinal cord.  This lack of spinal cord expression may 
be due to minimal amount of enzyme in the cerebellum + brainstem which was 
~7 fold wild type levels overall and had reduced spread as seen in Xgal staining 
(Fig. 3.15b).  We hypothesize that this level was insufficient to spread thought the 
tissue through cross correction between neighboring cells.  This theory was 
supported at the higher dose CB6 High which was able to successfully spread 
throughout the tissues and achieved a non-significant difference from the original 
vector in cerebellum + brainstem, but was still an average of 20 fold lower in 
enzyme expression than CBA-WPRE vector in that tissue.  Excitingly, storage 
clearance and Filipin presence was the most telling result as the original vector 
CBA-WPRE still displayed abnormal Filipin presence at the injection site (Fig. 
3.16a, d), but this was minimized to absent in the CB6 High vector (Fig. 3.16o, r) 
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which was able to clear GM1 from the spinal cord where CBA-WPRE was not 
(Fig. 3.17e-f versus a-b).  This finding is revealing as in both this study and our 
lab’s previous attempt at intracranial gene therapy as the extreme 
overexpression in the cerebellum may have been the culprit for the inability to 
reach the spinal cord (Fig. 3.6a, d, f and Fig. 3.17e, f) (198).  As we show here, 
supraphysiological levels of enzyme has deleterious consequences in the 
surrounding cells and could lead to dysregulation of lysosomal function and 
initiate immune and astrogliosis responses (240, 241, 251).  We hypothesize that 
cells in the DCN that overexpress βgal are taxed beyond ability to compensate 
and are unable to properly connect to the spinal cord either through dysfunction 
or cell death in the corresponding nuclei.  Furthering testing of this theory could 
be achieved by a selective, targeted destruction of the DCN using methods such 
as in Parkinson’s’ studies where site specific neurodegeneration is accomplished 
by introduction of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  (252).  
In the current study we achieved therapeutic success by lowering the total output 
from each vector we reduce the strain on each cell to process protein loads, and 
by increasing vector dose an increased ability to spread throughout neuronal 
connections was possible.      
Taken together this work demonstrates that lysosomal storage disorders 
treated with viral expressing transgenes do not have unlimited capacity to 
withstand protein expression and this effect occurs in both disease and non-
diseased animals.  Importantly, immune and astrogliosis related responses 
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occurred in response to high levels of protein within the brain, but not to the viral 
capsid alone.  Finally, mitigating the amount of enzyme produced from a single 
vector we reduced the burden of a single cell, and by increasing the total viral 
load we were able to utilize the network of connections functioning throughout 
the CNS.  This work reveals that using a lower expressing promoter offers a 
larger dynamic range then high expressing transgenes and allows for the fine 
control of therapeutic intervention necessary for a lysosomal storage disorder 
affecting the central nervous system.  
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 CHAPTER V:  Final Summary and Conclusions 
 
The work in this thesis comprises the investigation into multiple aspects 
and practical considerations for the therapeutic treatment of the lysosomal 
storage disorder, GM1-gangliosidosis.  In addition, the benefit of these studies 
will have far reaching implications to the field of lysosomal storage disorder 
research and the practice of intracranial gene therapy.   
Chapter II and III investigated two therapeutic approaches for the 
treatment of GM1-gangliosidosis in a mouse model which both achieved 
unprecedented increases in survival.  In Chapter II, the investigation of a 
systemic approach utilizing AAV9 was presented.  Here, we found that in the 
GM1-ganglioside mouse model we could express enzyme in the CNS at low but 
efficient levels with therapeutic impact.  This expression was move effective in 
females than males, as noted previously (190, 191), and this difference led to 
increased storage clearance of the GM1 ganglioside in the brain and spinal cord 
in female mice.  Despite the overall reduced response in the brain of male mice, 
higher liver expression in those animals did result in a corresponding increase in 
serum levels of the mβgal enzyme and uptake of this enzyme from the serum is 
also an efficient method for delivering enzyme to the CNS.  Similar work by Ruzo 
et al used an intravenous administration of AAV8 with a liver-directed promoter to 
deliver a sulfamidase enzyme for the LSD, MPS IIIA which lead to correction of 
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CNS pathology in diseased mice.  Consistent with our data, the male response 
was more robust then females with 4 fold greater liver expression (253).  Notably, 
in our studies dose delivered to each animal was not adjusted for weight and 
therefore the possibility of less total vector genomes(vg) per kg of weight could 
be a factor in the resulting overall success of this therapy.  This could lead to 
animal or sex based variation as male animals were typically larger then females 
at time of injection. To further probe this hypothesis future experiments could 
include adjustment of vg to kg of each animal and using testosterone injection 
into female animals to see if the male vs. female difference are still present (191).   
Interestingly, in our IV approach we saw that even minimal expression in 
the CNS led to unprecedented behavior correction in this model where 
normalization of most parameters were noted for female mice at 30 weeks of 
age.  Eventually, these animals all developed tremor which may be related to the 
lack of enzyme in the deep brain structures (thalamus and striatum) as well as 
the purkinje and molecular layers of the cerebellum,  while the mobility retention 
may be due to success in targeting the spinal cord.  As mentioned earlier, the 
deep cerebellar nuclei has been shown to have connections to the spinal cord as 
determined in a series of experiment in a rat model using anterograde labeling 
with biotinylated dextran (254-258), and also with therapeutic gene in a mouse 
model (215).  In turn, successful spinal cord and then DCN expression could be 
due to the innervating neuronal connections from muscle to spinal cord where 
movement of the viral vector/ secreted βgal enzyme could originate from the viral 
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transduced and high enzyme expressing skeletal muscle (259).  Therefore, 
storage correction in DCN could be caused by enzyme uptake at axonal 
terminals the spinal cord and its retrograde transport to the cell body.  This 
hypothesis could be tested by the intravenous injection of a vector expressing 
mβgal with muscle specific promoter muscle creatin kinase (MCK) (260) and/or 
with a muscle targeting capsid such as AAV1 or AAV6 (261), or with a direct 
muscle injection.  Another approach for teasing out this effect would be to include 
a microRNA detargeting sequence for muscle, miR-1 (189).    
In our IV study, hallmarks of the disease (6) were apparent in the poorly 
treated regions where astrogliosis occurred.  Interestingly, previous studies in an 
LSD model using AAV9 IV also had a challenge in accessing these regions (187) 
and was consistent even when utilizing a self complimentary (sc) AAV vector 
(216).  Importantly, significant extension in life span (p < 0.0001) was seen in all 
groups and genders.  Together, this data raise the possibility that a higher dose, 
or more efficient promoter may be even more effective then 3e11vg, however 
caution regarding liver overexpression is justified and a liver detargeted vector 
suggested (183, 189).   
Chapter III employed an intracranial approach for GM1-gangliosisdosis 
which was superior to previous approaches in lifespan and motor function (197, 
198).  However, in the course of this work we also noted abnormal findings from 
the GM1-ganglioside identifying staining, Filipin, which was dose dependent and 
correlated with neuropathological morphological changes at the injection site and 
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warranted further investigation.  We confirmed this abnormal staining was not 
disease dependent by using normal animals and developed a vector series to 
probe the cause.  In these experiments we found an association with protein 
presence, but not enzyme activity at injection site.  Furthermore, using a 
microarray approach we were able to determine that astrogliosis and immune 
responses (240, 241, 251) occurred at the injection site when using a high 
expressing vector, but was mitigated or absent if the expression was low.  
Importantly, a vector containing only promoter and post-translational elements, 
but not a protein product had almost no effect on the system.  Previous studies 
investigating immune responses to intracranial injection include AAV2 encoding 
thymidine kinase (TK) or human aromatic L-ammino acid decarboxylase (hAADC) 
in NHP brains (236), AAV1 expressing a humanized green fluorescent protein 
from Renilla reniformis  (hGFP) in NHP brains (156), and AAV9 expressing 
hAADC or GFP in rat brains (155).  In these studies, a relation to transgene and 
immune response was made, but only when the capsid itself was found to 
transduce antigen presenting cells (APC) that then trigged a cellular immune 
response to the transgene in AAV1 (156) or AAV9 (155) and not AAV2 (236).  In 
our study, immune responses were determined to be protein dependent due to 
the high expression of the enzyme in a CBA-mβgal-WPRE transgene, but not  
when a highly expressing promoter was replaced and post translational element 
was removed, CB6-mβgal.  Both the high and low enzyme producing transgenes 
carried the species-specific mβgal cDNA which was not foreign to the βgal+/- 
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mouse that carries one functional copy of that gene.  The AAVrh8 capsid did not 
have a consistent response across all vectors indicating that the capsid was not 
responsible for the immune response.  In addition, previous studies intracranial 
injected AAVrh8 capsid expressing various transgenes within neonatal mice with 
GFP (231), in cats with mβgal (200), and in cats with hexosaminidase α and β 
(199) no immune responses were seen.   
To further understand the role of enzyme overexpression in a highly 
expressing transgene a single cell-based analysis would be appropriate.  
RNAscope (Advanced Cell Dynamics, Hayward, CA) is a multiplex colorimetric or 
fluorescent method to perform in situ hybridization which provides the ability to 
view up to three different targets at once, and at sensitivities as low as single 
RNA molecules.  This analysis would allow for single cell confirmation of the 
microarray results in conjunction with the detection a number of mβgal transcripts 
present, allowing quantification of the number of transcripts needed for an 
immune or toxic responses to occur.  Laser capture micro-dissection for 
transduced cells in each cohort and subsequent biochemical analysis would also 
be useful in isolating only the subset of cells most highly expressing the 
transgene.  Finally, neuronal cell culture could be employed to assess the effects 
of extreme enzyme overexpression with and without a viral capsid, as well as 
temporal effects that are more difficult to perform when in the context of a mouse 
model.   
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Continuing the intracranial study, we then brought these findings back into 
diseased mice and were able to achieve a therapeutic benefit of storage 
clearance throughout the CNS when using the lower expressing vector  CB6- 
mβgal with a log higher dose.  Importantly, the spinal cord which was not 
targeted successfully in all previous attempts (197, 198) had unprecedented 
therapeutic impact with normalization of GM1 storage.  As stated above, the 
DCN is employed as a conduit within the brain to access the spinal cord for 
delivery of a therapeutic transgene (215).  Connections between the DCN and 
spinal cord have been traced in previous studies (254-258), however the 
disruption of the DCN leading to loss of these connection have not been 
demonstrated.  Direct injection of the CBA-mβgal-WPRE vector into the DCN 
resulted in neuropathological effects and resulted in loss of enzyme expression 
and storage clearance in the spinal cord.  Therefore, we hypothesized that the 
extreme over expression of these enzymes in the DCN were leading to these 
downstream consequences.  To further test this hypothesis, track-tracing of the 
connections in the DCN after expression of CBA-mβgal-WPRE or other cell 
damaging methods could be employed such as radiation, ischemic insult or 
hypoxia, or known toxic agents.  
This work indicates that gene therapy for LSD is a fragile system and 
despite the many benefits of secreted enzymes in this therapy, that caution must 
be employed toward the injection site.  By reducing the burden through a low 
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expressing promoter and increasing viral spread through higher dose it is 
possible to avoid these adherent responses.  .   
This work provides vital insight into the treatment of lysosomal storage 
disorders affecting the central nervous system however, additional questions 
exist.  Which population of cells is sensitive to this pathological effect within the 
brain and is there another cell type that could act as a safer enzyme-producing 
center.   To understand these implications experiments could be performed on 
cell culture with specific populations of cells such as neurons, astrocytes or brain 
endothelia, or the generation of mice that express the mβgal enzyme in a cre 
dependent manner.  Another question remains regarding the universality of these 
findings; is this specific to mβgal, all lysosomal enzymes, all secreted enzymes?. 
Richness to this work can be provided by the analysis of a variety of disorders 
affecting the central nervous system.    
The next challenge for viral therapy approaches is the ability to have fine 
control over the transgene output.  In this work, we have shown a method that 
creates a dynamic range of expression levels and therefore the capacity to 
provide variable treatment modalities which can be scaled for larger animals.  
Additional levels of transgene regulation can be obtained through TET promoters 
in which transgene expression is controlled ON or OFF with an inducible 
transcriptional activator by the addition or removal of tetracycline or derivatives 
(262, 263).  However, these promoters can be leaky and the need for turning off 
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of the transgene may be too late to keep damage from occurring.  A next 
generation of Tet-like regulation that was responsive to cell stress rather than 
provided by the user would be an advantage for researchers and patients alike.  
Cell type specific promoters for the CNS(264) and RNAi detargeting sites (189) 
can also be employed to restrict expression to certain cell populations or tissues 
providing further control over transgene expression.   
Taken together these studies show that a balance of vector targeting, 
CNS accessibility, enzyme expression and cellular stress must be factored into 
therapeutic approaches for LSD’s.  These studies have implications for 
translation to human studies as the ability to have fine control over a viral 
transgene is paramount.  Long term expression of a transgene in the CNS could 
both treat a devastating disorder and lead to additional issues within the system.  
In the future, a holistic approach may be the most beneficial where a low 
expressing, regulated, direct injection can access deep brain structures, and a 
liver detargeted systemic vector can treat the periphery for safe and effective 
therapeutic intervention. 
  
164 
 
BIBLIOGRAPHY 
 
 
1 Vitner, E.B., Platt, F.M. and Futerman, A.H. (2010) Common and uncommon pathogenic 
cascades in lysosomal storage diseases. The Journal of biological chemistry, 285, 20423-20427. 
2 Norman, R.M., Urich, H., Tingey, A.H. and Goodbody, R.A. (1959) Tay-Sachs' disease with 
visceral involvement and its relationship to Niemann-Pick's disease. J Pathol Bacteriol, 78, 409-
421. 
3 Okada, S. and O'Brien, J.S. (1968) Generalized gangliosidosis: beta-galactosidase 
deficiency. Science, 160, 1002-1004. 
4 Tessitore, A., del, P.M.M., Sano, R., Ma, Y., Mann, L., Ingrassia, A., Laywell, E.D., 
Steindler, D.A., Hendershot, L.M. and d'Azzo, A. (2004) GM1-ganglioside-mediated activation of 
the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. 
Mol Cell, 15, 753-766. 
5 Sano, R. (2009) GM1-ganglioside accumulation at the mitochondria-associated ER 
membranes links ER stress to Ca(2+)-dependent mitochondrial apoptosis. Mol Cell, 36, 500-511. 
6 Jeyakumar, M., Thomas, R., Elliot-Smith, E., Smith, D.A., van der Spoel, A.C., d'Azzo, A., 
Perry, V.H., Butters, T.D., Dwek, R.A. and Platt, F.M. (2003) Central nervous system inflammation 
is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain, 126, 974-
987. 
7 Suzuki, Y., Oshima, A. and Nanba, E. (2008), In The Online Metabolic and Molecular 
Bases of Inherited Disease. McGraw Hill, New York, in press., pp. 1-101. 
8 Callahan, J.W. (1999) Molecular basis of GM1 gangliosidosis and Morquio disease, type 
B. Structure-function studies of lysosomal beta-galactosidase and the non-lysosomal beta-
galactosidase-like protein. Biochim Biophys Acta, 1455, 85-103. 
9 Chamoles, N.A., Blanco, M.B., Iorcansky, S., Gaggioli, D., Specola, N. and Casentini, C. 
(2001) Retrospective diagnosis of GM1 gangliosidosis by use of a newborn-screening card. Clin 
Chem, 47, 2068. 
10 Uribe, A. and Giugliani, R. (2013) Selective screening for lysosomal storage diseases with 
dried blood spots collected on filter paper in 4,700 high-risk Colombian subjects. JIMD Rep., 11, 
107-116. 
11 Warner, T.G., Robertson, A.D., Mock, A.K., Johnson, W.G. and O'Brien, J.S. (1983) 
Prenatal diagnosis of GM1 gangliosidosis by detection of galactosyl-oligosaccharides in amniotic 
fluid with high-performance liquid chromatography. American journal of human genetics, 35, 
1034-1041. 
12 Brunetti-Pierri, N. and Scaglia, F. (2008) GM1 gangliosidosis: review of clinical, 
molecular, and therapeutic aspects. Mol Genet Metab, 94, 391-396. 
13 Privitera, S., Prody, C.A., Callahan, J.W. and Hinek, A. (1998) The 67-kDa enzymatically 
inactive alternatively spliced variant of beta-galactosidase is identical to the elastin/laminin-
binding protein. The Journal of biological chemistry, 273, 6319-6326. 
14 Mochizuki, S., Brassart, B. and Hinek, A. (2002) Signaling pathways transduced through 
the elastin receptor facilitate proliferation of arterial smooth muscle cells. The Journal of 
biological chemistry, 277, 44854-44863. 
165 
 
15 Caciotti, A., Donati, M.A., Bardelli, T., d'Azzo, A., Massai, G., Luciani, L., Zammarchi, E. 
and Morrone, A. (2005) Primary and secondary elastin-binding protein defect leads to impaired 
elastogenesis in fibroblasts from GM1-gangliosidosis patients. Am J Pathol, 167, 1689-1698. 
16 van der Spoel, A., Bonten, E. and d'Azzo, A. (2000) Processing of lysosomal beta-
galactosidase. The C-terminal precursor fragment is an essential domain of the mature enzyme. 
The Journal of biological chemistry, 275, 10035-10040. 
17 McCarter, J.D., Burgoyne, D.L., Miao, S.C., Zhang, S.Q., Callahan, J.W. and Withers, S.G. 
(1997) Identification of Glu-268 as the catalytic nucleophile of human lysosomal beta-
galactosidase precursor by mass spectrometry. Journal of Biological Chemistry, 272, 396-400. 
18 Ohto, U., Usui, K., Ochi, T., Yuki, K., Satow, Y. and Shimizu, T. (2012) Cyrstal structure of 
human beta-galactosidase:  structural basis of GM1 Gangliosidosis and Morquio B diseases. 
Journal of Biological Chemistry, 287, 1801-1812. 
19 Kolter, T., Proia, R.L. and Sandhoff, K. (2002) Combinatorial ganglioside biosynthesis. The 
Journal of biological chemistry, 277, 25859-25862. 
20 Hanada, K., Kumagai, K., Yasuda, S., Miura, Y., Kawano, M., Fukasawa, M. and Nishijima, 
M. (2003) Molecular machinery for non-vesicular trafficking of ceramide. Nature, 426, 803-809. 
21 Nomura, T., Takizawa, M., Aoki, J., Arai, H., Inoue, K., Wakisaka, E., Yoshizuka, N., 
Imokawa, G., Dohmae, N., Takio, K. et al. (1998) Purification, cDNA cloning, and expression of 
UDP-Gal: glucosylceramide beta-1,4-galactosyltransferase from rat brain. The Journal of 
biological chemistry, 273, 13570-13577. 
22 Pohlentz, G., Klein, D., Schwarzmann, G., Schmitz, D. and Sandhoff, K. (1988) Both Ga2, 
Gm2, and Gd2 synthases and Gm1b, Gd1a, and Gt1b synthases are single enzymes in golgi 
vesicles from rat-liver. Proc Natl Acad Sci U S A, 85, 7044-7048. 
23 Wilkening, G., Linke, T., Uhlhorn-Dierks, G. and Sandhoff, K. (2000) Degradation of 
membrane-bound ganglioside GM1. Stimulation by bis(monoacylglycero)phosphate and the 
activator proteins SAP-B and GM2-AP. The Journal of biological chemistry, 275, 35814-35819. 
24 Sandhoff, K. and Harzer, K. (2013) Gangliosides and gangliosidoses: principles of 
molecular and metabolic pathogenesis. J Neurosci, 33, 10195-10208. 
25 Ngamukote, S., Yanagisawa, M., Ariga, T., Ando, S. and Yu, R.K. (2007) Developmental 
changes of glycosphingolipids and expression of glycogenes in mouse brains. J Neurochem, 103, 
2327-2341. 
26 Svennerholm, L., Bostrom, K., Fredman, P., Mansson, J.E., Rosengren, B. and Rynmark, 
B.M. (1989) Human brain gangliosides: developmental changes from early fetal stage to 
advanced age. Biochim Biophys Acta, 1005, 109-117. 
27 Sheikh, K.A., J., S., Liu, Y., Kawai, H., Crawford, T.O.P., R. L. , Griffin, J.W. and Schnaar, 
R.L. (1999) Mice lacking complex gangliosides develop Wallerian degeneration and myelination 
defects. Proc Natl Acad Sci U S A, 96, 7532-7537. 
28 Simons, K. and Toomre, D. (2000) Lipid rafts and signal transduction. Nat Rev Mol Cell 
Biol, 1, 31-39. 
29 Posse de Chaves, E. and Sipione, S. (2010) Sphingolipids and gangliosides of the nervous 
system in membrane function and dysfunction. FEBS Lett., 584, 1748-1759. 
30 Sonnino, S., Mauri, L., Chigorno, V. and Prinetti, A. (2007) Gangliosides as components 
of lipid membrane domains. Glycobiology, 17, 1R-13R. 
166 
 
31 Wu, G., Xie, X., Lu, Z.H. and Ledeen, R.W. (2009) Sodium-calcium exchanger complexed 
with GM1 ganglioside in nuclear membrane transfers calcium from nucleoplasm to endoplasmic 
reticulum. Proc Natl Acad Sci U S A, 106, 10829-10834. 
32 Ledeen, R.W. and Wu, G. (2002) Ganglioside function in calcium homeostasis and 
signaling. Neurochem Res, 27, 637-647. 
33 Denny, C.A., Desplats, P.A., Thomas, E.A. and Seyfried, T.N. (2010) Cerebellar lipid 
differences between R6/1 transgenic mice and humans with Huntington's disease. J Neurochem, 
115, 748-758. 
34 Maglione, V., Marchi, P., Di Pardo, A., Lingrell, S., Horkey, M., Tidmarsh, E. and Sipione, 
S. (2010) Impaired ganglioside metabolism in Huntington's disease and neuroprotective role of 
GM1. J Neurosci, 30, 4072-4080. 
35 Di Pardo, A., Maglione, V., Alpaugh, M., Horkey, M., Stwal, R.S., Sassone, J., Ciammola, 
A., Steffan, J.S., Fouad, K., Truant, R. et al. (2012) Ganglioside GM1 induces phosphorylation of 
mutant huntingtin and restores normal motor behavior in Huntington disease mice. Proc Natl 
Acad Sci U S A, 109, 3528-3533. 
36 Wei, J., Fujita, M., Nakai, M., Waragai, M., Sekigawa, A., Sugama, S., Takenouchi, T., 
Masliah, E. and Hashimoto, M. (2009) Protective role of endogenous gangliosides for lysosomal 
pathology in a cellular model of synucleinopathies. Am J Pathol, 174, 1891-1909. 
37 Hadjiconstantinou, M., Rossetti, Z.L., Paxton, R.C. and Neff, N.H. (1986) Administration 
of GM1 ganglioside restores the dopamine content in striatum after chronic treatment with 
MPTP. Neuropharmacology, 25, 1075-1077. 
38 Pope-Coleman, A., Tinker, J.P. and Schneider, J.S. (2000) Effects of GM1 ganglioside 
treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian 
monkeys. Synapse (New York, N.Y.), 36, 120-128. 
39 Schneider, J.S., Gollomp, S.M., Senedek, S., Colcher, A. and Cambi, F.D., W. (2013) A 
randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease 
patients. J Neurol Sci., 324, 140-148. 
40 Kakio, A., Nishimoto, S., Yanagisawa, K., Kozutsumi, Y. and Matsuzaki, K. (2002) 
Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: 
importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. 
Biochemistry, 41, 7385-7390. 
41 Molander-Melin, M., Blennow, K., Bogdanovic, N., Dellheden, B., Mansson, J.E. and 
Fredman, P. (2005) Structural membrane alterations in Alzheimer brains found to be associated 
with regional disease development; increased density of gangliosides GM1 and GM2 and loss of 
cholesterol in detergent-resistant membrane domains. J Neurochem, 92, 171-182. 
42 Barrier, L., Ingrand, S., Damjanac, M., Rioux Bilan, A., Hugon, J. and Page, G. (2007) 
Genotype-related changes of ganglioside composition in brain regions of transgenic mouse 
models of Alzheimer's disease. Neurobiology of aging, 28, 1863-1872. 
43 Kreutz, F., Frozza, R.L., Breier, A.C., de Oliveria, V.A., Horn, A.P., Pettenusso, L.F., Netto, 
C.A., Sabego, C.G. and Trindade, V.M. (2011) Amyloid-β induced toxicity involves ganglioside 
expression and is sensitive to GM1 neuroprotective action. Neurochem Int., 59, 648-655. 
44 Kreutz, F., Scherer, E.B., Ferreira, A.G., Petry Fdos, S., Pereira, C.L., Santana, F., de Souza 
Wyse, A.T., Salbego, C.G. and Trindade, V.M. (2013) Alterations on Na⁺,K⁺-ATPase and 
acetylcholinesterase activities induced by amyloid-β peptide in rat brain and GM1 ganglioside 
neuroprotective action. Neurochem Res, 38, 2342-2350. 
167 
 
45 Takamura, A., Higaki, K., Kajimaki, K., Otsuka, S., Ninomiya, H., Matsuda, J., Ohno, K., 
Suzuki, Y. and Nanba, E. (2008) Enhanced autophagy and mitochondrial aberrations in murine 
G(M1)-gangliosidosis. Biochem Biophys Res Commun, 367, 616-622. 
46 Sano, R., Tessitore, A., Ingrassia, A. and d'Azzo, A. (2005) Chemokine-induced 
recruitment of genetically modified bone marrow cells into the CNS of GM1-gangliosidosis mice 
corrects neuronal pathology. Blood, 106, 2259-2268. 
47 Dawson, V.L. and Dawson, T.M. (1998) R. Ranney Mize, T.M.D.V.L.D. and Michael, J.F. 
(eds.), In Progress in Brain Research. Elsevier, Vol. Volume 118, pp. 215-229. 
48 Matsuda, J., Suzuki, O., Oshima, A., Ogura, A., Naiki, M. and Suzuki, Y. (1997) 
Neurological manifestations of knockout mice with beta-galactosidase deficiency. Brain Dev, 19, 
19-20. 
49 Itoh, M., Matsuda, J., Suzuki, O., Ogura, A., Oshima, A., Tai, T., Suzuki, Y. and Takashima, 
S. (2001) Development of lysosomal storage in mice with targeted disruption of the beta-
galactosidase gene: a model of human G(M1)-gangliosidosis. Brain Dev, 23, 379-384. 
50 Matsuda, J., Suzuki, O., Oshima, A., Oqura, A., Noguchi, Y., Yamamoto, Y., Asano, T., 
Takimoto, K., Sukegawa, K., Suzuki, Y. et al. (1997) Beta-galactosidase-deficient mouse as an 
animal model for GM1-gangliosidosis. Glycoconj J., 14, 729-736. 
51 Hahn, C.N., del Pilar Martin, M., Schroder, M., Vanier, M.T., Hara, Y., Suzuki, K., Suzuki, 
K. and d'Azzo, A. (1997) Generalized CNS disease and massive GM1-ganglioside accumulation in 
mice defective in lysosomal acid beta-galactosidase. Hum Mol Genet, 6, 205-211. 
52 Tanaka, H. and Suzuki, K. (1977) Substrate specificities of the two genetically distinct 
human brain beta-galactosidases. Brain Res, 122, 325-335. 
53 Fingerhut, R., van der Horst, G.T., Verheijen, F.W. and Conzelmann, E. (1992) 
Degradation of gangliosides by the lysosomal sialidase requires an activator protein. European 
journal of biochemistry / FEBS, 208, 623-629. 
54 Li, S.C., Li, Y.T., Moriya, S. and Miyagi, T. (2001) Degradation of G(M1) and G(M2) by 
mammalian sialidases. Biochem, 360, 233-237. 
55 Suzuki, K. and Chen, G.C. (1967) Brain ceramide hexosides in Tay-Sachs disease and 
generalized gangliosidosis (GM1-gangliosidosis). J Lipid Res, 8, 105-113. 
56 Sano, R., Trindade, V.M., Tessitore, A., d'Azzo, A., Vieira, M.B., Giugliani, R. and Coelho, 
J.C. (2005) G(M1)-ganglioside degradation and biosynthesis in human and murine G(M1)-
gangliosidosis. Clin Chim Acta, 354, 131-139. 
57 Baker, H.J. and Lindsey, J.R. (1974) Animal model: feline GM1 gangliosidosis. Am J 
Pathol, 74, 649-652. 
58 Baker, H.J.J., Lindsey, J.R., McKhann, G.M. and Farrell, D.F. (1971) Neuronal GM1 
gangliosidosis in a Siamese cat with beta-galactosidase deficiency. Science, 174, 838-839. 
59 Baker, H.J., Reynolds, G.D., Walkley, S.U., Cox, N.R. and Baker, G.H. (1979) The 
gangliosidoses: comparative features and research applications. Vet Pathol, 16, 635-649. 
60 Read, D.H., Harrington, D.D., Keenana, T.W. and Hinsman, E.J. (1976) Neuronal-visceral 
GM1 gangliosidosis in a dog with beta-galactosidase deficiency. Science, 194, 442-445. 
61 Alroy, J., Orgad, U., DeGasperi, R., Richard, R., Warren, C.D., Knowles, K., Thalhammer, 
J.G. and Raghavan, S.S. (1992) Canine GM1-gangliosidosis:  a clinical, morphologic, 
histochemical, and biochemical comparison of two different models. Am J Pathol, 140, 675-689. 
168 
 
62 Wang, Z.H., Zeng, B., Shibuya, H., Johnson, G.S., Alroy, J., Pastores, G.M., Raghavan, S. 
and Kolodny, E.H. (2000) Isolation and characterization of the normal canine beta-galactosidase 
gene and its mutation in a dog model of GM1-gangliosidosis. J Inherit Metab Dis, 23, 593-606. 
63 Yamato, O., Masuoka, Y., Yonemura, M., Hatakeyama, A., Satoh, H., Kobayashi, A., 
Nakayama, M., Asano, T., Shoda, T., Yamasaki, M. et al. (2003) Clinical and clinico-pathologic 
characteristics of Shiba dogs with a deficiency of lysosomal acid beta-galactosidase: a canine 
model of human GM1 gangliosidosis. J Vet Med Sci, 65, 213-217. 
64 Yamato, O., Ochiai, K., Masuoka, Y., Hayashida, E., Tajima, M., Omae, S., Iijima, M., 
Umemura, T. and Maede, Y. (2000) GM1 gangliosidosis in shiba dogs. Vet Rec, 146, 493-496. 
65 Hasegawa, D., Yamato, O., Nakamoto, Y., Ozawa, T., Yabuki, A., Itamoto, K., Kuwabara, 
T., Fujita, M., Takahashi, K., Mizoguchi, S. et al. (2012) Serial MRI features of canine GM1 
gangliosidosis: a possible imaging biomarker for diagnosis and progression of the disease. 
TheScientificWorldJournal, 2012, 250197. 
66 Satoh, H., Yamauchi, T., Yamasaki, M., Maede, Y., Yabuki, A., Chang, H.S., Asanuma, T. 
and Yamato, O. (2011) Rapid detection of GM1 ganglioside in cerebrospinal fluid in dogs with 
GM1 gangliosidosis using matrix-assisted laser desorption ionization time-of-flight mass 
spectrometry. J Vet Diagn Invest., 23, 1202-1207. 
67 Satoh, H., Yamato, O., Asano, T., Yonemura, M., Yamauchi, T., Hasegawa, D., Orima, H., 
Arai, T., Yamasaki, M. and Maede, Y. (2007) Cerebrospinal fluid biomarkers showing 
neurodegeneration in dogs with GM1 gangliosidosis: possible use for assessment of a 
therapeutic regimen. Brain Res, 1133, 200-208. 
68 O'Neill, K., Chen, S. and Diaz Brinton, R. (2004) Impact of the selective estrogen receptor 
modulator, tamoxifen, on neuronal outgrowth and survival following toxic insults associated 
with aging and Alzheimer's disease. Exp Neurol, 188, 268-278. 
69 Orlino, E.N., Jr., Olmstead, C.E., Lazareff, J.A., Peacock, W.J., Fisher, R.S. and Fluharty, 
A.L. (1997) An enzyme immunoassay for neuron-specific enolase in cerebrospinal fluid. 
Biochemical and molecular medicine, 61, 41-46. 
70 Hatfield, R.H. and McKernan, R.M. (1992) CSF neuron-specific enolase as a quantitative 
marker of neuronal damage in a rat stroke model. Brain Res, 577, 249-252. 
71 Donnelly, W.J., Sheahan, B.J. and Rogers, T.A. (1973) GM1 gangliosidosis in Friesian 
calves. J Pathol, 111, 173-179. 
72 Ryder, S.J. and Simmons, M.M. (2001) A lysosomal storage disease of Romney sheep 
that resembles human type 3 GM1 gangliosidosis. Acta Neuropathol, 101, 225-228. 
73 Prieur, D.J., Ahern-Rindell, A.J. and Murnane, R.D. (1991) Ovine GM-1 gangliosidosis. Am 
J Pathol, 139, 1511-1513. 
74 Muthupalani, S., Torres, P.A., Wang, B.C., Zeng, B.J., Eaton, S., Erdelyi, I., Ducore, R., 
Maganti, R., Keating, J., Perry, B.J. et al. (2014) GM1-gangliosidosis in American black bears: 
Clinical, pathological, biochemical and molecular genetic characterization. Mol Genet Metab, 
111, 513-521. 
75 Minet, J.C., Fowler, B. and Litschg, J. (2004) GM1 gangliosidosis therapeutical trial with 
Miglustat (Zavesca)  a case report. Neuropediatrics, 35, P85. 
76 Caciotti, A.e.a. (2011) GM1 gangliosidosis and Morquio B disease: an update on genetic 
alterations and clinical findings. Biochim Biophys Acta, 7, 782-790. 
77 Garzone, A., Pompilio, A., Ciuccarelli, F., Andresciani, E., Ficcadenti, A., De Meo, M., 
Mannucci, A., Marzioni, P., Buccolini, M., Carloni, L. et al. (2013) CPC-086 Miglustat off-label in a 
169 
 
pediatric formulation for a rare metabolic disease: early infantile GM1 gangliosidosis. European 
Journal of Hospital Pharmacy: Science and Practice, 20, A196. 
78 Elliot-Smith, E., Speak, A.O., Lloyd-Evans, E., Smith, D.A., van der Spoel, A.C., Jeyakumar, 
M., Butters, T.D., Dwek, R.A., d'Azzo, A. and Platt, F.M. (2008) Beneficial effects of substrate 
reduction therapy in a mouse model of GM1 gangliosidosis. Mol Genet Metab, 94, 204-211. 
79 Matsuda, J., Suzuki, O., Oshima, A., Yamamoto, Y., Noguchi, A., Takimoto, K., Itoh, M., 
Matsuzaki, Y., Yasuda, Y., Ogawa, S. et al. (2003) Chemical chaperone therapy for brain 
pathology in G(M1)-gangliosidosis. Proc Natl Acad Sci U S A, 100, 15912-15917. 
80 Kasperzyk, J.L., El-Abbadi, M.M., Hauser, E.C., D'Azzo, A., Platt, F.M. and Seyfried, T.N. 
(2004) N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse 
model of GM1 gangliosidosis. J Neurochem, 89, 645-653. 
81 Aguilar-Moncayo, M., Takai, T., Higaki, K., Mena-Barragan, T., Hirano, Y., Yura, K., Li, L., 
Yu, Y., Ninomiya, H., Garcia-Moreno, M.I. et al. (2012) Tuning glycosidase inhibition through 
aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosis. 
Chemical communications, 48, 6514-6516. 
82 O'Brien, J.S., Storb, R., Raff, R.F., Harding, J., Appelbaum, F., Morimoto, S., Kishimoto, Y., 
Graham, T., Ahern-Rindell, A. and O'Brien, S.L. (1990) Bone marrow transplantation in canine 
GM1 gangliosidosis. Clinical genetics, 38, 274-280. 
83 Shield, J.P., Stone, J. and Steward, C.G. (2005) Bone marrow transplantation correcting 
beta-galactosidase activity does not influence neurological outcome in juvenile GM1-
gangliosidosis. J Inherit Metab Dis, 28, 797-798. 
84 Sawada, T., Tanaka, A., Higaki, K., Takamura, A., Nanba, E., Seto, T., Maeda, M., 
Yamaguchi, E., Matsuda, J. and Yamano, T. (2009) Intracerebral cell transplantation therapy for 
murine GM1 gangliosidosis. Brain Dev, 31, 717-724. 
85 Hickman, S., Shapiro, L.J. and Neufeld, E.F. (1974) A recognition marker required for 
uptake of a lysosomal enzyme by cultured fibroblasts. Biochem Biophys Res Commun, 57, 55-61. 
86 Jessup, W. and Dean, R.T. (1982) Secretion by mononuclear phagocytes of lysosomal 
hydrolases bearing ligands for the mannose-6-phosphate receptor system of fibroblasts: 
evidence for a second mechanism of spontaneous secretion? Biochem Biophys Res Commun, 
105, 922-927. 
87 Klumperman, J., Hille, A., Veenendaal, T., Oorschot, V., Stoorvogel, W., von Figura, K. 
and Geuze, H.J. (1993) Differences in the endosomal distributions of the two mannose 6-
phosphate receptors. J Cell Biol, 121, 997-1010. 
88 Fratantoni, J.C., Hall, C.W. and Neufeld, E.F. (1968) Hurler and Hunter syndromes: 
mutual correction of the defect in cultured fibroblasts. Science, 162, 570-572. 
89 Samoylova, T.I., Martin, D.R., Morrison, N.E., Hwang, M., Cochran, A.M., Samoylov, 
A.M., Baker, H.J. and Cox, N.R. (2008) Generation and characterization of recombinant feline 
beta-galactosidase for preclinical enzyme replacement therapy studies in GM1 gangliosidosis. 
Metab Brain Dis, 23, 161-173. 
90 Reynolds, G.D., Baker, H.J. and Reynolds, R.H. (1978) Enzyme replacement using 
liposome carriers in feline GM1 gangliosidosis fibroblasts. Nature, 275, 754-755. 
91 Obermeier, B., Daneman, R. and Ransohoff, R.M. (2013) Development, maintenance and 
disruption of the blood-brain barrier. Nat Med, 19, 1584-1596. 
92 Cardone, M., Porto, C., Tarallo, A., Vicinanza, M., Rossi, B., Polishchuk, E., Donaudy, F., 
Andria, G., De Matteis, M.A. and Parenti, G. (2008) Abnormal mannose-6-phosphate receptor 
170 
 
trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts. 
Pathogenetics, 1, 6. 
93 Sun, B., Li, S., Bird, A., Yi, H., Kemper, A., Thurberg, B.L. and Koeberl, D.D. Antibody 
formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific 
transgene expression in murine Pompe disease. J Gene Med, 12, 881-891. 
94 Koeberl, D.D., Luo, X., Sun, B., McVie-Wylie, A., Dai, J., Li, S., Banugaria, S.G., Chen, Y.T. 
and Bali, D.S. Enhanced efficacy of enzyme replacement therapy in Pompe disease through 
mannose-6-phosphate receptor expression in skeletal muscle. Mol Genet Metab, 103, 107-112. 
95 Dickson, P.I. and Chen, A.H. Intrathecal enzyme replacement therapy for 
mucopolysaccharidosis I: translating success in animal models to patients. Curr Pharm 
Biotechnol, 12, 946-955. 
96 Dickson, P.I., Hanson, S., McEntee, M.F., Vite, C.H., Vogler, C.A., Mlikotic, A., Chen, A.H., 
Ponder, K.P., Haskins, M.E., Tippin, B.L. et al. Early versus late treatment of spinal cord 
compression with long-term intrathecal enzyme replacement therapy in canine 
mucopolysaccharidosis type I. Mol Genet Metab, 101, 115-122. 
97 Dierenfeld, A.D., McEntee, M.F., Vogler, C.A., Vite, C.H., Chen, A.H., Passage, M., Le, S., 
Shah, S., Jens, J.K., Snella, E.M. et al. (2010) Replacing the enzyme alpha-L-iduronidase at birth 
ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. Sci 
Transl Med, 2, 60ra89. 
98 Chen, A., Volgler, C., McEntee, M., Hanson, S., Ellinwood, N.M., Jens, J., Snella, E., 
Passage, M., Le, S., Guerra, C. et al. (2011) Glycosaminoglycan storage in neuroanatomical 
regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase. 
APMIS, 119, 513-521. 
99 Vite, C.H., Wang, P., Patel, R.T., Walton, R.M., Walkley, S.U., Sellers, R.S., Ellinwood, 
N.M., Cheng, A.S., White, J.T., O'Neill, C.A. et al. (2011) Biodistribution and pharmacodynamics 
of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected 
cats following multiple intrathecal administrations. Mol Genet Metab, 103, 268-274. 
100 Chang, M., Cooper, J.D., Sleat, D.E., Cheng, S.H., Dodge, J.C., Passini, M.A., Lobel, P. and 
Davidson, B.L. (2008) Intraventricular enzyme replacement improves disease phenotypes in a 
mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther, 16, 649-656. 
101 Ziegler, R.J., Salegio, E.A., Dodge, J.C., Bringas, J., Treleaven, C.M., Bercury, S.D., 
Tamsett, T.J., Shihabuddin, L., Hadaczek, P., Fiandaca, M. et al. Distribution of acid 
sphingomyelinase in rodent and non-human primate brain after intracerebroventricular 
infusion. Exp Neurol, 231, 261-271. 
102 Sly, W.S., Vogler, C., Grubb, J.H., Levy, B., Galvin, N., Tan, Y., Nishioka, T. and Tomatsu, S. 
(2006) Enzyme therapy in mannose receptor-null mucopolysaccharidosis VII mice defines roles 
for the mannose 6-phosphate and mannose receptors. Proc Natl Acad Sci U S A, 103, 15172-
15177. 
103 Grubb, J.H., Vogler, C., Tan, Y., Shah, G.N., MacRae, A.F. and Sly, W.S. (2008) Infused Fc-
tagged beta-glucuronidase crosses the placenta and produces clearance of storage in utero in 
mucopolysaccharidosis VII mice. Proc Natl Acad Sci U S A, 105, 8375-8380. 
104 O'Mahony, A.M., Godinho, B.M.D.C., Cryan, J.F. and O'Driscoll, C.M. (2013) Non-viral 
nanosystems for gene and small interfering RNA delivery to the central nervous system: 
formulating the solution. J Pharm Sci, 102, 3469-3484. 
171 
 
105 Giacca, M. and Zacchigna, S. (2012) Virus-mediated gene delivery for human gene 
therapy. Journal of Controlled Release, 161, 377-388. 
106 Bryne, B.J., Falk, D.J., Clement, N. and Mah, C.S. (2012) Gene therapy approaches for 
lysosomal storage disease: next-generation treatment. Hum Gene Ther, 23, 808-815. 
107 Atchison, R.W., C., C.B. and Hammon, W.M. (1965) Adenovirus-assocaited defective 
virus particles. Science, 149, 754-756. 
108 Gerry, H.W., Kelly, T.J.J. and Berns, K.I. (1973) Arrangement of nucleotide sequences in 
adeno-associated virus DNA. J Mol Biol, 79, 207-225. 
109 Lusby, E., Fife, K.H. and Berns, K.I. (1980) Nucleotide sequence of the inverted terminal 
repetition in adeno-associated virus DNA. J Virol, 34, 402-409. 
110 Srivastava, A., Lusby, E.W. and Berns, K.I. (1983) Nucleotide sequence and organization 
of the adeno-associated virus 2 genome. J Virol, 45, 555-564. 
111 Wistuba, A., Weger, S., Kern, A. and Kleinschmidt, J.A. (1995) Intermediates of adeno-
associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap 
proteins. J Virol, 1995, 9. 
112 Sonntag, F., Schmidt, K. and Kleinschmidt, J.A. (2010) A viral assembly factor promotes 
AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci U S A, 107, 10220-10225. 
113 Sonntag, F., Kother, K., Schmidt, K., Weghofer, M., Raupp, C., Nieto, K., Kuck, A., 
BGerlach, B., Bottcher, B., Muller, O.J. et al. (2011) The assembly-activating protein promotes 
capsid assembly of different adeno-associated virus serotypes. J Virol, 85, 12686-12697. 
114 Naumer, M., Sonntag, F., Schmidt, K., Nieto, K., Panke, C., Davey, N.E., Popa-Wagner, R. 
and Kleinschmidt, J.A. (2012) Properties of the adeno-associated virus assembly-activating 
protein. J Virol, 86, 13038-13048. 
115 Duan, D., Yan, Z., Yue, Y. and Engelhardt, J.F. (1999) Structural analysis of adeno-
associated virus transduction circular intermediates. Virology, 261, 8-14. 
116 Bartlett, J.S., Wilcher, R. and Samulski, R.J. (2000) Infectious entry pathway of adeno-
associated virus and adeno-associated virus vectors. J Virol, 74, 2777-2785. 
117 Duan, D., Li, Q., Kao, A.W., Yue, Y., Pessin, J.E. and Engelhardt, J.F. (1999) Dynamin is 
required for recombinant adeno-associated virus type 2 infection. J Virol, 73, 10371-10376. 
118 Nonnenmacher, M. and Weber, T. (2011) Adeno-Associated Virus 2 Infection Requires 
Endocytosis through the CLIC/GEEC Pathway. Cell Host & Microbe, 10, 563-576. 
119 Gao, G., Alvira, M.R., Somanathan, S., Lu, Y., Vandenberghe, L.H., Rux, J.J., Calcedo, R., 
Sanmiguel, J., Abbas, Z. and Wilson, J.M. (2003) Adeno-associated viruses undergo substantial 
evolution in primates during natural infections. Proceedings of the National Academy of 
Sciences, 100, 6081-6086. 
120 Gao, G., Vandenberghe, L.H. and Wilson, J.M. (2005) New recombinant serotypes of AAV 
vectors. Curr Gene Ther, 5, 285-297. 
121 Gao, G.P., Alvira, M.R., Wang, L.L., Calcedo, R., Johnston, J. and Wilson, J.M. (2002) 
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. P Natl 
Acad Sci USA, 99, 11854-11859. 
122 Wu, Z., Miller, E., Agbandje-McKenna, M. and Samulski, R.J. (2006) Alpha2,3 and 
alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated 
virus types 1 and 6. J Virol, 80, 9093-9103. 
172 
 
123 Ng, R., Govindasamy, L., Gurda, B.L., McKenna, R., Kozyreva, O.G. and Samulski, R.J. 
(2010) Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J 
Virol, 84, 12945-12957. 
124 Weller, M.L., Amornphimoltham, P., Schmidt, M., Wilson, P.A., Gutkind, J.S. and Chiorini, 
J.A. (2010) Epidermal growth factor receptor is a co-receptor for adeno-associated virus 
serotype 6. Nat Med, 16, 662-664. 
125 Summerford, C. and Samulski, R.J. (1998) Membrane-associated heparan sulfate 
proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol, 72, 1438-1445. 
126 Akache, B., Grimm, D., Pandey, K., Yant, S., Xu, H. and Kay, M.A. (2006) The 37/67-
kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J 
Virol, 80, 9831-9836. 
127 Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V. and Srivastava, A. (1999) Human 
fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. 
Nat Med, 5, 71-77. 
128 Kashiwakura, Y., Tamayose, K., Iwabuchi, K., Hira, Y., Shimada, T., Matsomoto, K., 
Nakamura, T., Watanabe, M., Oshima, K. and Daida, H. (2005) Hepatocyte growth factor 
receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol, 79, 609-614. 
129 Asokan, A., Hamra, J.B., Govindasamy, L., Agbandje-McKenna, M. and Samulski, R.J. 
(2006) Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential 
for viral cell entry. J Virol, 80, 8961-8969. 
130 Kaludov, N., Brown, K.E., Walters, R.W., Zabner, J. and Chiorini, J.A. (2001) Adeno-
associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for 
hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol, 75, 
6884-6893. 
131 Walters, R.W., Yi, S.M., Keshavjee, S., Brown, K.E., Welsh, M.J., Chiorini, J.A. and Zabner, 
J. (2001) Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene 
transfer. The Journal of biological chemistry, 276, 20610-20616. 
132 Di Pasquale, G., Davidson, B.L., Stein, C.S., Martins, I., Scudiero, D., Monks, A. and 
Chiorini, J.A. (2003) Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med, 9, 
1306-1312. 
133 Shen, S., Bryant, K.D., Brown, S.M., Randell, S.H. and Asokan, A. (2011) TerminalN-Linked 
Galactose Is the Primary Receptor for Adeno-associated Virus 9. The Journal of biological 
chemistry, 286, 13532-13540. 
134 Zinn, E. and Vandenberghe, L.H. (2014) Adeno-associated virus: fit to serve. Current 
opinion in virology, 8c, 90-97. 
135 Bantel-Schaal, U., Hub, B. and Kartenbeck, J. (2002) Endocytosis of adeno-associated 
virus type 5 leads to accumulation of virus particles in the Golgi compartment. J Virol, 76, 2340-
2349. 
136 Xiao, P.J. and Samulski, R.J. (2012) Cytoplasmic trafficking, endosomal escape, and 
perinuclear accumulation of adeno-associated virus type 2 particles are facilitated by 
microtubule network. J Virol, 86, 10462-10473. 
137 Kelkar, S., De, B.P., Gao, G., Wilson, J.M., Crystal, R.G. and Leopold, P.L. (2006) A 
common mechanism for cytoplasmic dynein-dependent microtubule binding shared among 
adeno-associated virus and adenovirus serotypes. J Virol, 80, 7781-7785. 
173 
 
138 Kronenberg, S., Bottcher, B., von der Lieth, C.W., Bleker, S. and Kleinschmidt, J.A. (2005) 
A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of 
hidden VP1 N termini. J Virol, 79, 5296-5303. 
139 Sonntag, F., Bleker, S., Leuchs, B., Fischer, R. and Kleinschmidt, J.A. (2006) Adeno-
associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated 
prior to passage through the cytoplasm and are maintained until uncoating occurs in the 
nucleus. J Virol, 80, 11040-11054. 
140 Cotmore, S.F., D'Abramo A, M., Jr., Ticknor, C.M. and Tattersall, P. (1999) Controlled 
conformational transitions in the MVM virion expose the VP1 N-terminus and viral genome 
without particle disassembly. Virology, 254, 169-181. 
141 Girod, A., Wobus, C.E., Zadori, Z., Ried, M., Leike, K., Tijssen, P., Kleinschmidt, J.A. and 
Hallek, M. (2002) The VP1 capsid protein of adeno-associated virus type 2 is carrying a 
phospholipase A2 domain required for virus infectivity. The Journal of general virology, 83, 973-
978. 
142 Grieger, J.C., Snowdy, S. and Samulski, R.J. (2006) Separate basic region motifs within 
the adeno-associated virus capsid proteins are essential for infectivity and assembly. J Virol, 80, 
5199-5210. 
143 Johnson, J.S., Li, C., DiPrimio, N., Weinberg, M.S., McCown, T.J. and Samulski, R.J. (2010) 
Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic 
amino acids in trafficking and cell-specific transduction. J Virol, 84, 8888-8902. 
144 Nicolson, S.C. and Samulski, R.J. (2014) Recombinant adeno-associated virus utilizes host 
cell nuclear import machinery to enter the nucleus. J Virol, 88, 4132-4144. 
145 Thomas, C.E., Storm, T.A., Huang, Z. and Kay, M.A. (2004) Rapid uncoating of vector 
genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus 
vectors. J Virol, 78, 3110-3122. 
146 Stieger, K., Schroeder, J., Provost, N., Mendes-Madeira, A., Belbellaa, B., Le Meur, G., 
Weber, M., Deschamps, J.Y., Lorenz, B., Moullier, P. et al. (2009) Detection of intact rAAV 
particles up to 6 years after successful gene transfer in the retina of dogs and primates. Mol 
Ther, 17, 516-523. 
147 Zhong, L., Li, W., Yang, Z., Qing, K., Tan, M., Hansen, J., Li, Y., Chen, L., Chan, R.J., Bischof, 
D. et al. (2004) Impaired nuclear transport and uncoating limit recombinant adeno-associated 
virus 2 vector-mediated transduction of primary murine hematopoietic cells. Hum Gene Ther, 
15, 1207-1218. 
148 Ferrari, F.K., Samulski, T., Shenk, T. and Samulski, R.J. (1996) Second-strand synthesis is a 
rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J 
Virol, 70, 3227-3234. 
149 Fisher, K.J., Gao, G.P., Weitzman, M.D., DeMatteo, R., Burda, J.F. and Wilson, J.M. (1996) 
Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-
strand synthesis. J Virol, 70, 520-532. 
150 Nakai, H., Storm, T.A. and Kay, M.A. (2000) Recruitment of single-stranded recombinant 
adeno-associated virus vector genomes and intermolecular recombination are responsible for 
stable transduction of liver in vivo. J Virol, 74, 9451-9463. 
151 Lusby, E., Bohenzky, R. and Berns, K.I. (1981) Inverted terminal repetition in adeno-
associated virus DNA: independence of the orientation at either end of the genome. J Virol, 37, 
1083-1086. 
174 
 
152 Yang, J.S., Zhou, W.H., Zhang, Y.L., Zidon, T., Ritchie, T. and Engelhardt, J.F. (1999) 
Concatamerization of adeno-associated virus circular genomes occurs through intermolecular 
recombination. Journal of Virology, 73, 9468-9477. 
153 Miao, C.H., Snyder, R.O., Schowalter, D.B., Patijn, G.A., Donahue, B., Winther, B. and 
Kay, M.A. (1998) The kinetics of rAAV integration in the liver. Nat Genet, 19, 13-15. 
154 Gao, G., Wang, Q., Calcedo, R., Mays, L., Bell, P., Wang, L., Vandenberghe, L.H., Grant, 
R., Sanmiguel, J., Furth, E.E. et al. (2009) Adeno-associated virus-mediated gene transfer to 
nonhuman primate liver can elicit destructive transgene-specific T cell responses. Hum Gene 
Ther, 20, 930-942. 
155 Ciesielska, A., Hadaczek, P., Mittermeyer, G., Zhou, S., Wright, J.F., Bankiewicz, K.S. and 
Forsayeth, J. (2013) Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-
mediated immune responses. Mol Ther, 21, 158-166. 
156 Hadaczek, P., Forsayeth, J., Mirek, H., Munson, K., Bringas, J., Pivirotto, P., McBride, J.L., 
Davidson, B.L. and Bankiewicz, K.S. (2009) Transduction of nonhuman primate brain with adeno-
associated virus serotype 1: vector trafficking and immune response. Hum Gene Ther, 20, 225-
237. 
157 Kotin, R.M., Sinsicalco, M., Samulski, R.J., Zhu, X.D., Hunter, L., Laughlin, C.A., 
MCLaughlin, S., Muzycka, N., Rocchi, M. and Berns, K.I. (1990) Site-specific integration by adeno-
associated virus. Proc Natl Acad Sci U S A, 87, 2211-2215. 
158 Kotin, R.M., Menninger, J.C., Ward, D.C. and Berns, K.I. (1991) Mapping and direct 
visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. 
Genomics, 10, 831-834. 
159 McCarty, D.M., Young, S.M., Jr. and Samulski, R.J. (2004) Integration of adeno-
associated virus (AAV) and recombinant AAV vectors. Annual review of genetics, 38, 819-845. 
160 Flotte, T.R. and Berns, K.I. (2005) Adeno-associated virus vectors for gene therapy. 
Elsevier. 
161 Samulski, R.J., Berns, K.I., Tan, M. and Muzyczka, N. (1982) Cloning of adeno-associated 
virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl 
Acad Sci U S A, 79, 2077-2081. 
162 Duan, D., Yue, Y., Yan, Z. and Engelhardt, J.F. (2000) A new dual-vector approach to 
enhance recombinant adeno-associated virus-mediated gene expression through intermolecular 
cis activation. Nat Med, 6, 595-598. 
163 McCarty, D.M., Monahan, P.E. and Samulski, R.J. (2001) Self-complementary 
recombinant adeno-associated virus (scAAV) vectors promote efficient transduction 
independently of DNA synthesis. Gene Ther, 8, 1248-1254. 
164 McCarty, D.M. (2008) Self-complementary AAV vectors; advances and applications. Mol 
Ther, 16, 1648-1656. 
165 Passini, M.A., Lee, E.B., Heuer, G.G. and Wolfe, J.H. (2002) Distribution of a lysosomal 
enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J 
Neurosci, 22, 6437-6446. 
166 Liu, G., Martins, I., Wemmie, J.A., Chiorini, J.A. and Davidson, B.L. (2005) Functional 
correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated 
virus type 4 vectors. J Neurosci, 25, 9321-9327. 
175 
 
167 Broekman, M.L., Tierney, L.A., Benn, C., Chawla, P., Cha, J.H. and Sena-Esteves, M. 
(2009) Mechanisms of distribution of mouse beta-galactosidase in the adult GM1-gangliosidosis 
brain. Gene Ther, 16, 303-308. 
168 Cearley, C.N. and Wolfe, J.H. (2006) Transduction characteristics of adeno-associated 
virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther, 13, 528-
537. 
169 Cearley, C.N., Vandenberghe, L.H., Parente, M.K., Carnish, E.R., Wilson, J.M. and Wolfe, 
J.H. (2008) Expanded repertoire of AAV vector serotypes mediate unique patterns of 
transduction in mouse brain. Mol Ther, 16, 1710-1718. 
170 Cearley, C.N. and Wolfe, J.H. (2007) A single injection of an adeno-associated virus 
vector into nuclei with divergent connections results in widespread vector distribution in the 
brain and global correction of a neurogenetic disease. J Neurosci, 27, 9928-9940. 
171 Salegio, E.A., Samaranch, L., Kells, A.P., Mittermeyer, G., San Sebastian, W., Zhou, S., 
Beyer, J., Forsayeth, J. and Bankiewicz, K.S. (2013) Axonal transport of adeno-associated viral 
vectors is serotype-dependent. Gene Ther, 20, 348-352. 
172 Kells, A.P., Hadaczek, P., Yin, D., Bringas, J., Varenika, V., Forsayeth, J. and Bankiewicz, 
K.S. (2009) Efficient gene therapy-based method for the delivery of therapeutics to primate 
cortex. Proc Natl Acad Sci U S A, 106, 2407-2411. 
173 Castle, M.J., Gershenson, Z.T., Giles, A.R., Holzbaur, E.L. and Wolfe, J.H. (2014) Adeno-
associated virus serotypes 1, 8, and 9 share conserved mechanisms for anterograde and 
retrograde axonal transport. Hum Gene Ther, 25, 705-720. 
174 Dodge, J.C., Clarke, J., Song, A., Bu, J., Yang, W., Taksir, T.V., Griffiths, D., Zhao, M.A., 
Schuchman, E.H., Cheng, S.H. et al. (2005) Gene transfer of human acid sphingomyelinase 
corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease. 
Proc Natl Acad Sci U S A, 102, 17822-17827. 
175 Cachon-Gonzalez, M.B., Wang, S.Z., McNair, R., Bradley, J., Lunn, D., Ziegler, R., Cheng, 
S.H. and Cox, T.M. (2012) Gene Transfer Corrects Acute GM2 Gangliosidosis-Potential 
Therapeutic Contribution of Perivascular Enzyme Flow. Mol Ther, 20, 1489-1500. 
176 Priller, J., Flugel, A., Wehner, T., Boentert, M., Haas, C.A., Prinz, M., Fernandez-Klett, F., 
Prass, K., Bechmann, I., de Boer, B.A. et al. (2001) Targeting gene-modified hematopoietic cells 
to the central nervous system: use of green fluorescent protein uncovers microglial 
engraftment. Nat Med, 7, 1356-1361. 
177 Biffi, A., De Palma, M., Quattrini, A., Del Carro, U., Amadio, S., Visigalli, I., Sessa, M., 
Fasano, S., Brambilla, R., Marchesini, S. et al. (2004) Correction of metachromatic 
leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic 
stem cells. J Clin Invest, 113, 1118-1129. 
178 Visigalli, I., Delai, S., Politi, L.S., Di Domenico, C., Cerri, F., Mrak, E., D'Isa, R., Ungaro, D., 
Stok, M., Sanvito, F. et al. Gene therapy augments the efficacy of hematopoietic cell 
transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. 
Blood, 116, 5130-5139. 
179 Gentner, B., Visigalli, I., Hiramatsu, H., Lechman, E., Ungari, S., Giustacchini, A., Schira, 
G., Amendola, M., Quattrini, A., Martino, S. et al. Identification of hematopoietic stem cell-
specific miRNAs enables gene therapy of globoid cell leukodystrophy. Sci Transl Med, 2, 58ra84. 
180 Biffi, A., Aubourg, P. and Cartier, N. Gene therapy for leukodystrophies. Hum Mol Genet, 
20, R42-53. 
176 
 
181 Foust, K.D., Nurre, E., Montgomery, C.L., Hernandez, A., Chan, C.M. and Kaspar, B.K. 
(2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat 
Biotechnol, 27, 59-65. 
182 Zhang, H., Yang, B., Mu, X., Ahmed, S.S., Su, Q., He, R., Wang, H., Mueller, C., Sena-
Esteves, M., Brown, R. et al. (2011) Several rAAV vectors efficiently cross the blood-brain barrier 
and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther, 
19, 1440-1448. 
183 Yang, B., Li, S., Wang, H., Guo, Y., Gessler, D.J., Cao, C., Su, Q., Kramer, J., Zhong, L., 
Ahmed, S.S. et al. (2014) Global CNS transduction of adult mice by intravenously delivered 
rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. Mol Ther, 22, 1299-1309. 
184 Bevan, A.K., Duque, S., Foust, K.D., Morales, P.R., Braun, L., Schmelzer, L., Chan, C.M., 
McCrate, M., Chicoine, L.G., Coley, B.D. et al. (2011) Systemic gene delivery in large species for 
targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther, 19, 1971-
1980. 
185 Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.M., Fyfe, J., 
Moullier, P., Colle, M.A. and Barkats, M. (2009) Intravenous administration of self-
complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther, 17, 1187-
1196. 
186 Foust, K.D., Wang, X., McGovern, V.L., Braun, L., Bevan, A.K., Haidet, A.M., Le, T.T., 
Morales, P.R., Rich, M.M., Burghes, A.H. et al. (2010) Rescue of the spinal muscular atrophy 
phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol, 28, 271-274. 
187 Fu, H., Dirosario, J., Killedar, S., Zaraspe, K. and McCarty, D.M. (2011) Correction of 
neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain 
barrier gene delivery. Mol Ther, 19, 1025-1033. 
188 Ruzo, A., Marco, S., Garcia, M., Villacampa, P., Ribera, A., Ayuso, E., Maggioni, L., 
Mingozzi, F., Haurigot, V. and Bosch, F. (2012) Correction of pathological accumulation of 
glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through 
systemic AAV9 gene transfer. Hum Gene Ther, 23, 1237-1246. 
189 Xie, J., Xie, Q., Zhang, H., Ameres, S.L., Hung, J.H., Su, Q., He, R., Mu, X., Seher Ahmed, S., 
Park, S. et al. (2011) MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-
restricted transgene expression. Mol Ther, 19, 526-535. 
190 Ruzo, A., Garcia, M., Ribera, A., Villacampa, P., Haurigot, V., Marco, S., Ayuso, E.A., X. M., 
Roca, C., Agudo, J., Ramos, D. et al. (2012) Liver production of sulfamidase reverses peripheral 
and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice. Mol Ther, 20, 254-266. 
191 Davidoff, A.M., Ng, C.Y.C., Zhou, J.F., Spence, Y. and Nathwani, A.C. (2003) Sex 
significantly influences transduction of murine liver by recombinant adeno-associated viral 
vectors through an androgen-dependent pathway. Blood, 102, 480-488. 
192 Maguire, C.A., Crommentyijn, M.H., Mu, D., Hudry, E., Serrano-Pozo, A., Hyman, B.T. and 
Tannos, B.A. (2013) Mouse gender influences brain transduction by intravascularly administered 
AAV9. Mol Ther, 21, 1470-1471. 
193 Chen, Y.H., Chang, M. and Davidson, B.L. (2009) Molecular signatures of disease brain 
endothelia provide new sites for CNS-directed enzyme therapy. Nat Med, 15, 1215-1218. 
194 Chen, Y.H., Clafin, K., Geoghegan, J.C. and Davidson, B.L. (2012) Sialic acid deposition 
impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse 
model of lysosomal storage disease. Mol Ther, 7, 1393-1399. 
177 
 
195 Oehmig, A., Cortes, M.L., Perry, K.F., Sena-Esteves, M., Fraefel, C. and Breakefield, X.O. 
(2007) Integration of active human beta-galactosidase gene (100 kb) into genome using 
HSV/AAV amplicon vector. Gene Ther, 14, 1078-1091. 
196 Takaura, N., Yagi, T., Maeda, M., Nanba, E., Oshima, A., Suzuki, Y., Yamano, T. and 
Tanaka, A. (2003) Attenuation of ganglioside GM1 accumulation in the brain of GM1 
gangliosidosis mice by neonatal intravenous gene transfer. Gene Ther, 10, 1487-1493. 
197 Broekman, M.L., Baek, R.C., Comer, L.A., Fernandez, J.L., Seyfried, T.N. and Sena-
Esteves, M. (2007) Complete correction of enzymatic deficiency and neurochemistry in the 
GM1-gangliosidosis mouse brain by neonatal adeno-associated virus–mediated gene delivery. 
Molecular Therapy, 15, 30-37. 
198 Baek, R.C., Broekman, M.L., Leroy, S.G., Tierney, L.A., Sandberg, M.A., d'Azzo, A., 
Seyfried, T.N. and Sena-Esteves, M. (2010) AAV-mediated gene delivery in adult GM1-
gangliosidosis mice corrects lysosomal storage in CNS and improves survival. PLoS One, 5, 
e13468. 
199 Bradbury, A.M., Cochran, J.N., McCurdy, V.J., Johnson, A.K., Brunson, B.L., Gray-
Edwards, H., Leroy, S.G., Hwang, M., Randle, A.N., Jackson, L.S. et al. (2013) Therapeutic 
response in feline sandhoff disease despite immunity to intracranial gene therapy. Mol Ther, 21, 
1306-1315. 
200 McCurdy, V.J., Johnson, A.K., Gray-Edwards, H.L., Randle, A.N., Brunson, B.L., Morrison, 
N.E., Salibi, N., Johnson, J.A., Hwang, M., Beyers, R.J. et al. (2014) Sustained normalization of 
neurological disease after intracranial gene therapy in a feline model. Sci Transl Med, 6, 
231ra248. 
201 O'Brien, J.S., Stern, M.B., Landing, B.H., O'Brien, J.K. and Donnell, G.N. (1965) 
Generalized Gangliosidosis:  another inborn error of ganglioside metabolism? American journal 
of diseases of children (1960), 109, 338-346. 
202 Suzuki, K. (1968) Cerebral GM1-gangliosidosis: chemical pathology of visceral organs. 
Science, 159, 1471-1472. 
203 Dickson, P.I. and Chen, A.H. (2011) Intrathecal enzyme replacement therapy for 
mucopolysaccharidosis I: translating success in animal models to patients. Curr Pharm 
Biotechnol, 12, 946-955. 
204 Dickson, P.I., Hanson, S., McEntee, M.F., Vite, C.H., Vogler, C.A., Mlikotic, A., Chen, A.H., 
Ponder, K.P., Haskins, M.E., Tippin, B.L. et al. (2010) Early versus late treatment of spinal cord 
compression with long-term intrathecal enzyme replacement therapy in canine 
mucopolysaccharidosis type I. Mol Genet Metab, 101, 115-122. 
205 Bosch, A., Perret, E., Desmaris, N. and Heard, J.M. (2000) Long-term and significant 
correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV 
vectors. Mol Ther, 1, 63-70. 
206 Skorupa, A.F., Fisher, K.J., Wilson, J.M., Parente, M.K. and Wolfe, J.H. (1999) Sustained 
production of beta-glucuronidase from localized sites after AAV vector gene transfer results in 
widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of 
brain in mucopolysaccharidosis VII mice. Exp Neurol, 160, 17-27. 
207 Kaplitt, M.G., Feigin, A., Tang, C., Fitzsimons, H.L., Mattis, P., Lawlor, P.A., Bland, R.J., 
Young, D., Strybing, K., Eidelberg, D. et al. (2007) Safety and tolerability of gene therapy with an 
adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I 
trial. Lancet, 369, 2097-2105. 
178 
 
208 Worgall, S., Sondhi, D., Hackett, N.R., Kosofsky, B., Kekatpure, M.V., Neyzi, N., Dyke, J.P., 
Ballon, D., Heier, L., Greenwald, B.M. et al. (2008) Treatment of late infantile neuronal ceroid 
lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 
cDNA. Hum Gene Ther, 19, 463-474. 
209 Tardieu, M., Zerah, M., Husson, B., de Bournonville, S., Deiva, K., Adamsbaum, C., 
Vincent, F., Hocquemiller, M., Broissand, C., Furlan, V. et al. (2014) Intracerebral administration 
of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in 
children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum Gene 
Ther, 25, 506-516. 
210 Xu, L.F., Daly, T., Gao, C.H., Flotte, T.R., Song, S.H., Byrne, B.J., Sands, M.S. and Ponder, 
K.P. (2001) CMV-beta-actin promoter directs higher expression from an adeno-associated viral 
vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in 
therapeutic levels of human factor X in mice. Human Gene Therapy, 12, 563-573. 
211 Folch, J., Lees, M. and Sloane Stanley, G.H. (1957) A simple method for the isolation and 
purification of total lipides from animal tissues. The Journal of biological chemistry, 226, 497-
509. 
212 Jeyakumar, M., Butters, T.D., Cortina-Borja, M., Hunnam, V., Proia, R.L., Perry, V.H., 
Dwek, R.A. and Platt, F.M. (1999) Delayed symptom onset and increased life expectancy in 
Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc. Natl. Acad. Sci. USA, 96, 
6388-6393. 
213 Steele, A.D., Jackson, W.S., King, O.D. and Lindquist, S. (2007) The power of automated 
high-resolution behavior analysis revealed by its application to mouse models of Huntington's 
and prion diseases. Proc Natl Acad Sci U S A, 104, 1983-1988. 
214 Arthur, J.R., Heinecke, K.A. and Seyfried, T.N. (2011) Filipin recognizes both GM1 and 
cholesterol in GM1 gangliosidosis mouse brain. Journal of Lipid Research, 52, 1345-1351. 
215 Dodge, J.C., Haidet, A.M., Yang, W., Passini, M.A., Hester, M., Clarke, J., Roskelley, E.M., 
Treleaven, C.M., Rizo, L., Martin, H. et al. (2008) Delivery of AAV-IGF-1 to the CNS extends 
survival in ALS mice through modification of aberrant glial cell activity. Mol Ther, 16, 1056-1064. 
216 Gray, S.J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S.R. and Samulski, R.J. (2011) 
Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of 
adult mice and nonhuman primates. Mol Ther, 19, 1058-1069. 
217 Bonten, E.J., Annunziata, I. and d'Azzo, A. (2014) Lysosomal multienzyme complex: pros 
and cons of working together. Cellular and molecular life sciences : CMLS, 71, 2017-2032. 
218 Cotugno, G., Annunziata, P., Tessitore, A., O'Malley, T., Capalbo, A., Faella, A., 
Bartolomeo, R., O'Donnell, P., Wang, P., Russo, F. et al. (2011) Long-term amelioration of feline 
Mucopolysaccharidosis VI after AAV-mediated liver gene transfer. Mol Ther, 19, 461-469. 
219 Pulicherla, N., Shen, S., Yadav, S., Debbink, K., Govindasamy, L., Agbandje-McKenna, M. 
and Asokan, A. (2011) Engineering liver-detargeted AAV9 vectors for cardiac and 
musculoskeletal gene transfer. Mol Ther, 19, 1070-1078. 
220 Karageorgos, L.E., Isaac, E.L., Brooks, D.A., Ravenscroft, E.M., Davey, R., Hopwood, J.J. 
and Meikle, P.J. (1997) Lysosomal biogenesis in lysosomal storage disorders. Exp Cell Res, 234, 
85-97. 
221 Helip-Wooley, A. and Thoene, J.G. (2004) Sucrose-induced vacuolation results in 
increased expression of cholesterol biosynthesis and lysosomal genes. Exp Cell Res, 292, 89-100. 
179 
 
222 Sardiello, M., Palmieri, M., di Ronza, A., Medina, D.L., Valenza, M., Gennarino, V.A., Di 
Malta, C., Donaudy, F., Embrione, V., Polishchuk, R.S. et al. (2009) A gene network regulating 
lysosomal biogenesis and function. Science, 325, 473-477. 
223 Medina, D.L., Fraldi, A., Bouche, V., Annunziata, F., Mansueto, G., Spampanato, C., Puri, 
C., Pignata, A., Martina, J.A., Sardiello, M. et al. (2011) Transcriptional activation of lysosomal 
exocytosis promotes cellular clearance. Dev Cell, 21, 421-430. 
224 Li, Z.J., Sun, P., Zhang, H.D., Li, S.F., Liu, X. and Wang, R.Z. (2010) Corpus callosum: a 
favorable target for rSFV-mediated gene transfer to rat brain with broad and efficient 
expression. J Mol Neurosci, 42, 255-260. 
225 Ziegler, R.J., Salegio, E.A., Dodge, J.C., Bringas, J., Treleaven, C.M., Bercury, S.D., 
Tamsett, T.J., Shihabuddin, L., Hadaczek, P., Fiandaca, M. et al. (2011) Distribution of acid 
sphingomyelinase in rodent and non-human primate brain after intracerebroventricular 
infusion. Exp Neurol, 231, 261-271. 
226 Magnusson, T., Haase, R., Schleef, M., Wagner, E. and Ogris, M. (2011) Sustained, high 
transgene expression in liver with plasmid vectors using optimized promoter-enhancer 
combinations. Journal of Gene Medicine, 13, 382-391. 
227 Virella-Lowell, I., Zusman, B., Foust, K., Loiler, S., Conlon, T., Song, S., Chesnut, K.A., 
Ferkol, T. and Flotte, T.R. (2005) Enhancing rAAV vector expression in the lung. J Gene Med, 7, 
842-850. 
228 Loeb, J.E., Cordier, W.S., Harris, M.E., Weitzman, M.D. and Hope, T.J. (1999) Enhanced 
expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis 
virus posttranscriptional regulatory element: implications for gene therapy. Hum Gene Ther, 10, 
2295-2305. 
229 Mastroyiannopoulos, N.P., Feldman, M.L., Uney, J.F., Mahadevan, M.S. and Phylactou, 
L.A. (2005) Woodchuck post-transcriptional element induces nuclear export of myotonic 
dystrophy 3' untranslated region transcripts. EMBO Rep, 6, 458-463. 
230 Suzuki, Y. (2013) Chaperone therapy update: Fabry disease, GM1-gangliosidosis and 
Gaucher disease. Brain Dev, 35, 515-523. 
231 Broekman, M.L.D., Comer, L.A., Hyman, B.T. and Siena-Esteves, M. (2006) Adeno-
associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or-2 
serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience, 138, 501-
510. 
232 Whitfield, G.B., Brock, T.D., Ammann, A., Gottlieb, D. and Carter, H.E. (1955) Filipin, an 
Antifungal Antibiotic: Isolation and Properties. Journal of the American Chemical Society, 77, 
4799-4801. 
233 Fu, H., Samulski, R.J., McCown, T.J., Picornell, Y.J., Fletcher, D. and Muenzer, J. (2002) 
Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by 
adeno-associated virus-mediated gene delivery. Mol Ther, 5, 42-49. 
234 Van Vliet, K.M., Blouin, V., Brument, N., Agbandje-McKenna, M. and Snyder, R.O. (2008) 
The role of the adeno-associated virus capsid in gene transfer. Methods in molecular biology 
(Clifton, N.J.), 437, 51-91. 
235 Carty, N., Lee, D., Dickey, C., Ceballos-Diaz, C., Jansen-West, K., Golde, T.E., Gordon, 
M.N., Morgan, D. and Nash, K. (2010) Convection-enhanced delivery and systemic mannitol 
increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the 
adult mouse brain. Journal of neuroscience methods, 194, 144-153. 
180 
 
236 Hadaczek, P., Kohutnicka, M., Krauze, M.T., Bringas, J., Pivirotto, P., Cunningham, J. and 
Bankiewicz, K. (2006) Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) 
into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther, 17, 291-302. 
237 Kyle, J.W., Birkenmeier, E.H., Gwynn, B., Vogler, C., Hoppe, P.C., Hoffmann, J.W. and Sly, 
W.S. (1990) Correction of murine mucopolysaccharidosis VII by a human beta-glucuronidase 
transgene. Proc Natl Acad Sci U S A, 87, 3914-3918. 
238 Vogler, C., Galvin, N., Levy, B., Grubb, J., Jiang, J., Zhou, X.Y. and Sly, W.S. (2003) 
Transgene produces massive overexpression of human beta -glucuronidase in mice, lysosomal 
storage of enzyme, and strain-dependent tumors. Proc Natl Acad Sci U S A, 100, 2669-2673. 
239 Salegio, E.A., Samaranch, L., Jenkins, R.W., Clarke, C.J., Lamarre, C., Beyer, J., Kells, A.P., 
Bringas, J., Sebastian, W.S., Richardson, R.M. et al. (2012) Safety study of adeno-associated virus 
serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain. 
Hum Gene Ther, 23, 891-902. 
240 Chiu, I.M., Morimoto, E.T., Goodarzi, H., Liao, J.T., O'Keeffe, S., Phatnani, H.P., Muratet, 
M., Carroll, M.C., Levy, S., Tavazoie, S. et al. (2013) A neurodegeneration-specific gene-
expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse 
model. Cell reports, 4, 385-401. 
241 Zamanian, J.L., Xu, L., Foo, L.C., Nouri, N., Zhou, L., Giffard, R.G. and Barres, B.A. (2012) 
Genomic analysis of reactive astrogliosis. J Neurosci, 32, 6391-6410. 
242 Winkler, I.G., Hendy, J., Coughlin, P., Horvath, A. and Lévesque, J.-P. (2005) Serine 
protease inhibitors serpina1 and serpina3 are down-regulated in bone marrow during 
hematopoietic progenitor mobilization. The Journal of Experimental Medicine, 201, 1077-1088. 
243 Burckstummer, T., Baumann, C., Bluml, S., Dixit, E., Durnberger, G., Jahn, H., Planyavsky, 
M., Bilban, M., Colinge, J., Bennett, K.L. et al. (2009) An orthogonal proteomic-genomic screen 
identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol, 10, 266-272. 
244 Degrandi, D., Konermann, C., Beuter-Gunia, C., Kresse, A., Wurthner, J., Kurig, S., Beer, S. 
and Pfeffer, K. (2007) Extensive characterization of IFN-induced GTPases mGBP1 to mGBP10 
involved in host defense. Journal of immunology (Baltimore, Md. : 1950), 179, 7729-7740. 
245 Ugrinovic, S., Brooks, C.G., Robson, J., Blacklaws, B.A., Hormaeche, C.E. and Robinson, 
J.H. (2005) H2-M3 major histocompatibility complex class Ib-restricted CD8 T cells induced by 
Salmonella enterica serovar Typhimurium infection recognize proteins released by Salmonella 
serovar Typhimurium. Infection and immunity, 73, 8002-8008. 
246 Zijlstra, M., Li, E., Sajjadi, F., Subramani, S. and Jaenisch, R. (1989) Germ-line 
transmission of a disrupted [beta]2microglobulin gene produced by homologous recombination 
in embryonic stem cells. Nature, 342, 435-438. 
247 Bouchon, A., Dietrich, J. and Colonna, M. (2000) Cutting edge: inflammatory responses 
can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. Journal 
of immunology (Baltimore, Md. : 1950), 164, 4991-4995. 
248 Melchior, B., Garcia, A.E., Hsiung, B.K., Lo, K.M., Doose, J.M., Thrash, J.C., Stalder, A.K., 
Staufenbiel, M., Neumann, H. and Carson, M.J. (2010) Dual induction of TREM2 and tolerance-
related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based 
therapies for Alzheimer's disease. ASN neuro, 2, e00037. 
249 Azeredo da Silveira, S., Kikuchi, S., Fossati-Jimack, L., Moll, T., Saito, T., Verbeek, J.S., 
Botto, M., Walport, M.J., Carroll, M. and Izui, S. (2002) Complement activation selectively 
181 
 
potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte 
autoantibody. J Exp Med, 195, 665-672. 
250 Harraz, M.M., Marden, J.J., Zhou, W., Zhang, Y., Williams, A., Sharov, V.S., Nelson, K., 
Luo, M., Paulson, H., Schoneich, C. et al. (2008) SOD1 mutations disrupt redox-sensitive Rac 
regulation of NADPH oxidase in a familial ALS model. J Clin Invest, 118, 659-670. 
251 Jessen, K.R. and Mirsky, R. (1980) Glial cells in the enteric nervous system contain glial 
fibrillary acidic protein. Nature, 286, 736-737. 
252 Dauer, W. and Predborski, S. (2003) Parkinson's disease: mechanisms and models. 
Neuron, 39, 889-909. 
253 Ruzo, A., Garcia, M., Ribera, A., Villacampa, P., Haurigot, V., Marco, S., Ayuso, E., 
Anguela, X.M., Roca, C., Agudo, J. et al. (2012) Liver production of sulfamidase reverses 
peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice. Mol Ther, 20, 
254-266. 
254 Matsushita, M. (1999) Projections from the lowest lumbar and sacral-caudal segments 
to the cerebellar nuclei in the rat, studied by anterograde axonal tracing. The Journal of 
comparative neurology, 404, 21-32. 
255 Matsushita, M. (1999) Projections from the upper lumbar cord to the cerebellar nuclei 
in the rat, studied by anterograde axonal tracing. The Journal of comparative neurology, 412, 
633-648. 
256 Matsushita, M. and Gao, X. (1997) Projections from the thoracic cord to the cerebellar 
nuclei in the rat, studied by anterograde axonal tracing. The Journal of comparative neurology, 
386, 409-421. 
257 Matsushita, M. and Xiong, G. (1997) Projections from the cervical enlargement to the 
cerebellar nuclei in the rat, studied by anterograde axonal tracing. The Journal of comparative 
neurology, 377, 251-261. 
258 Matsushita, M. and Yaginuma, H. (1995) Projections from the central cervical nucleus to 
the cerebellar nuclei in the rat, studied by anterograde axonal tracing. The Journal of 
comparative neurology, 353, 234-246. 
259 Kaspar, B.K., et al. (2003) Retrograde Viral Delivery of IGF-1Prolongs Survival in a Mouse 
ALS Model. Science, 301, 839-842. 
260 Wang, B., Li, J., Fu, F.H., Chen, C., Zhu, X., Zhou, L., Jiang, X. and Xiao, X. (2008) 
Construction and analysis of compact muscle-specific promoters for AAV vectors. Gene Ther, 15, 
1489-1499. 
261 Arnett, A.L., Beutler, L.R., Quintana, A., Allen, J., Finn, E., Palmiter, R.D. and 
Chamberlain, J.S. (2013) Heparin-binding correlates with increased efficiency of AAV1- and 
AAV6-mediated transduction of striated muscle, but negatively impacts CNS transduction. Gene 
Ther, 20, 497-503. 
262 Baron, U. and Bujard, H. (2000) Tet repressor-based system for regulated gene 
expression in eukaryotic cells: principles and advances. Methods in enzymology, 327, 401-421. 
263 Furth, P.A., St Onge, L., Boger, H., Gruss, P., Gossen, M., Kistner, A., Bujard, H. and 
Hennighausen, L. (1994) Temporal control of gene expression in transgenic mice by a 
tetracycline-responsive promoter. Proc Natl Acad Sci U S A, 91, 9302-9306. 
264 Gray, S.J., Foti, S.B., Schwartz, J.W., Bachaboina, L., Taylor-Blake, B., Coleman, J., Ehlers, 
M.D., Zylka, M.J., McCown, T.J. and Samulski, R.J. (2011) Optimizing promoters for recombinant 
182 
 
adeno-associated virus-mediated gene expression in the peripheral and central nervous system 
using self-complementary vectors. Hum Gene Ther, 22, 1143-1153. 
 
